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Abstract 
Background 
Rheumatoid arthritis (RA) is a systemic, inflammatory disease with an estimated 
global prevalence of 0.3–1.0%. Evidence suggests that RA is initiated in the 
lungs. Cigarette smoking and various occupations associated with vapour, gas, 
dust, and fume (VGDF) inhalation can increase the risk of RA development. The 
association of VGDF, smoking, development of rheumatoid autoantibodies such 
as rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) and 
their relationship to RA disease development is poorly understood. 
Structure 
There are seven chapters in the dissertation. Chapter 1 introduces the 
dissertation reasoning and hypothesis. Chapter 2 is a published review of 
literature on RA and inhaled occupational exposures. Chapters 3 and 4 are 
published empirical studies analysing the clustering pattern of RF and ACPA, 
suggesting a potential common autoantigen in RA. Chapter 5 is a published 
empirical study analysing the pattern of autoantibody development with 
inhalational exposures to smoking and VGDF in male RA. Chapter 6 analyses 
the role of cadmium (as a common factor in smoking and VGDF), in relation to 
autoantibody development in nodular and non-nodular RA. Chapter 7 discusses 
further the strengths, limitations, unanswered questions and future direction of 
research. 
Conclusions 
Overall, this research provides evidence that RA, particularly in males, is 
precipitated by inhaled environmental exposures and RA patients with multiple 
inhalational insults are likely to have higher RF and ACPA levels. Empirical and 
laboratory evidence suggests a common autoantigen in RA to explain 
autoantibody clustering. Nodular RA patients demonstrate higher rheumatoid 
autoantibody levels, and significantly higher cadmium levels were found in female 
nodular RA patients. A model of heavy metal adsorption onto VGDF particles in 
vitro is proposed, stimulating pulmonary nodule formation and generating 
autoantibodies in response to a common autoantigen: post-translationally 
modified heavy chain fragments of immunoglobulin G.  
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Chapter 1: Introduction 
1.1.1 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is an inflammatory disease, primarily targeting the 
small joints of the hands [1]. Individuals with RA develop debilitating fatigue and 
joint inflammation, resulting in weakened grip and development of joint 
deformities impairing physical function [2].  Global RA prevalence is estimated at 
0.3–1.0% [3]. In the UK, a 2013 study of RA patients with disease duration of 10-
15 years reported an annual direct health care cost of approximately £3000 per 
patient [4]. Overall UK direct health cost of RA was estimated at £700 million in 
2010, with a further £8 billion lost to the UK economy when productivity loss and 
state benefit requirements were considered [5].    
1.1.2 Inhalation in rheumatoid arthritis 
The lung is established as a primary site for RA disease development [6], 
although the exact aetiology remains unclear. Genetic susceptibility plays a role, 
however low concordance rates of 9.1% (95% Confidence Interval [CI] 1.9 to 
24.3) in monozygotic twins have been found [7], suggesting that environmental 
factors are significant in RA pathogenesis. Cigarette smoking is arguably the most 
important environmental trigger factor for RA, with a strong association between 
ever smoking in monozygotic twin pairs demonstrating an odds ratio (OR) of 12.0, 
(95% Confidence Interval [CI] 1.78–513) for RA development [8]. Smoking is 
associated with triggering a measurable immune response in RA through the 
development of rheumatoid associated autoantibodies. It is associated with 
development of both rheumatoid factor (RF) and antibodies to citrullinated 
peptide antigens (ACPA) rather than RF- and ACPA- negative RA [9], which 
suggests that inhalation may trigger autoantibody development.  
Further inhaled environmental risk factors for RA have been suggested including 
exposure to: silica [10-14], construction work [14-16], asbestos [17,18], mineral 
oils [19,20] farming and pesticide exposure [15,17,20,21], electrical and 
electronics work [15,16], textiles [22], and roadside dust [23,24]. Specific 
occupations have been associated with ACPA positive RA [15,16,19,21,23]. 
Citrullination of proteins in the lungs, as found in the longevity-associated RA risk 
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identified in cigarette smoke inhalation [25,26], could equally occur in other 
inhalational exposures [26], which show an increased risk for RA when seen in 
combination with cigarette smoking [14]. Such exposures predominantly relate to 
occupation in male populations, and was noted anecdotally amongst the male RA 
population of Cornwall, UK.  Evidence exists linking RA risk to female 
occupational inhalation, such as recently seen in textile workers [22] and 
inhalational exposures in the wider environment [21,23,24].  
1.1.3 Autoantibody generation and clustering 
A history of smoking, specific human leukocyte antigen (HLA-DRB1) alleles that 
code a “shared epitope” (SE), and ACPA have emerged as the “trinity” of RA 
pathogenesis [27]. However, in routine clinical practice, the use of both RF and 
ACPA remains, and for good reason: the presence of RF and ACPA in healthy 
individuals increases the risk of RA development over and above ACPA alone 
[28]; and a positive RF and ACPA confer a far poorer radiological prognosis in 
established RA compared to either of these autoantibodies alone [29].  The 2010 
ACR/EULAR RA classification criteria [30] include a criterion that scores highly 
for those individuals with a strongly positive RF or ACPA (scoring 3 points), 
acknowledging that a strongly positive RF is of equal weight in RA diagnosis to a 
strongly positive ACPA.  
Furthermore, an important association between the two RA autoantibodies was 
observed in the rheumatoid- associated chronic lung condition of bronchiectasis.  
a prospective study following 122 bronchiectasis (BR) patients demonstrated that 
the presence of both RF and ACPA in the sera of patients with bronchiectasis was 
significantly more prevalent than in healthy controls and predicted the 
development of RA [31]. From this, it was suggested that there may be a common 
autoantigen; the potential antigenicity of RF (that is, heavy chain fragments of 
immunoglobulin G (IgGH)) triggers B cell activation in the lung, whereby post-
translational modification to IgGH orchestrates a local (lung) and distant (joint) 
immune response that involves the production of multiple autoantibodies, 
potentially triggering RA [32]. 
1.1.4 Cadmium and rheumatoid arthritis 
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RA-associated inhalational exposures involve the inhalation of vapours, gas, dust 
or fumes; and the potential exists for the direct inhalation of toxic elements such 
as cadmium, or by adsorption of such toxins onto inhaled substrates from 
concurrent environmental heavy metal co-exposure (most commonly through 
cigarette smoke). Cadmium has been described as the most important toxin in 
inhaled cigarette smoke [33]. Cadmium is found in cement dust, wood dust, and 
coal dust, and is associated with the finishing of textiles as a pigment and 
stabilising agent. Cadmium can enter the food chain through air, water, soil and 
plants, agricultural runoff and in industrial effluent. The process of lung adsorption 
is seen in, but not exclusive to, silica dusts, whereby toxic heavy metals such as 
cadmium bind directly onto the inhaled intra-pulmonary substrate, dramatically 
increasing total body levels. Once cadmium enters the body it may be stored and 
accumulated in tissues over a number of years, building up in concentration and 
toxicity [33]. Adsorption potentially explains the pronounced interaction of silica 
dust and smoking co-exposure amongst exposed workers (OR 14.9; 95% CI 
5.32-37.84) [12], and the RA risk attenuation seen in silica and non-silica dust 
exposed never smokers [14].  
Other environmental RA risk factors include: lower socio-economic class, low 
formal education levels and residing close to main roads [34]. Intriguingly, these 
risk factors are also associated with high levels of cadmium exposure [35]. 
Further evidence for the role of cadmium in driving inflammatory arthritis has been 
demonstrated in an animal model. Rat lung instilled with cadmium-containing 
silica nanoparticles has demonstrated greater expression of pro-inflammatory 
cytokines and granuloma formation than in lungs exposed to cadmium alone or 
silica nanoparticles alone [36]. All exposures demonstrated parenchymal 
inflammation, granuloma formation, cytokine expression, and stromal fibrogenic 
reactions. 
Environmental cadmium contamination is a long term health concern, with an 
historical antecedent and a modern industrial equivalent. For example, toxic 
blood cadmium levels have been demonstrated in 85% of children living in a 
Turkish coal mining area (mean serum cadmium 13.1 µg/L) [37]. Recent South 
Korean literature reports that the RA prevalence odds ratios rise with increasing 
cadmium concentrations [38].   
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1.1.5 Historical and geographical clinical context 
1.1.5.1 Cornish socio-economic deprivation  
It is well established that better health associates with improving socio-economic 
status, with modelling of general socio-economic, cultural and environmental 
conditions as the main determinants of health being widely cited [39] and 
systematically reviewed [40]. Work-related ill health was the fourth most prevalent 
cause of total disease burden in the pre-2004 European Union [41], with work 
and work-related psychosocial factors disproportionately affecting those at the 
lower end of the socio-enonomic gradient [40]. This is of relevance as Cornwall 
is a relatively deprived area of the UK: Indices of Multiple Deprivation 2015 data 
show that Cornwall currently ranks 143 out of 326 local authority areas for 
deprivation (1= highest population proportion living in the most deprived 
neighbourhoods) [42].  However, this overall ranking masks a polarisation 
between relatively more and less deprived areas, with 5% of neighbourhoods in 
Cornwall among the most deprived in England. This is particularly pertinent given 
the historical industrial decline that has occurred in parts of Cornwall. The former 
mining areas which have formed the backbone of Cornwall’s major towns 
continue to show a marked difference in deprivation to the more affluent areas. 
Combined analysis of neighbourhoods the former mining areas of Camborne/ 
Redruth, St Austell/ China Clay, West Penwith, Bodmin and Liskeard reveals 
31/128 (24.2%) neighbourhoods ranking in the in the 20% most deprived in 
England. This is significantly higher than the 13/198 (6.6%) remaining 
neighbourhoods in the rest of Cornwall’s predominantly non-mining areas, p< 
0.00001 [42]. 
1.1.5.2 Cornish metal mining and ill health 
Cornwall’s mining history predates the first notes on ill health of miners by 
Hippocrates (c. 430 BC, “a man from the mines being pale, livid and breathing 
with difficulty” [43]). Diodorus Siculus described well established mining of trading 
of tin in this part of the Ancient British Isles in the first century BC [44], and it has 
been suggested that the “pthsis” suffered by ancient miners was a form of silicosis 
caused by inhalational exposure [45]. Primarily ores of copper and tin were 
extracted in Cornwall, accelerating in production from the 16th century [43]. 
Though these were the dominant ores extracted, others were sought including 
arsenic, iron, lead, cadmium, tungsten, uranium, zinc, antimony, gold, lithium, 
rare earths, manganese, silver and molybdenite, and the discovery of "new" 
metals such as titanium [46]. Production exploded through the 18th and 19th 
centuries, with Cornish miners accessing deep underground seams through the 
technological advancement of steam-driven pumping through engineers such as 
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Newcomen, Trevithick and Woolf. However, conditions were reported as 
particularly poor in Cornish mines. Cornish miners of all ages showed excess 
mortaility when compared to Cornish non-miners and to Northern UK coal miners, 
with more than double the mortality rates of these comparison groups in all age 
bands above the age of 45 [47]. In 1832, Charles Thackrah, a Leeds physician 
and widely cited pioneer of occupational medicine, drew attention to dust 
inhalation as a cause of morbidity and mortality amongst miners, including 
suggestions for watering to the rock, regular bathing facilities and ventilation [48]. 
A Royal Commission into the Condition of Mines in Great Britain, reported in 
1864, led directly to the first legislation to improve conditions, primarily ventilation, 
enacted in 1872 [47]. Further rising mortality in Cornish mines through the 19th 
century led to a specific investigation by JS Haldane in 1904, which followed 
eradication procedures to cure hookworm infection amongst miners, who had 
previously been blamed for their own poor health due to poor hygiene [47]. 
Haldane concluded that inhalation of dust particles, complicated by potential 
tuberculous infection, was the cause of excess mining mortality. This was 
evidenced by the dramatic increase in the mortality amongst heavily dust 
exposed machine drill operators (compared to those not working machine drills, 
with lower levels of dust exposure): amongst miners aged 25-35 in the Redruth 
area during 1900-1902, a six- fold increase in machine driller mortality was 
observed [47]. Research into the suppression of dust in mining environments to 
minimise the effects from inhalational exposure in the early part of the twentieth 
century is thoroughly described by Holman’s history of silicosis, used as a term 
for inhalational lung disease [48]. Measures such as advancing ventilation 
design, wetting equipment for dust suppression, automatic drifting drill heads and 
longer piston drills all reducing the need for miners to be close to the drilling 
surface are discussed. However, the profitability of deep mining in Cornwall fell 
throughout the twentieth century, culminating in the global collapse of tin price 
control in 1985/6 [49]. Cornish metal mines did not survive, with the last Cornish 
tin mine at South Crofty closing in 1998, making direct industrial exposure a 
largely historical antecedent.  However, the scale and duration of mining in 
Cornwall has left a legacy of contamination, with elevated levels of elemental 
concentrations noted in residential soil [50], household dust [50], and private 
water supplies [51], in addition to the previously mentioned legacy of social 
deprivation through post-industrial decline [42]. 
1.1.5.3 Cornish kaolin mining and ill health 
More pertinent to this thesis, primarily due to ongoing activity within the Cornish 
economy and a potential exposure affecting the present day Cornish workforce, 
is the extraction of China Clay (kaolin). Kaolin has been mined around the St. 
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Austell area of Cornwall for over 250 years.  It is used as a substrate in ceramic, 
paint, building, pharmaceutical and paper industries. A broad term given to a 
range of naturally occurring substances, predominantly made up of aluminium 
silicate Al2Si2O5(OH)4, it contains impurities of other metal oxides and is found in 
association with ancillary minerals [52]. It is water insoluble and when heated, 
kaolin develops cationic charges between layers, attracting anionic heavy metals 
which can then be adsorbed resulting in contamination [53]. Importantly, Kaolin 
does not react as free silica, and as such the effects of respiratory disease related 
to kaolin exposure cannot be accurately described as silicosis. 
Kaolin is mined by directed water jets, streaming and separation pumping, 
following which it is dried to a moisture content of 1% by milling.  It is during the 
drying and handling phases of production of this “dry” substrate that inhalation of 
microscopic kaolin particles occurs [54]. Kaolinosis describes the pulmonary 
fibrotic changes seen in kaolin workers, of which it has been suggested that 23% 
have abnormal chest radiographs [55]. 
A review of 68 kaolin workers in South West UK found a common pattern of small, 
rounded opacities 1.5-3mm on chest radiography, predominantly at the bases but 
affecting all zones [56]. Intriguingly, 3% (2/68) cases also had seropositive 
rheumatoid arthritis, with demonstrable large peripheral pulmonary nodules 
typical of Caplan Syndrome.  This contrasts with a much lower rate of 0.4% seen 
in the coal workers of South Wales where this specific type of inhalation-related 
lung disease was discovered [57].  
Anecdotal over-representation of RA males in Cornwall with occupational kaolin 
dust exposure, particularly with progressive, nodular disease, was noted, and 
marked the starting point for the formulation of this thesis and investigation 
therein. 
1.1.6 Development timeline and ethical approval 
I commenced this research whilst a senior house officer in the Rheumatology 
Department, Royal Cornwall Hospital. I registered the initial data collection as an 
internal clinical audit, began the data collection, and wrote up the initial clinical 
case reports, one of which is included at the end of this chapter as a published 
example [58]. The narrative of the patient detailed in this published case report 
was a typical example, providing the starting point for the overall hypothesis and 
aims, developed from detailed histories of individual patient experiences of RA in 
Cornwall, UK. 
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 As the project grew, I co-ordinated and led an interdisciplinary team of junior 
doctors, nurses and secretarial support in data collection. To allow time for this 
project to develop, I outlined my hypotheses and ideas for research to the Royal 
College of General Practitioners Peninsula Deanery, who were kind enough to 
allow me to take an “out of programme” research year from general practice 
training to dedicate specific time to this project. I also was given a year-long 
honorary research fellow/ staff grade doctor clinical post within the Rheumatology 
Department, Royal Cornwall Hospital. Figure 1 summaries the progression of the 
study development as detailed below. 
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Figure 1. Flow diagram of study progression 
 
The initial discussion to investigate this phenomenon as a research project 
centred on taking detailed occupational and smoking histories of individual 
patients with RA under follow up at the Royal Cornwall Hospital, UK. The 
hypotheses (specifically detailed above) were presented at a local meeting of the 
National Rheumatoid Arthritis Society, attended by over 100 members, the 
majority of whom were RA patients.  Subsequent interest following the meeting 
led to further discussion as to the development of a protocol that would be 
acceptable to patients in terms of its design and acceptability.  From initial ideas, 
this was refined and presented to the Committee of the Cornwall Arthritis Trust, a 
local charity supporting arthritis patients.   
Department
al audit
• Identification of RA cases (Chapter 1)
• Occupational and smoking histories
NRAS 
meeting
• >100 members, agreement to investigate further
• Subsequent literature search (Chapter 2)
Ethical and 
HRA 
approval
• Submission of protocol and IRAS application (Appendix 1)
• Following local R&D approval
Patient 
feedback
• Wording of consent forms
• Questionaire design, follow up arrangements
Commence 
research
• Provision of written information, invitation to clinical appointment, administration of questionnaire for occupation and smoking histories
• Autoantibody and urinary cadmium analysis as per protocol
Interim 
analysis
• ACPA- positive rheumatoid arthritis was primarily determined by RF titre and the shared epitope rather than smoking per se (Chapter 3)
• Lysine carbamylation and arginine citrullination at the Fc region of immunoglobulin G potentiates a risk factor for rheumatoid arthritis development 
(Chapter 4)
Key initial 
findings: 
Posters
• Over-representation of dusty trades such as kaolin and wood dust in male RA population
• Presented in poster form and oral presentation at the European League Against Rheumatism annual conference
Inhalational 
exposures
• Vapour, gas, dust and fume occupational exposures in male rheumatoid arthritis patients resident in Cornwall (UK) and their association with 
rheumatoid factor and anti-cyclic protein antibodies: a retrospective observational study (Chapter 5)
Urinary Cd 
findings
• Significantly higher urinary cadmium (Cd), rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) levels in nodular rheumatoid 
arthritis (RA) smokers. A retrospective clinical study of patients in Cornwall, UK (Chapter 6)
Discussion 
• Adsorption, autoantibody associations and  IgG as a common autoantigen
• Expposure prevalence, nodular disease, respiraotory mortality and treatment implications
Future 
directions
• Case control study with non-RA controls, Histological analysis of lung tissue
• Wider public health implications
Final study 
report
• Under authorship of Dr. D Murphy, Academic supervision: Dr. D Hutchinson, Dr. P Eggleton, Prof. L. Fleming
• Dissemination of results via peer reviewed publication, collated as a PhD thesis
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Specific feedback was offered on the wording of consent forms, questionnaire 
design and arrangements for follow up on patients who may not have been able 
to complete written questionnaires. The subsequent protocol, questionnaires and 
patient information sheets are contained within Appendix 1. Patient involvement 
in this process was invaluable for how best to manage and undertake the 
research in a way that was minimally intrusive for patients in their regular clinical 
care. Also, at the recommendation of the patients, a search was undertaken to 
review the literature on the possible associations between rheumatoid arthritis 
with occupational exposures and/or tobacco smoking, detailed in Chapter 2 [59].  
Detailed data collection on rheumatoid arthritis patient smoking and occupational 
histories began in February 2015, registered and ethically approved as a clinical 
audit at the Royal Cornwall Hospital, Truro, Cornwall. 
As hypothesis generation progressed, I wrote the Heath Research Authority 
protocol IRAS ID 194833: Dust, Cadmium and Rheumatoid Arthritis (Appendix 
1), submitting to the Integrated Research Application System in November 2015. 
I attended the Ethics Review at the South West Research Ethical Committee to 
answer questions. I authored all aspects including the patient information sheets 
(Appendix 1) and I obtained Ethics permission for the data collection at peripheral 
GP sites for non-disease controls (Appendix 1), to obtain specific blood and urine 
sampling of patients to investigate autoantibodies and cadmium.  
The project was submitted initially as a postgraduate dissertation by publication 
to the University of Exeter Medical School in March 2016, funded by the Cornwall 
Arthritis Trust. 
Review by the South West Regional Ethical Committee (UK) was completed in 
May 2016, with approval being granted in August 2016 as project IRAS ID 194833 
(Appendix 1). A simultaneous application was made to store samples at the 
National Institute for Health Research (NIHR) Exeter Clinical Research Facility, 
Exeter, UK, for the potential use in future studies (Appendix 2), approved in July 
2016 under portfolio number CRF 249. Approval for a new collection of serum, 
extracted DNA and urine was obtained. Patient consent and sample collection 
took place via the clinical team in the Rheumatology Department, Royal Cornwall 
Hospital, to August 2017. I set up clinics across peripheral sites in Cornwall, 
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collecting data and samples with assistance from departmental junior doctors, 
medical students and nurses.  I arranged secretarial support in clinic 
administration and data input, and formulated a service level agreement to 
process samples between the Clinical Chemistry Department, Royal Cornwall 
Hospital, the Clinical Research Facility (Exeter), and the Supra-Regional Assay 
Service Trace Elements Laboratory, Guildford, Surrey. 
Interim data analysis of collected information on autoantibody levels of RA 
patients led to the fascinating results seen in Chapter 3 [60], in that ACPA- 
positive rheumatoid arthritis was primarily determined by RF titre and the shared 
epitope rather than smoking per se, published in July 2017. In analysing the 
impact of environmental exposures on autoantibody generation, wider 
consideration was given to how such autoantibodies might be generated, and 
how their generation might be linked. Further hypothesis generation led to 
preliminary laboratory work on investigating the underlying pathophysiological 
mechanisms linking RA autoantibodies, detailed in Chapter 4 [61], published in 
July 2017. 
Key findings on specific over-represented exposures such as wood dust [62] and 
kaolin dust [63] were presented in poster form and oral presentation at the 
European League Against Rheumatism annual conference in June 2017. 
Collation and analysis of smoking and occupational data as detailed in Chapter 
5 [64] took place up to December 2017, written up for publication and published 
in April 2018.  Analysis of results relating to nodular patients and urinary cadmium 
took place to June 2018, with Chapter 6 [65] submitted for publication in August 
2018. 
Further analysis of cadmium levels and recruitment of non-RA control groups for 
comparison is ongoing. 
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1.2 Published case report: Rheumatoid Pulmonary Nodules and 
Significantly Elevated Urinary Cadmium in a Kaolin (China Clay) Worker: 
Could Cadmium Adsorption onto Occupationally Inhaled Dust Explain 
Caplan's Syndrome? 
 
As an example of a typical Cornish male rheumatoid arthritis case, this published 
report is included as a way of introducing the hypotheses that led to the 
development of this research project. The narrative history of this patient case 
report demonstrates the starting point from which my hypotheses were formed, 
developing from detailed histories of individual patient experiences of RA in 
Cornwall, UK. [58]. 
 
Citation: Murphy D, Marshall R, Harrington C, Taylor A, Hutchinson D (2017) 
Rheumatoid Pulmonary Nodules and Significantly Elevated Urinary Cadmium in 
a Kaolin (China Clay) Worker: Could Cadmium Adsorption onto Occupationally 
Inhaled Dust Explain Caplan's Syndrome?. J Rheum Dis Treat. 2017;3:057. 
 
1.2.1 Introduction 
 
Caplan’s syndrome, first described in 1953 amongst Welsh coal miners, 
classically occurs in individuals with both rheumatoid arthritis (RA) and coal dust 
exposure [57]. It is characterised by development of pulmonary nodules 0.5-5cm 
throughout the lung field, distinct from silicosis [57,66]. This is of contemporary 
interest as lung inflammation is now considered to be an important site of RA 
initiation.  
 
Regional differences in the prevalence of Caplan’s syndrome have been reported 
in pneumoconiosis patients, from 0.4-1.5% [66]. This raises an intriguing 
question; what is the specific component of coal dust responsible for the 
development of rheumatoid pulmonary nodules and the development of RA? 
 
We hypothesise that kaolinite mineral adsorption predisposes to increased 
pulmonary cadmium levels as a result of both a direct cadmium load and 
enhanced pulmonary cadmium adsorption from cigarette smoke. 
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We describe a kaolin worker with Caplan’s syndrome and elevated urinary 
cadmium levels and discuss the relevant literature to support the hypothesis that 
cadmium can trigger rheumatoid pulmonary nodule formation and RA 
development. 
 
1.2.2 Case report 
 
A 65 year old male from Cornwall, UK, developed nodular RA aged 32. Rose-
Waaler testing at diagnosis was 1/2048 and a forefoot arthroplasty was 
undertaken within a year. He had worked for 16 years in kaolin drying refineries 
in Cornwall, UK, with consequent dust inhalation. He accumulated 20 pack years 
of cigarette smoking to age 30 years.  
Treatment with prednisolone was commenced. Disease progression required 
multiple surgical interventions. Further disease modifying treatments included: 
penicillamine 1983-1985; myocrisin 1985-1992; sulphasalazine 1992-1996; and 
methotrexate from 1996 onwards. Aged 44, he ceased working in the Kaolin 
refinery as employers refused to grant adequate sickness leave. 
Aged 55 he presented with a pulmonary embolus (PE), confirmed on CT 
pulmonary angiography (CTPA). Further CTPA imaging excluded recurrent PE as 
a cause of escalating shortness of breath symptoms. Radiology review of 
sequential CT chest imaging (2006-2008) demonstrated multiple pulmonary 
nodules consistent with Caplan’s syndrome (Figure 2). Subsequent development 
of rheumatoid vasculitis has been treated effectively with rituximab.  
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Figure 2.  Horizontal CT single slice: Caplan’s nodules. Black frames 
highlight multiple well circumscribed >0.5cm Caplan’s nodules throughout 
lower lobes bilaterally, more marked on left than right. 
 
 
Contemporary serology levels demonstrated a rheumatoid factor of 481.7 iu/ml 
(0-10 normal range) and an anti-cyclic citrullinated peptide antibody of >500 u/ml 
(0-17 normal range). 
Given our interest in the role of occupation in RA development with reference to 
cadmium inhalation, a urinary cadmium level was undertaken, (0.66 µmol/mol 
creatinine, UK median 0.17, 95th centile 0.57) [67]. We suggest occupational 
kaolin dust inhalation has resulted in the significantly raised urinary cadmium 
level reported here. 
 
1.2.3 Discussion 
 
A diagnosis of Caplan’s syndrome is evident by a diagnosis of RA, occupational 
dust exposure and radiological evidence of multiple pulmonary nodules. Kaolin 
workers are at high risk of Caplan’s syndrome [56]. Kaolinosis is a complication 
of kaolin exposure, distinct from silicosis. Caplan's syndrome prevalence in 
kaolinosis is over seven times higher than originally reported in pneumoconiosis 
claimants (3% vs. 0.4%) [56,57]. 
Inhalation of fine kaolin dust can occur, particularly in drying phases of production. 
An experienced Cornish pathologist described being able to remove kaolin from 
the lungs of workers at post mortem “with a tablespoon” (Figure 3). 
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Figure 3. Post mortem lung tissue sample from a kaolin worker showing 
macroscopic kaolinosis. 
 
Kaolin related employment in Cornwall declined to 900 people in 2014.  However, 
52/700 (7.4%) RA males under follow up at the Royal Cornwall Hospital have 
worked for >1 year in the kaolin industry, 12 times more than expected based on 
current occupational data. Likewise in Staffordshire (UK) underground coal 
miners have been demonstrated to have a significantly increased risk of RA 
development (odds ratio 8.47, 95% CI 2.59-27.66) [68].  
 
Kaolin and coal dusts share a predisposition for a common contaminant: 
elemental cadmium. Cadmium content of coal varies, with a strong association 
noted between the kaolinite mineralisation of coal and cadmium content [69]. Far 
higher cadmium levels have been observed in West African kaolin (11.2-15.9 
mg/kg), suggestive of local contamination by adsorption [70]. Mineral kaolinite is 
formed by geological feldspar decomposition, comprising a (Si2O5)2+ tetrahedral 
layer and an (Al2[OH]4)2+ octahedral layer bonded together by shared oxygen 
atoms between adjacent silicon and aluminium atoms [71]. Substitution of Si4+ by 
Al3+ gives rise to “permanent” active sites for adsorption in surface tetrahedral 
sheets, with “variable” pH-dependent adsorption occurring on alumina faces and 
crystal edges via direct covalent bonding. This renders kaolin as extremely 
effective at adsorbing heavy metals in environmental contamination [71]. 
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Within coal, occurrence of trace elements such as cadmium is importantly 
dependent on the principal mineral species, in addition to coal age and individual 
elemental characteristics. We suggest kaolinite as an adsorption substrate in coal 
as a reason for Caplan's syndrome. Given that the original source for cadmium 
in coal is adsorption onto fine particle clay matter at formation [72], we suggest 
that interaction between the adsorption characteristics of principal mineral 
species and trace element contamination explains the variance of Caplan’s 
syndrome found in global mining populations. Bituminous coals may display 
higher affinity for formation of organo-metal complexes and organic acid salts, 
thereby potentially containing higher cadmium levels at extraction or point of 
inhalation. However, we suggest that mineral capacity for further adsorption to 
inhaled dust causes the hitherto unexplained risk interaction seen in dust and 
cigarette smoke co-exposure [14]. This phenomenon explains the pronounced 
interaction of silica dust and current smoking >20 pack years co-exposure 
amongst exposed workers (OR 14.9, 95%CI 5.32-37.84) [11].  The phenomenon 
of an inhaled substrate predisposing to cadmium adsorption is observed in 
bitumen asphalters: smokers demonstrated a six-fold increase in serum cadmium 
compared to either non-smoking colleagues or control smokers [73].  Further 
evidence is seen in an animal model.  Rat lung instilled with cadmium-containing 
silica nanopaticles demonstrated greater expression of pro-inflammatory 
cytokines and granuloma formation than lung exposed to cadmium alone or silica 
nanoparticles alone [36]. All exposures demonstrated parenchymal inflammation, 
granuloma formation, cytokine expression and stromal fibrogenic reactions. 
 
Cadmium contamination of coal is a long term health concern. Toxic blood 
cadmium levels have been demonstrated in 85% of children living in a Turkish 
coal mining area (mean serum cadmium 13.1 µg/L) [37]. Recent South Korean 
literature reports RA prevalence odds ratio increasing by 1.62 per 1µg/L increase 
in serum cadmium [38].   
 
We postulate that kaolin dust in this ex-smoker's lungs adsorbed cadmium from 
cigarette smoke, increasing intra-pulmonary cadmium concentration, stimulating 
inflammation and disease development. 
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This case highlights the importance of occupational dust exposure in RA, and 
further studies are underway to determine if kaolin workers have high levels of 
bodily cadmium and an increased RA risk. We highlight the process of adsorption 
as an overlooked factor, explaining the interaction of silica and non-silica based 
dust and cigarette smoking seen in RA. 
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1.3 Study hypotheses and aims 
 
Hypothesis 1: RA is precipitated by inhaled environmental exposures, and 
patients with multiple inhalation exposures are more likely to have elevated 
autoantibody levels to both rheumatoid factor (RF) and anti-citrullinated protein 
antibody (ACPA). 
Aim:  To conduct a literature search into inhalational exposures in RA with 
reference to occupation (Chapter 2) [59]. 
Aim: To collect and analyse data on autoantibody levels in RA patients 
[60,61], and to compare autoantibody levels in patients exposed to 
cigarette smoke and/or vapour, gas dust and fumes (VGDF), (Chapters 5 
and 6) [64,65]. 
Hypothesis 2:  There is a common autoantigen in many RA patients to explain 
autoantibody clustering of both RF and ACPA. 
Aim: To investigate the possibility of a common autoantigen to explain 
autoantibody clustering (Chapters 3 and 4) [60,61]. 
Hypothesis 3: The presence of nodular RA is associated with raised rheumatoid 
factor (RF) and anti-citrullinated protein antibody (ACPA) levels irrespective of the 
smoking history. 
Aim: Utilising the findings of Chapter 3 [60], to further analyse the 
relationship between subcutaneous nodules, rheumatoid autoantibodies 
and smoking (Chapter 6) [65]. 
Hypothesis 4: RA smokers exposed to VGDF develop pulmonary nodules, 
adsorbing heavy metal toxins into lung granulomata rather than into the systemic 
circulation.  
Aim: Utilising the findings and of Chapters 3 and 5 [60,64], to compare 
urinary cadmium levels amongst nodular and non-nodular rheumatoid 
arthritis patients, analysing for differences in exposures (Chapter 6) [65]. 
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Chapter 2. Is Male Rheumatoid Arthritis an Occupational Disease? A 
Review. 
 
Citation: Murphy D, Hutchinson D. Is Male Rheumatoid Arthritis an Occupational 
Disease? A Review. Open Rheumatol J. 2017;11:88–105. 
 
2.1 Abstract 
 
Background: Rheumatoid arthritis (RA) is a systemic, inflammatory disease with 
an estimated global prevalence of 0.3–1.0%. An unexplained association exists 
between low formal education and the development of RA independent of 
smoking. It is established that RA is initiated in the lungs and that various 
occupations associated with dust, fume and metal inhalation can increase the risk 
of RA development. 
Objective: The objective of this review is to evaluate published clinical reports 
related to occupations associated with RA development. We highlight the concept 
of a “double-hit” phenomenon involving adsorption of toxic metals from cigarette 
smoke by dust residing in the lung as a result of various work exposures. We 
discuss the relevant pathophysiological consequences of these inhalational 
exposures in relation to RA associated autoantibody production. 
Method: A thorough literature search was performed using available databases 
including Pubmed, Embase, and Cochrane database to cover all relative reports, 
using combinations of keywords: rheumatoid arthritis, rheumatoid factor, anti-
citrullinated peptide antibody silica, dust, fumes, metals, cadmium, cigarette 
smoking, asbestos, mining, bronchial associated lymphoid tissue, heat shock 
protein 70, and adsorption. 
Conclusion: We postulate that the inhalation of dust, metals and fumes is a 
significant trigger factor for RA development in male patients and that male RA 
should be considered an occupational disease. To the best of our knowledge, this 
is the first review of occupations as a risk factor for RA in relation to the potential 
underlying pathophysiology.  
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2.2 Introduction 
 
2.2.1 Background 
 
Rheumatoid arthritis (RA) is a common autoimmune inflammatory disease with 
an estimated global prevalence of 0.3–1.0% [1], and primarily targets the small 
joints of the hands [2]. The overall cost to the individual with RA as a consequence 
of fatigue, joint inflammation and the subsequent development of joint deformities 
are impaired physical functioning, reduced work productivity and activities of daily 
living [3]. The overall economic cost of RA to society is substantial. A study of RA 
patients in Norfolk UK with longstanding disease of 10-15 years reported an 
annual cost of approximately £3000 per patient (2013 prices) for direct health 
care alone [4]. Therefore studies identifying potential causes of RA that are 
avoidable are of huge importance to at risk individuals and also wider society.  
 
Literature has established the lung as a primary site for disease development [5], 
although the exact aetiology remains unclear. Whilst genetic susceptibility plays 
a role, concordance rates of 9.1% (95% CI 1.9 to 24.3) in monozygotic twins have 
been found [6] suggesting that environmental factors are of great importance 
regarding the pathogenesis of RA. Cigarette smoking has emerged as an 
important risk factor for RA, with a strong association between ever smoking and 
RA in monozygotic twin pairs demonstrating an odds ratio (OR) 12.0, (95% CI 
1.78–513) [7]. Smoking, as the most important environmental trigger factor for 
RA, associates with rheumatoid factor (RF) and antibodies to citrullinated peptide 
antigens (ACPA) rather than RF and ACPA negative RA [8]. Further inhaled 
environmental risk factors for RA have been suggested including exposure to 
silica [9-13], construction work [13-15], asbestos [16,17], mineral oils [18,19] 
farming and pesticide exposure [14,16,19,20], electrical and electronics work 
[14,15], textiles [21] and roadside dust [22,23]. Specific occupations have been 
associated with ACPA positive RA [14,15,18,20,22]. Citrullination of proteins in 
the lungs, as found in the longevity-associated RA risk identified in cigarette 
smoke inhalation [24], could equally be applied to other inhalational exposures 
[25]. Such exposures predominantly relate to occupation in male populations, 
though evidence exists linking RA risk to female occupational inhalation, such as 
recently seen in textile workers [21] and inhalational exposures in the wider 
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environment [20,22,25,26].  
 
2.2.2 Key question 
 
Why do people exposed to workplace dust or fumes in addition to cigarette smoke 
demonstrate a greatly elevated risk of RA? 
 
2.2.3 Hypothesis 
 
In short, we suggest that RA should be considered an occupational disease as a 
consequence of dust and fume inhalation in the workplace, as such exposures 
stimulate immune tolerance breakdown. Furthermore, these exposures form a 
lung substrate that can adsorb heavy metals from other environmental sources 
such as cigarette smoke. 
 
We argue that metals have the potential to induce lymphoid tissue in the lung, 
generating ACPA and RF production locally. We highlight the process of 
adsorption as critical for RA disease development in men and discuss the 
pathophysiology of autoantibody generation resulting from occupational 
inhalation in stimulating RA disease development.  
 
2.3 Methods 
 
A literature search was performed using Pubmed, Embase, and Cochrane 
databases and to cover all relative reports.  Titles and abstracts of identified 
articles were screened for eligibility and relevance to the key question and a priori 
hypothesis generation as detailed above. Duplicates and reports generated that 
were not relevant to the study aims were removed. Reference lists of relevant 
articles were searched for further evidence by hand around mechanisms of action 
and further hypothesis refinement. 
 
2.3.1 Occupational exposure 
 
Initial searches were conducted using the following keywords: “occupation OR 
mining OR silica”, in combination with disease specific term “Rheumatoid 
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arthritis”. Subsequent searches of disease and exposure detail were made using 
the terms “Rheumatoid factor OR anti-citrullinated protein antibody/ies”, AND 
“silica OR dust OR fumes OR metals OR cadmium OR asbestos OR mining”. A 
separate search was made using the combination terms  “rheumatoid AND 
smoking AND occupation”. Following hypothesis generation and in the process 
of refinement, further searches were made using the combination terms 
“Rheumatoid arthritis AND bronchial associated lymphoid tissue OR adsorption 
OR heat shock protein 70” (Figure 4). 
 
2.3.2 Appraisal 
 
For occupational exposures, studies were examined for information relevant to 
output fields of sex, country of study, follow up period and exposure type. 
Reported or calculable RA risk being statistically significant for increased RA risk 
(with lower 95% confidence interval greater than 1.0) was used for inclusion. 
 
2.3.4 Integration 
 
For critical review purposes, statistically significant data pertaining to increased 
RA risk in male occupational exposures was integrated into a single table (Table 
1), for descriptive comparison. Data not reaching statistical significance was not 
included in the table, though elements of non-statistical significance are included 
in the discussion. Heterogeneity in study populations, comparison groups and 
outcome measures precluded further pooled analysis or systematic review.
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Figure 4. Literature retrieval flowchart 
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2.4 Inhalational workplace exposures.  
 
2.4.1 Mining/ Quarry workers 
 
Mining has long been associated with RA [27]. A cohort follow up study of 1026 
Finnish granite quarry and processing yard workers from 1940-1981, 
demonstrated RA incidence rate ratio (defined as award to disability pension for 
RA), over five times higher than expected, compared to general population 
statistics. Silica exposure was postulated as the primary mechanism of aetiology 
[9]. Interestingly, RA was seen in the absence of frank silicosis, suggesting 
silicosis per se does not account for the observed increased risk of RA and an 
alternate pathophysiology is likely. 
 
Stolt et al [11] found elevated ACPA+ RA risk in silica exposed Swedish quarry 
workers compared to unexposed controls (OR 1.67, 95% CI 1.13–2.48), but no 
increased risk of ACPA- RA when compared to unexposed controls.  This was 
particularly evident amongst men exposed to stone dust and rock drilling. In terms 
of outcome, Swedish miners and quarry workers have also demonstrated the 
highest and most consistent standardised incidence ratios (SIR) across three 
cohorts of patients hospitalised due to RA (SIR 1.4, 95% CI 1.0-1.9 for 43 RA 
miners as per 1960 and 1970 census data) [14].   
 
An association was seen in mortality odds ratio between postulated silica 
exposure and RA (OR 1.19, 95% CI 1.12-1.25) on analysis of death certificate 
data from 27 USA states from 1982-1995 [12]. Comparing 15/1237 RA silicotics 
with 20/6185 RA controls, this study was limited by the death certificate record of 
occupation rather than complete occupational history, and diseases/conditions 
contributing to cause of death. Categorisation of silica exposure was made based 
on occupation type rather than duration or intensity of exposure. However, 
stringent exclusion criteria would suggest bias towards the null hypothesis, 
suggesting that the significant risks presented may be an underestimate. 
 
Mining has long been associated with extra-articular RA manifestations such as 
pulmonary nodules. Caplan’s syndrome, first described in 1953, classically 
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occurs in coal dust exposed RA cases, characterised by development of 
pulmonary nodules 0.5-5cm throughout the lung field, distinct from silicosis [27]. 
Given that the lung is an important site of RA initiation [5], this is of contemporary 
interest in RA aetiology. Radiological changes of Caplan’s syndrome can precede 
RA development, and regional differences in the incidence of Caplan’s syndrome 
in coal miners have been noted [28]. Underground coal miners in Staffordshire, 
UK, demonstrated a significantly increased risk of RA development (OR 8.47, 
95% CI 2.59 to 27.66) [29]. Workers exposed to Kaolin (China clay) dust 
demonstrate the highest prevalence of Caplan’s syndrome ever reported, 12 
times higher than the prevalence noted in coal dust associated pneumoconiosis 
claimants (2/68, 3% [30] vs. 37/14000, 0.26% [27]). This raises intriguing 
questions as to the common components of inhaled dust responsible for RA 
pulmonary nodule development, and suggests that both dusts are implicated in 
RA development. 
 
2.4.2 Construction workers 
 
Elevated RA risk has been demonstrated amongst construction workers. Li et al. 
found significantly elevated risk amongst three cohorts of general construction 
workers studied, with SIR of 1.4 (95% CI 1.2-1.6), for RA hospitalisations 1964-
2004 comparing to census data for occupations over census periods covering 
1960-1970 [14]. No elevated SIR was seen amongst woodworkers or bricklayers. 
A recent abstract on the Epidemiological Investigation of Rheumatoid Arthritis 
(EIRA) study of 3295 new RA cases in defined Swedish geographical areas 
compared to 4912 controls, suggested an OR of 2.6 (95% CI 1.3-4.9) for 
bricklayers and concrete workers [15]. However, this abstract does not detail 
actual numbers in the trades listed, and whilst the authors report that results are 
adjusted for smoking, no methodology is given.  Furthermore, the authors 
included patients aged 18-70, and only report “last occupation” listed. Given the 
longevity of risk from the known inhalational insult of smoking [24], some 
acknowledgement of risk longevity conferred by other inhalational exposures 
would be expected. With the notable exception of mineral oil exposure, 
polarisation of RA risk estimates occurs when a latency period is used in 
occupational exposures [18], indicating a long induction period between exposure 
and RA development.  Ergo, an upper age cut off of 70 years may miss those 
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occupationally exposed cases over the age of 50, who may not present until well 
into their 70s and crucially will not account for multiple occupational co-
exposures. 
 
Asbestos exposure, commonly found in historical building trade populations, was 
found to be an RA risk factor amongst 12/74 incident cases compared to 19/382 
referents in multivariate analysis of lifelong occupational exposures (OR 2.5, 95% 
CI 1.0-6.8) [16]. Further evidence is found in a case-control study of community 
residents and workers exposed to asbestos contaminated vermiculite in 
Montana, USA, who demonstrated a strikingly elevated RA risk in those aged 
over 65 (OR 3.23 (95% CI 1.31-7.96) [17]. Interestingly, no significant increased 
risk was seen in those aged under 65, further highlighting the need to 
acknowledge a latency period between exposure and disease development. 
 
2.4.3 Electrical workers and workers exposed to metal fumes. 
 
Electrical workers demonstrated a non-significant, though consistent elevated RA 
hospitalisation risk (OR 1.1-1.3, (95% CI 1.0-1.3) [14]. Ilar et al suggest an OR of 
1.8 (95%CI 1.0-3.1) for ACPA+ RA, and OR 2.1 (95%CI 1.1-4.0) for ACPA- RA, 
amongst electrical and electronics workers [15].  In the UK, electricians represent 
a subset of construction industry workers with multiple co-exposures. Inhalation 
of silica, non-silica inorganic, and organic dusts from physical interactions with 
building industry substrates. Activities such as drilling and chiselling out concrete, 
wood and gypsum plasterboard are likely to be relevant. Further specific aspects 
to electrical work involve handling and assembly of componentry that exposes 
workers to metal fumes. Toxic elements (such as cadmium) have been 
sequentially reduced and eliminated from solder, plastics and brazing fillers in 
modern European applications [31]. However, a longitudinal study of ten workers 
exposed to silver solder in the UK demonstrated the longevity of historical heavy 
metal fume exposure [32].   
 
Other direct metal fume exposed trades demonstrate increased RA risk. An 
increased RA risk was reported in 29/74 Swedish mechanics, sheet metal 
workers and welders (OR 1.8, 95% CI 1.0-3.4) [16]. A single cohort of Li et al’s 
study [14] showed a significantly elevated SIR of 1.2 (95%CI 1.1-1.4) amongst 
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foundry workers, with two large cohorts of mechanics and metal workers 
demonstrating slight, though insignificant, SIR of 1.1 (95%CI 1.0-1.1) and 1.0 
(95% CI 1.0-1.1) respectively. Ilar et al [15] suggest an OR of 2.6 (OR 1.0-7.4) for 
ACPA+ RA in smelters and metal foundry workers.   A retrospective cohort study 
of workers recycling scrap metals at an electrical arc furnace in Italy noted 3/331 
incident cases of RA over a 20 year follow up period, a dramatically increased 
RR of 6.18 (95%CI 2.00-19.02), when compared to 420/20332 incident RA cases 
in the same town over the same period [33]. Despite the relatively small sample 
size and lack of directly comparable working group, this cohort demonstrated an 
appreciably elevated RA risk, thought due to foundry dust exposure containing a 
range of potential toxins including heavy metals [34].  
 
2.4.4 Mechanics and workers exposed to mineral oils 
 
In an analysis of 281 cases to 507 referents aged 25-75 years presenting to a 
single secondary care hospital in southeast Sweden, an increased though non-
significant RA risk was seen amongst machine and engine repairers (OR 2.1, 
95% CI 0.8-5.6), with specific exposure to hydraulic oils demonstrating an OR of 
1.8, (95% CI 0.7-4.3) [35]. Li et al found that engine and motor operators 
demonstrated consistent though insignificant SIR elevation across three cohorts 
(SIR 1.1-1.2, 95% CI 1.0-1.5 combined) [14].   
 
A report on the EIRA study compared 135 RA males exposed to different types 
of mineral oil to 132 controls, comparing seropositive and seronegative RA [18]. 
Exposure to any mineral oil demonstrated an increased risk (OR 1.3, 95%CI 1.0-
1.3), with motor oil exposure (OR 1.2, 95%CI 0.9-1.8) carrying higher risk than 
others. When subdivided by autoantibody positivity, significantly increased risk to 
any mineral oil exposure was only seen in seropositive disease (ACPA+ OR 1.6, 
95%CI 1.1-2.2). No significant increased risk for asphalt exposure was seen, 
unlike findings elsewhere (OR 14.0, 95%CI 1.2-99.9), albeit in limited numbers 
(4 cases: 1 referent) [16]. Limited correction for smoking was made via “ever” and 
“never” smoker categories. The authors noted a possible interaction between 
smoking and mineral oil exposure, but report an inability to reach a firm 
conclusion due to small numbers (ACPA+ RA attributable portion due to 
interaction= 0.5, 95%CI -0.2-1.2). No attributable portion was reported for RF+ 
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RA. 
 
2.4.5 Farm workers 
 
Farming has long been associated with increased RA risk.  A small but persistent 
SIR was noted in 821 RA farmers in Li at al's combined cohort as per 1960-1970 
data (SIR 1.1, 95% CI 1.1-1.2) [14].  A further study of incident cases in Sweden 
found an OR 2.4 (95% CI 1.1-5.2) amongst 20 farm worker RA cases to 41 
referents [16].  Interestingly, this study examined potential exposures which farm 
workers may encounter.  On multivariate analysis with adjustment for age and 
smoking, no statistically significant increased risk was found for exposure to 
pesticides, farm animals, mineral oils or organic dusts.  However, subsequent 
pooled analysis of specific occupational exposures with at least 50 exposed 
subjects amongst 176 cases and 630 referents, with adjustment for age and 
smoking, showed statistically significant increased risk amongst those exposed 
to crops and forage (OR 3.2, 95% CI 1.6-6.7 for >20 years exposure), and for 
fertilisers (OR 3.0, 95% CI 1.3-3.8).  No dose-duration relationship was observed. 
 
A longitudinal American study of 23570 spouses of pesticide license applicants 
from 1993-1997 found no association of RA with growing up on a farm or years 
living on a farm, on structured follow up interview in 2010 [19].  Detailed exposure 
analysis of 271 RA cases revealed increased risk from lifetime pesticide use (OR 
1.4, 95% CI 1.0-1.6), and application of chemical fertilizers (OR 1.7, 95% CI 1.1-
2.7).  Amongst specific pesticides examined, an elevated but non-significant risk 
was seen for DDT (OR 1.9, 95% CI 0.97-3.6). Significant risks were seen for 
maneb/ manecozeb fungicides (OR 3.3, 95% CI 1.5-7.1), and chemical fertilizers 
(OR 1.7, 95% CI 1.1-2.7).  
 
2.5 Discussion 
 
Low formal education has consistently been found to be associated with RA [36-
38]. All the occupations listed in Table 1 require no formal academic qualifications 
and it is noteworthy that no study as yet has considered an individual’s occupation 
as a confounding factor when considering low formal education levels as a risk 
factor for RA development. Likewise the stark contrast in mortality reported by 
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Pincus et al [39] in RA patients over a nine year period with a low formal education 
(45% mortality) compared to those with the highest formal education (5% 
mortality) has not been explained. However, occupations undertaken by working 
class individuals that expose them to vapours, gas, dust or fumes greatly 
increases the risk of chronic obstructive pulmonary disease (COPD) particularly 
in smokers, with an OR 14.1 (9.33-21.2) compared to never smokers with no such 
work exposures [40]. The “double-hit” of occupational exposure and smoking 
combined risk was far higher than the OR of 6.71 (4.58-9.82) in those smokers 
without such work exposures (Figure 5). 
 
Figure 5. COPD risk: interaction between smoking and 
vapour/gas/dust/fume (VGDF) exposure. Adapted from Blanc et al [40]. 
 
 
Whist the contribution of occupational exposures to chronic obstructive airways 
disease has been acknowledged [41], these occupations demonstrate only 
modest odds ratio rises in non-smokers. This is exemplified by Blanc’s study 
where significant but only modest differences were seen in never smokers when 
combined into broad categories of vapours, gas, dust and fume exposure in the 
longest held occupation (OR 1.98 (1.26-3.09) [40]. The impact of these exposures 
becomes particularly apparent when occurring in combination with smoking 
(Figure 5). This phenomenon is highly relevant to RA as men who work in dusty 
trades are highly likely to have smoked as the vast majority of male RA patients 
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have been smokers (77%) [8].  
 
Occupational risk alongside smoking delivers a substantial “double-hit” for 
disease development. For example, silica dust exposure and smoking combined 
confer an increased risk of ACPA positive RA [11,15,18]. Interestingly, a 
pronounced risk interaction of silica dust and cigarette smoking for ACPA+ RA 
development was seen amongst co-exposed workers: silica only, OR 1.15 (95% 
CI 0.42-3.15); current smoking, OR 2.78 (95% CI 1.77-4.38); silica + current 
smoking OR 7.36 (95% CI 3.31-16.38), rising to OR 14.9, (95% CI 5.32-37.84) 
for >20 pack years smoked (Figure 6). This risk exceeded the expected separate 
effects of silica exposure and current smoking, indicating an interaction between 
these exposures (attributable proportion due to interaction = 0.60 95% CI 0.26-
0.95). No explanation for this important interaction has been proposed in the 
literature.  
 
Figure 6. Risk interaction of ACPA+ RA in Swedish quarry workers with 
smoking and silica dust exposure, compared to unexposed never smoking 
controls, adapted from Stolt et al [11]. 
 
Recent analysis of 240,983 construction industry workers in Sweden suggested 
that “other inorganic” dusts are independent RA risk factors, in addition to silica 
[13]. Among ever smokers, both silica and other inorganic dust exposure were 
associated with increased RA risk: RR 1.36 (95% CI 1.11-1.68) and 1.42 (95% CI 
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1.17-1.73) respectively. However, no increased risk was seen amongst dust-
exposed never smokers (Figure 7). This poses interesting questions, both as to 
the risk posed by inorganic dusts other than silica, and to the pathophysiology of 
the risk interaction of dust and cigarette smoke co-exposure. 
 
Figure 7. Relative RA risk: interaction between dust exposure and smoking 
amongst Swedish construction workers, adapted from Blanc et al [13]. 
 
 
Here we suggest that silica and non-silica inorganic dusts act as an adsorber of 
heavy metals entering the lung via cigarette smoke. Cigarette smoke contains the 
metals aluminium, cadmium, chromium, copper, lead, manganese, mercury, 
nickel, selenium, vanadium and zinc. Cadmium has emerged as the most 
important of these metals in terms of increased levels relative to non-smokers 
and the associated increased risk of cardiovascular disease and COPD [42]. 
It has been hypothesised that inhalation of the metal cadmium links the 
established risk of smoking for RA and many of the occupations demonstrated to 
have an elevated RA risk [43]. Recent South Korean literature reports a significant 
RA OR rise of 1.62 per 1µg/L increase in serum cadmium, and a smaller 
significant OR rise in serum lead. [44]. Importantly cadmium has recently been 
demonstrated to citrullinate intracellular cytokeratins [45], which may potentially 
lead to immune tolerance breakdown and ACPA generation. Furthermore in 
micromolar concentrations (1–10 µM range), cadmium is associated with a pro-
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inflammatory state [46], and high dose administration to Wistar rats has been 
shown to exacerbate collagen induced arthritis disease development, 
demonstrating pro-inflammatory cytokine expression [47].  
 
2.5.1 Limitations of evidence 
 
Over the course of an occupational lifetime, many workers will be exposed to 
multiple agents. For example, in less skilled labouring construction workers, co-
exposure to silica dust, inorganic non-silica dust and wood dust is common. This 
is particularly true in poorer populations, where trade sub-specialisation and 
adherence to health and safety legislation will be less evident.  As previously 
described, lower socio-economic status is linked with RA [36-38]. Given the 
longevity of increased risk for RA found in smoking [24], occupational exposure 
to dust or fumes may not present until long after exposure cessation. 
 
Therefore, studies may be confounded by multiple inhalational insults, even when 
correcting for smoking. Blanc et al [13] excluded 40645 workers who were 
exposed to wood dust, gas or fumes to reduce confounding in their analysis of 
silica vs. non-silica dust exposed construction workers.  In the above study, 
capturing data from occupational health service records for unionised 
construction workers existing from 1968-1993, culminated in enrolment of 
approximately 80% of the eligible workers. Analysis of the “missing” 20% and the 
excluded, co-exposed workers would be interesting; one would suggest 
predominance towards lower socio-economic status groups. Such workers are 
more likely to reside in unskilled “itinerant” trades, and thus become excluded 
from analysis. Non-unionised workers are not mentioned, which may have limited 
relevance in Swedish construction but is highly relevant when generalising 
findings elsewhere. We suggest many co-exposed cases of interest may have 
been excluded, underestimating risk. 
 
As with construction workers, farmers perform a heterogenous mix of tasks in 
their work which can result in inhalation exposures.  Soil type, rainfall and wind 
patterns affect aerosolisation of particles. Oil exposures from machinery vary, 
along with solvent, concrete, cement and general building dust exposure from the 
variety of tasks that some farmers perform.  Metal fumes from welding have been 
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associated with increased RA risk amongst spouses of farmers [20]. We have 
previously suggested that heavy metal-laden particle inhalation may be an RA 
risk factor for farmers using pesticides and fertilisers [26]. Maneb and mancozeb 
fungicides are approximately 21% manganese by weight. Their use associates 
with increased levels in residential house dust, with concentrations declining with 
distance from use. Long-term Mancozeb use has shown evidence of wider 
environmental contamination [48].  Additionally, cadmium exposure from 
phosphate fertiliser may account for the RA risk seen in farmers. Rates of 
cadmium contamination in soil can range from 0.3 to 1.2 g/ha from contaminated 
fertiliser application [49], though this specific risk is largely of historical 
significance due to controls on the use of such fertilisers. Detailed information of 
exposure type and duration and intensity is needed to refine the potential risks 
that farmers face. 
 
Swedish case referent studies utilising census defined occupations and 
hospitalisation records dominate the literature for occupational risk in RA. Whilst 
illuminating, such studies do have limitations. Patients in manual jobs may 
present to hospital more readily as they may be unable to complete tasks that 
would not present a problem in sedentary occupations, leading to possible risk 
overestimation in hospitalisation data. Symptomatic RA patients pre-census may 
have already switched from “heavier” manual occupations to lighter trades, whilst 
similarly symptomatic patients in those lighter trades may have been able to 
continue in the same occupation. As such, single cohort registry data may 
underestimate risk in heavier, manual trades, and overestimate risk in lighter 
occupational categories in which working conditions can be adapted to meet the 
needs of RA patients.  Comparing occupation and socioeconomic status based 
on historical census occupation data, Li et al's [14] study was limited to those 
requiring hospital treatment, therefore misses non-hospitalised disease 
occurrence.  Linking RA hospitalisation to preceding census occupation may 
reflect selection bias towards ill health, and is a criticism that can be levelled at 
all large cohort surveys measuring disease incidence via hospitalisation records. 
In having a cohort of patients who held the same job in 1960 and 1970, this study 
includes patients who held the same occupation over a ten-year period, and may 
mitigate against occupational selection bias. Given these caveats, one may 
expect sedentary occupations to predominate, and the mix of active technical and 
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mechanical occupations seen here and elsewhere is therefore likely to be an 
underestimate.  Demonstrating elevated RA risk over different census reference 
periods, a strong argument can be made for miners, engine and motor operators, 
construction workers, electrical workers and farmers having an increased risk of 
RA.  
 
Extrapolating Swedish data to represent populations around the world has 
limitations. Cigarette smoking in Sweden has a fascinating reverse social class 
gradient on analysis of 55,000 participants in the 1960 census, with both long 
term and heavy smoking being twice as common amongst non-manual workers 
as manual workers, and ten times more common than in those working in farming 
and agriculture [50]. This trend is opposite to the UK, where smoking has 
consistently shown a lower socio-economic class predominance; in 1982, 49% 
unskilled working men smoked, compared to 20% non-manual professionals [51]. 
Inhalational co-exposure to dust and cigarette smoke is therefore less likely in the 
Swedish populations reported than in UK equivalents.  
 
 
2.5.2  Pathophysiologic considerations of vapour, gas dust and fume 
inhalation in relation to RA development  
 
2.5.2.1 Inducible bronchial associated lymphoid tissue (iBALT) 
 
The lung is now considered a principal site for the development of ACPA and RF 
positive RA [5]. A study of established RA demonstrated evidence of iBALT more 
commonly than in inflammatory lung disease without RA [52]. iBALT has the 
appearance of ectopic lymphoid follicles similar to those observed in rheumatoid 
joints [53]. iBALT contains numerous B cell follicles containing germinal centres 
and follicular dendritic cells.  Lymphocyte lung infiltration was more frequently 
found in ACPA-positive RA patients (50%) as compared with ACPA-negative RA 
patients (17%) and controls (13%). Critically germinal centres, B cells and plasma 
cells were only found in the lungs of ACPA-positive RA patients [54]. 
 
Cigarette smoking is strongly associated with the development of iBALT as the 
expression of iBALT was significantly more common in smokers than non-
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smokers (82% (14/17) v 14% (2/14) respectively) [55]. Furthermore silica has also 
been observed to generate iBALT in a murine model [56]. Rheumatoid pulmonary 
nodules have also been observed to contain lymphoid aggregates containing B 
lymphocytes and, in some cases, demonstrate characteristic features of lymphoid 
follicles [57]. The initial histological examination of the rheumatoid pulmonary 
nodules in the lungs of Welsh miners with Caplan’s syndrome eluded to the 
presence of germinal centres with lymphoid collections in the outer collagen layer 
[58], which have never been described in peripheral nodules [59]. Pulmonary 
rheumatoid nodules, therefore, have the potential to generate rheumatoid 
associated autoantibodies and it is unsurprising that pulmonary nodules have 
been noted to precede the development of RA, invariably being associated with 
seropositive rather than seronegative disease [60]. For example, the presence of 
pulmonary rheumatoid nodules in Welsh coal miners who had no history, signs, 
or symptoms of RA was associated with a high prevalence of positive rheumatoid 
factor tests (60%). The potential importance of pulmonary nodules may have 
been over looked as on plain chest x-rays lung nodules were present in only 0.3% 
of RA patients [61]. However a study utilising CT imaging of the lung 
demonstrated pulmonary nodules in 22% of RA patients and subpleural 
micronodules and/or pseudoplaques in a further 17% of patients [62].  
 
We suggest that accumulation of metals in the lung may predispose individuals 
to rheumatoid pulmonary nodules. The histology of a rheumatoid nodule is that 
of a granuloma with a palisade of cells proven to be a dual population of 
macrophages and fibroblastic cells clustered around a central necrotic core of 
fibrin. [63]. The macrophages are activated and have the appearance of epithelial 
cells and are termed epithelioid histiocytes [64]. Occasionally these histiocytes 
coalesce to form multinucleated giant cells in the rheumatoid nodule. Metal 
inhalation has been reported to be associated with the development of pulmonary 
macrophage derived multinucleated giant cells [65]. Metals such as beryllium are 
also linked to the formation of pulmonary nodules with histological features similar 
to rheumatoid nodules and can cause a chronic pulmonary granulomatous 
disease termed berylliosis which may arise long after exposure has ceased with 
a reported latency period of up to 40 years [66]. Raised levels of the heavy metals 
cobalt and chromium are associated with complications associated with metal on 
metal hip replacements. One of these complications includes the formation of 
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tertiary lymphoid tissue around the implant and this tissue is identical to that 
observed in joints of RA patients [67]. There appears to be an association 
between significant bodily levels of metals such as copper and cadmium in RA 
independent of smoking [68,69]. These data suggest that RA patients are 
exposed to metals and that heavy metals can induce the development of ectopic 
lymphoid tissue. 
 
Further animal model evidence strengthens the “double-hit” hypothesis in terms 
of granuloma formation. Rat lung instilled with cadmium-containing silica 
nanopaticles demonstrated greater expression of pro-inflammatory cytokines and 
granuloma formation than lung exposed to cadmium alone or silica nanoparticles 
alone [70]. Nanoparticle use per se may be of interest as an evolving occupational 
risk, as inhaled silica and carbon nanoparticles, aerosolised in electronics 
componentry and production of lightweight materials, can induce lung 
citrullination and activate peptidyl arginine deaminase [71]. Given that numerous 
metals are found in cigarette smoke [42], one possible explanation for the 
association between cigarette smoking and iBALT development is the 
accumulation of metals in the lungs of smokers; a process likely to be 
accentuated by the presence of various occupational dusts. 
 
2.5.2.2 Enhanced ACPA generation 
 
It is well documented that the generation of ACPAs occur prior to the development 
of RA and greatly increase the risk of disease development [72]. Examination of 
bronchoalveolar lavage fluid from RA detected ACPAs and the levels of these 
antibodies were increased in patients that had more well-developed iBALT [52]. 
These data suggest that ACPA antibodies are produced locally in the lung by 
plasma cells contained within iBALT. In addition to silica and cadmium inducing 
iBALT, both nanoparticles have been observed to citrullinate intracellular proteins 
such as cytokeratins [45, 71]. In the case of silica, citrullination occurred via the 
peptidylargininedeiminase (PAD)-dependent mechanism [71]. 
 
2.5.2.3 Rheumatoid factor production 
 
Rheumatoid factor is an autoantibody directed against the rheumatoid binding 
61 
 
site of the Fc of immunoglobulin G (IgG) [73]. Rheumatoid factor positivity is 
associated an enhanced risk of RA development [74]. Rheumatoid factor is more 
frequently observed in non-RA smokers [75], and individuals with lung disease 
associated with exposure to coal dust [60], asbestos [76] and silica [77]. 
Revealing the processes that result in RF generation may prove insightful for 
understanding how cigarette smoke and industrial inhalational exposures 
increase the risk of RA development. 
 
Newkirk et al [78] described a mechanism by which cigarette smoke induces 
either IgM RF or IgA RF to be generated by B cells. This mechanism is dependent 
on the generation of an IgG immune response to heat shock protein 70 (HSP 70). 
Complexes of IgG-HSP70 double bind to RF expressing B cells via an interaction 
with the B cell receptor and CD91 with the subsequent production of IgM RF and 
IgA RF [78]. Therefore, environmental insults that associate with the induction of 
HSP 70 with a secondary IgG response are likely to be important with regards to 
the generation of IgM RF and IgA RF. HSP 70 expression is enhanced in the 
rheumatoid joints and an IgG autoantibody response to HSP 70 is significantly 
raised in recent onset RA (53.0%) compared to normal controls (4%) [79]. 
Interestingly exposure to dusts alongside heat and noise in the work place can 
generate a significantly enhanced immune response to HSP 70 (40%) compared 
to office workers (19%) [80]. Likewise in smokers of North American Indian origin 
(an ethnic group with a very high risk for RA) there is a reported significantly 
increased prevalence of IgG anti-HSP70 positive individuals (40%) as opposed 
to non-smokers (5%) [78]. Cadmium and other metals (copper and mercury) are 
strongly linked to the upregulation of HSP 70 [81], as is silica [82]. No studies to 
date have correlated RF levels in RA with dual exposures to various dusts and 
cigarette smoke and the relationship between RF and IgG HSP 70 
autoantibodies. 
 
2.5.2.4 Adsorption in dust exposure 
 
All the occupations discussed involve inhalation of dust, fumes or particles, with 
the potential for adsorption of toxic elements such as heavy metals, from 
concurrent environmental co-exposure (most commonly through cigarette 
smoke).  This process is seen in, but not exclusive to, silica dusts, with adsorption 
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of toxic heavy metals such as cadmium directly onto the intra-pulmonary 
substrate inhaled previously, dramatically increasing total body levels. We 
suggest a hypothesis of adsorption of trace elements in vitro onto previously 
inhaled substrates as a cause of increased, interactive RA risk seen in sequential 
inhalational exposures. Cadmium has been described as the most important toxin 
in inhaled cigarette smoke [42]. Adsorption explains the pronounced interaction 
of silica dust and current smoking >20 pack years co-exposure amongst exposed 
workers (OR 14.9, 95%CI 5.32-37.84, Figure 6), described by Stolt [11], and the 
attenuation of risk seen by Blanc [13], in silica and non-silica dust exposed never 
smokers. 
 
Quantification of the exact adsorption capacity of dust varies. In laboratory 
analysis of a single known adsorption substrate, sorption depends heavily on 
experimental conditions such as pH, metal concentration, ligand concentration 
competing ions, and particle size. This is before consideration of the differing 
adsorption capacities of multiple dusts that workers may be exposed to. For 
example, a general builder may inhale fine sand, gypsum, cement, and sanded 
wood. Occupational exposure matrices have a limited ability to capture individual 
variability within this due to heterogeneity of tasks and substrates, with 
consequent potential for misclassification bias [83]. 
  
Adsorption capability generally results from a net negative charge on structural 
particles of substrates, attracting and binding positively charged heavy metal 
particles. Binding potential is enhanced by increasing surface area, seen in finer 
dust particles [84].  Within mineral dusts, occurrence of trace elements depends 
on principal mineral species of the substrate and individual characteristics of the 
sorption particle. For example, bituminous coals may display a high affinity for 
formation of organo-metal complexes and organic acid salts, thereby potentially 
containing higher trace element levels in situ. Conversely, the aluminiosilicate 
mineral content of fine dust from anthracite coals has greater potential for further 
adsorption of heavy metals due to surface charges [85]. Various organic dust 
particles have quantifiably demonstrated adsorption of heavy metals, such as 
cotton, wood, wool, moss, and waste from paper and seafood industries [84]. Of 
non-silica inorganic dusts, commercial gypsum and industrial gypsum by-product, 
both widely used in the construction industry for plasters and plasterboards, have 
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demonstrated adsorption of lead and cadmium in solution via sulphate binding 
[86]. An interesting analysis on cadmium binding via adsorption demonstrated 
interaction between sand, cement and clay to which construction workers would 
be exposed. Clay addition to sand-cement mix (a common process for enhancing 
mortar plasticity), exposed more ion exchange sites and altered pH, enhancing 
uptake capacity of cadmium via ion exchange of iron, magnesium and aluminium 
oxides bound in cement [87].  
 
We believe it is the “double hit” of inhaled particles with capacity for further 
adsorption from subsequent inhalation of trace elements that imparts excess risk. 
Most commonly, this would take the form of inhaled occupational dusts with the 
ability to adsorb trace elements from cigarette smoke. Further evidence for this 
compound exposure is demonstrated in Turkish bitumen asphalters, who 
demonstrated a six-fold increase in serum cadmium compared to either non-
smoking colleagues or control smokers [88], Figure 8.  
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Figure 8. Interaction of asphalt exposure and cigarette smoking on serum 
cadmium levels among Turkish asphalt workers, adapted from Atasoy at al 
[88]. 
 
 
2.6 Implications for treatment 
 
It is well established that cigarette smoking reduces the clinical response to both 
methotrexate and tumour necrosis factor (TNF) inhibitors (89,90). Cigarette 
smoking is strongly associated with the titres of RF [91], and it is noteworthy that 
a RF titre < 20 IU/ml was highly predictive for remission or low disease activity in 
RA patients with established disease receiving TNF inhibitors [92]. In this study 
RA patients with a RF titre < 20 IU/ml were significantly more likely (OR 18.9, 95 
% CI 10.79-38.36) to be in remission at 12 months than RA patients with a RF 
titre >20 IU/ml. This is important as our own observations have demonstrated that 
wood dust exposed carpenters have significantly higher RF titres than non-dust 
exposed RA cases. Control never smokers (n=40) were noted to have RF titre of 
16 IU/ml (IQR 6.7–47.2) compared to carpenter never smokers (n=8) RF titre of 
86.4 (IQR 19.5–230.3), p=0.04 [93]. It is therefore conceivable that individuals 
who have been exposed to dust in the work place have a blunted response to 
methotrexate and TNF inhibitors by virtue of high RF titres, generated by 
inhalational insults as discussed above.  
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2.7 Conclusion 
 
A variety of occupations have demonstrated increased risk for RA, primarily 
identified through Swedish case referent and linkage studies, and involve 
exposure to inhalational particles, in the form of dust, fumes or both. Global health 
and safety legislation, working patterns and smoking habits vary considerably. 
Studying populations where such co-exposures are common may demonstrate 
further areas of enhanced RA risk.   
 
Interaction is seen between occupational RA risk and cigarette smoking, and we 
present information to support a hypothesis of heavy metal adsorption onto 
inhaled dust particles to explain this.  Further work is needed to analyse the ability 
of inhaled dusts to stimulate immune tolerance breakdown in the causation of 
RA.  
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Table 1. Occupational exposures previously found to demonstrate significantly increased RA risk in males 
 
Author(s), 
publication year 
and reference 
no. 
Country, period 
of employment 
and follow–up 
Study 
population 
Exposure type Cases Controls Reported 
RA risk 
(95% CI) 
Comments 
Klokars et al 
1987 [9] 
Finland 1940–
1981 
1026, Cohort Granite quarry and 
processing yard 
workers 
35 7.5  Comparison with age 
matched Finnish 
population statistics for all 
workers 
Stolt et al 2010 
[11] 
Sweden 1996–
2006 
577 RA cases, 
659 age, 
gender, 
location 
matched 
controls 
Silica: stone dust, 
rock drilling, stone 
crushing 
54 69 1.39 
(1.13–
2.48) 
ACPA+ RA. ACPA– and 
combined RA failed to 
reach significance 
Stolt et al 2010 
[11] 
Sweden 1996–
2006 
577 RA cases, 
659 age, 
gender, 
location 
matched 
controls 
Silica: stone dust, 
rock drilling, stone 
crushing, current 
smokers 
21 13 7.36 
(3.31–
16.38) 
ACPA+ RA, silica and 
smoking interaction 
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Author(s), 
publication year 
and reference 
no. 
Country, period 
of employment 
and follow–up 
Study 
population 
Exposure type Cases Controls Reported 
RA risk 
(95% CI) 
Comments 
Calvert et al 
2003 [12] 
USA 1982-1995 4839231 death 
certificates  
from 27 states,  
silica exposed 
cases matched 
to non-silica 
Silica 15/1237 20/6185 3.75 
(19.2-
7.32 
Mortality odds ratio.  OR 
1.19 (1.12-1.25) following 
conditional logistic 
regression 
Li et al 2008 [14] Sweden 1964–
2004 
13820 
hospitalisations 
for RA, cohort 
Miners and quarry 
workers 
175 - 1.7 (1.5–
2.0) 
Comparison with 
standardised incidence 
ratio (SIR) by occupation 
category in 1960 census 
Li et al 2008 [14] Sweden 1964–
2004 
13820 
hospitalisations 
for RA, cohort 
Miners and quarry 
workers 
145 - 1.8 (1.6–
2.2) 
Comparison with SIR by 
occupation category in 
1970 census 
Turner and 
Cherry 2000 
[41] 
North 
Staffordshire, 
UK  
6353 male 
pottery 
workers, case–
referent  
Underground 
mining 
9/43 5/172 8.47 
(2.59–
27.66) 
Referents matched on age, 
sex and pottery exposure 
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Author(s), 
publication year 
and reference 
no. 
Country, period 
of employment 
and follow–up 
Study 
population 
Exposure type Cases Controls Reported 
RA risk 
(95% CI) 
Comments 
Li et al 2008 [14] Sweden 1964–
2004 
13820 
hospitalisations 
for RA, cohort 
Construction 
workers 
498 - 1.2 (1.1–
1.4) 
Comparison with 
standardised incidence 
ratio (SIR) by occupation 
category in 1960 census 
Li et al 2008 [14] Sweden 1964–
2004 
13820 
hospitalisations 
for RA, cohort 
Construction 
workers 
561 - 1.3 (1.2–
1.5) 
Comparison with SIR by 
occupation category in 
1970 census 
Li et al 2008 [14] Sweden 1964–
2004 
13820 
hospitalisations 
for RA, cohort 
Construction 
workers 
210 - 1.4 (1.2–
1.6) 
Comparison with SIR by 
occupation category in 
1960 and 1970 census 
Ilar et al 2016 
[15] 
Sweden, 
unreported 
3295 incident 
RA cases, 
4912 controls 
Bricklayers and 
concrete workers 
Unreported - 2.6 (1.3–
4.9) 
Abstract only publication 
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Author(s), 
publication year 
and reference 
no. 
Country, period 
of employment 
and follow–up 
Study 
population 
Exposure type Cases Controls Reported 
RA risk 
(95% CI) 
Comments 
Blanc et al 2015 
[13] 
Sweden, 1968–
1993 
240983 
unionised 
construction 
workers 
enrolled in 
occupational 
health service 
1968–1993 
Silica dust, ever 
smokers 
160/52419 273/108400 1.36 
(1.11–
1.68) 
 
Blanc et al 2015 
[13] 
Sweden, 1968–
1993 
240983 
unionised 
construction 
workers 
enrolled in 
occupational 
health service 
1968–1993 
Non–silica 
inorganic dust, 
ever smokers 
202/132583 273/108400 1.42 
(1.17–
1.73) 
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Author(s), 
publication year 
and reference 
no. 
Country, period 
of employment 
and follow–up 
Study 
population 
Exposure type Cases Controls Reported 
RA risk 
(95% CI) 
Comments 
Li et al 2008 [14] Sweden 1964–
2004 
13820 
hospitalisations 
for RA, cohort 
Electrical workers 282 - 1.2 (1.1–
1.3) 
Comparison with SIR by 
occupation category in 
1960 and 1970 census 
Ilar et al 2016 
[15] 
Sweden, 
unreported 
3295 incident 
RA cases, 
4912 controls 
Electrical workers unreported - 2.1 (1.1–
4.0) 
ACPA– RA 
Abstract only publication 
Olsson et al 
2004 [16] 
Sweden 1996-
1998 
74 incident 
male RA cases, 
382 referents 
Electricians, 
electromechanical 
workers, service 
personnel 
9/74 18/382 3.4 (1.2-
9.4) 
 
Li et al 2008 [14] Sweden 1964–
2004 
13820 
hospitalisations 
for RA, cohort 
Smelters and 
metal foundry 
workers 
271 - 1.2 (1.1–
1.4) 
Comparison with SIR by 
occupation category in 
1970 census 
Cappalletti et al 
2016 [45] 
Trentino, Italy 
1979-2009 
331 exposed 
workers, cohort 
Electric arc 
furnace workers 
3/331 420/20332 6.18 
(2.00-
19.02) 
Compared to incident 
cases in same town over 
same period 
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Author(s), 
publication year 
and reference 
no. 
Country, period 
of employment 
and follow–up 
Study 
population 
Exposure type Cases Controls Reported 
RA risk 
(95% CI) 
Comments 
Olsson et al 
2004 [16] 
Sweden 1996-
1998 
74 incident 
male RA cases, 
382 referents 
conductors, 
freight, transport 
workers 
3/74 2/382 17.8 
(1.5-
207.8) 
 
Li et al 2008 [14] Sweden 1964–
2004 
13820 
hospitalisations 
for RA, cohort 
Engine and Motor 
operators 
383 - 1.2 (1.1-
1.3) 
Comparison with 
standardised incidence 
ratio (SIR) by occupation 
category in 1960 census 
Svedrup et al 
2005 [18] 
Sweden 1996-
2003 
407  incident 
male RA cases, 
486 controls 
Mineral oil 
exposure 
93 132/486 1.6 
(1.1-2.2) 
ACPA + RA, any mineral oil 
exposure. Specific cohort 
size not given for 
ACPA+RA 
Olsson et al 
2000 [47] 
Sweden 1980-
1995 
102 RA cases, 
248 referents 
Asphalters 3/102 1/248 14.0 
(1.2-
799.0) 
 
Li et al 2008 [14] Sweden 1964–
2004 
13820 
hospitalisations 
for RA, cohort 
Farmers 821 - 1.2 (1.1-
1.2) 
Comparison with SIR by 
occupation category in 
1960 and 1970 census 
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Author(s), 
publication year 
and reference 
no. 
Country, period 
of employment 
and follow–up 
Study 
population 
Exposure type Cases Controls Reported 
RA risk 
(95% CI) 
Comments 
Olsson et al 
2004 [16] 
Sweden 1996-
1998 
74 incident 
male RA cases, 
382 referents 
Farmers 20/74 41/382 2.4 (1.1-
5.2) 
 
Parks et al 2016 
[20] 
USA 1993-2010 23570 spouses 
of pesticide 
applicants, 
cohort 
Farming: 
maneb/mancozeb 
perticides 
10/271 351/23570 3.3 (1.5-
7.1) 
 
Parks et al 2016 
[20] 
USA 1993-2010 23570 spouses 
of pesticide 
applicants, 
cohort 
Farming: chemical 
fertilisers 
23/132 2540/24018 1.7 (1.1-
2.7) 
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Chapter 3. Anti-citrullinated protein antibody positive rheumatoid arthritis 
is primarily determined by rheumatoid factor titre and the shared epitope 
rather than smoking per se. 
 
Citation: Murphy D, Mattey D, Hutchinson D. Anti-citrullinated protein antibody 
positive rheumatoid arthritis is primarily determined by rheumatoid factor titre and 
the shared epitope rather than smoking per se. PloS one. 2017;12:e0180655. 
 
3.1 Abstract 
 
Objective: To analyse the relationship between rheumatoid factor (RF) titre, 
smoking and HLA-DRB1 alleles coding a “shared epitope” (SE) in relation to anti-
citrullinated protein antibody (ACPA) positivity in rheumatoid arthritis (RA).  
Methods: RA patients (n=658) attending rheumatology clinics in Cornwall, UK 
(cohort 1) were stratified according to RF and ACPA titre, and smoking pack years 
at diagnosis.  A further 409 RA patients from North Staffordshire, UK (cohort 2) 
were studied to confirm the relationship between RF levels, smoking and ACPA 
positivity in relation to SE status. 
Results: In cohort 1 there was a trend (p<0.01) of increasing ACPA positivity rates 
with increasing levels of RF without statistically significant differences between 
patients who had never smoked and smokers (never smoked: 15/71 (21%) RF -
ve, vs. 43/64 (67%) RF weak +ve, vs 88/100 (88%) RF strong +ve, ever smoked: 
18/70 (26%) RF -ve vs. 66/83 (80%) RF weak +ve vs. 196/210 (93%) RF strong 
+ve). No significant gender difference was observed. No significant difference 
between smoking and ACPA positivity was seen in RF negative patients. Smoking 
>20 pack years conferred an increased risk of anti-CCP positive RA (158/200 
(79%)), compared to having never smoked (146/235 (62%), p=<0.01), but this 
increased risk correlated with smokers’ RF positivity as the principal determinant 
on subsequent regression analysis of cohort 2. In cohort 2, ACPA positivity rates 
significantly increased with RF positivity and carriage of 1 or 2 SE alleles 
(p<0.01). Little or no relationship was observed in patients lacking SE.  
Conclusions: ACPA positivity in RA strongly associates with increasing RF titre 
independent of smoking. This relationship is dependent on carriage of SE alleles. 
There is no relationship between ACPA and smoking in RF negative patients. 
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3.2 Introduction 
 
Over the last 2 decades, smoking, HLA-DRB1 alleles that code a “shared epitope” 
(SE), and anti-citrullinated protein antibodies (ACPA) have emerged as the trinity 
of RA pathogenesis [1]. However, in routine clinical practice the use of both RF 
and ACPA remains, and for good reason: the presence of RF and ACPA in healthy 
individuals increases the risk of RA development over and above ACPA alone [2], 
and a positive RF and ACPA confers a far poorer radiological prognosis in 
established RA compared to either of these autoantibodies alone [3].  The 2010 
ACR/EULAR RA classification criteria [4] includes a criterion that scores highly 
for those individuals with a strongly positive RF or ACPA (scoring 3 points), 
acknowledging that a strongly positive RF is of equal weighting in RA diagnosis 
to strongly positive ACPA. RF and ACPA co-exist in RA more than would be 
expected by chance alone: a study of established RA (n=784) in Sheffield, UK, 
observed that 93% of RF patients were also ACPA positive [3]. The clustering of 
RF and ACPA is more pronounced with high titre RF as a study of 102 RA patients 
observed that 61% of RA patients with a RF >50 U/ml were ACPA positive (the 
expected frequency is 18.5% if RF>50 U/ml and ACPA occurred independently of 
each other) as opposed to only 25% of RA patients with a RF <50 U/ml [5]. This 
raises the possibility that a common process generates high titre RF and ACPA 
and determines a poorer prognosis in RA.  
 
An important recent pooled analysis of 2234 RA patients casts significant doubt 
on the concept that smoking specifically associates with ACPA alone as RA ever 
smokers (n=1318) were found to have no significant association with single ACPA 
positivity, (OR 0.83, 95% CI 0.56-1.24), compared to ACPA and RF double 
seropositivity (OR 1.4, 95% CI 1.06-1.84) [6].  Moreover, this paper included a 
large cohort (n=9575) of non-RA cases. We suggest that in this non-RA cohort a 
much higher frequency of double autoantibody seropositivity for RF and ACPA 
exists than would be expected if RF and ACPA developed independently. 
Clustering of RF and ACPA was more pronounced in ever smokers (7 fold higher 
than expected) than never smokers (3 fold higher than expected), but was evident 
in the never smokers nonetheless. Accordingly, we have investigated this 
clustering of RF and ACPA in both smokers and never smokers for the first time. 
To date no studies have addressed if this co-existence is increased in those 
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strongly positive for RF irrespective of smoking. Surprisingly given the obvious 
clinical importance ascribed to a strongly positive RF, a literature search revealed 
no studies investigating the relationship between the presence and levels of a 
positive RF, cigarette smoking, carriage of the SE alleles and the frequency of 
ACPA in RA. We therefore set out to answer the following two important 
questions: Is there a relationship between RF levels at RA diagnosis and the 
likelihood of testing positive for ACPA irrespective of the smoking history of the 
patient? Is there a relationship between the presence of the shared epitope, RF 
and ACPA irrespective of the smoking history of the patient?  
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3.3  Methods 
Two cohorts of RA patients were studied. Cohort 1 consisted of males and 
females attending routine rheumatology clinics at the Royal Cornwall Hospital, 
Cornwall, UK from February 2015 to August 2016. The data was anonymised at 
source, collected as part of project IRAS ID 194833, approved by South West 
Regional Ethical Committee. This cohort was selected to achieve an intended 
total cohort size of six hundred gender matched patients for analysis. Patients 
reviewed in clinic with a new or existing diagnosis of RA during the study period 
were included for analysis, with 60 patients subsequently excluded (see below). 
298 male and 300 female RA patients were included to provide a suitable cohort 
size for serological subgroup analysis, with approximately equal numbers of each 
gender selected to detect potential differences in smoking rates, age of onset, 
and serological status rather than to represent the overall male to female 
prevalence ratio. Recruitment ceased when the target cohort size was reached. 
Data was recorded by clinicians in a standard questionnaire via face-to-face 
interview.  Missing data was obtained by follow up telephone conversation. Age, 
age of RA onset, disease duration, smoking history prior to disease development, 
RF levels at disease onset and subsequent ACPA levels were recorded as part 
of routine clinical practice. Testing for SE status does not form part of routine 
clinical practice and was therefore unavailable.  All patients fulfilled the 2010 
ACR/EULAR RA criteria at diagnosis [4]. 
 
RF was measured with Tina-quant Rheumatoid Factors I1 Test System, by Roche 
Diagnostics Corporation. A value of < 14 IU/ml was considered as negative as 
per manufacturer guidelines.  ACPA was measured by Roche Modular Analytics 
Second Generation E170 Anti-CCP analysis, with a negative value of <17 U/ml 
as per manufacturer guidelines. 
  
As per guidelines, a negative RF or ACPA was defined as a level within the normal 
range, a weakly positive RF or ACPA <3 times the upper limit of normal and a 
strongly positive RF or ACPA >3 times the upper limit of normal [4].  Six percent 
(18/318) of females and 12% (40/340) of males were excluded during the 
collection period due to >20 years between smoking and RA diagnosis. A further 
2/340 males were excluded due to incomplete data on subsequent review. Social 
deprivation analysis was undertaken through the UK government validated Index 
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of Multiple Deprivation (IMD) [7], a deprivation rank score of 32,844 
neighbourhoods weighted by income, health/disability, education, 
housing/service access, crime and living environment, converted to equal 
deciles. 
 
Table 2. Cohort 1 demographic data. 
 
A second cohort (n=409) of RA patients consisted of 154 males and 255 females 
attending rheumatology clinics at the Haywood Rheumatology Centre in North 
Staffordshire, UK, in whom SE status had been determined. Patients were 
recruited consecutively from a clinic established to monitor the effects of disease 
modifying anti-rheumatic drugs including hydroxychloroquine, sulfasalazine, D-
penicillamine, gold and methotrexate. Sample collection occurred from 1994 to 
2002 as part of a study to investigate the relationship between genetic factors 
and outcome in RA. Ethical approval was obtained from the North Staffordshire 
local research ethics committee and written informed consent was provided by 
all patients. All patients had established disease (median disease duration 9.2 
years), fulfilling 1987 RA criteria at time of diagnosis [8]. A full smoking history 
was obtained on 386/409 patients. Smokers were defined as smoking >1 
cigarette (or equivalent)/day for >1year, and categorised according to pack years 
smoked [9]. All patients had been genotyped for HLA-DRB1 as previously 
described [10].  
  
 Males 
n = 298 
Females 
n = 300 
Median age (yrs, IQR) 64 (55-73) 64 (52-72) 
Median age at disease onset 
(yrs, IQR) 
54 (46-63) 54 (41-62) 
Median disease duration (yrs, 
IQR) 
7 (4-12) 7 (2-12) 
RF + (%) 232/298 (78%) 225/300 (75%) 
ACPA + (%) 217/298 (73%) 208/300 (69%) 
Mean IMD (SD) 4.36 (1.69) 4.38 (1.79) 
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Table 3. Cohort 2 demographic data. 
 
IgM RF was measured by nephelometry at disease onset while ACPA was 
measured subsequently using a commercially available anti-CCP2 ELISA (Axis-
Shield, Dundee, Scotland).  RF levels were reported in International Units (IU). A 
level > 60 -180 IU/ml was considered weakly positive and a level >180 IU/ml was 
strongly positive. ACPA measurements above 5 units/ml were considered 
positive.   
 
3.3.1  Statistical analyses 
 
Chi square tests and multivariate logistic regression analysis were used to 
examine the relationships between ACPA, IgM RF, HLA-DRB1 shared epitope 
and cigarette smoking. Analyses were adjusted for age, sex and disease duration 
where appropriate. Mann-Whitney U testing was performed to analyse 
differences in RF titre. Given the heterogeneity between different cohorts, no 
pooled analysis was made. 
 
All analyses were carried out using the Number Cruncher Statistical System for 
Windows (NCSS60). 
 
3.4 Results 
 
3.4.1 Cohort 1  
 Males 
n = 154 
Females 
n = 255 
Median age (yrs, IQR) 59 (49 – 65) 58 (50 -68) 
Median age at disease onset 
(yrs, IQR) 
49 (40 – 56) 48 (38 – 56) 
Median disease duration (yrs, 
IQR) 
9.0 (5 -12) 9.3 (5 – 13) 
 RF + (%) 107/154 (69.4%) 140/255 (54.9%) 
ACPA + (%) 124/154 (80.5%) 183/255 (71.8%) 
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Twenty four percent (141/598) of patients were RF negative. The proportion of 
RF negative patients did not differ significantly with gender, with 75/300 (25%) 
females and 66/298 (22%) males testing negative. A weakly positive RF was 
observed in 77/300 (26%) females and 70/298 (23%) males, while a strongly 
positive RF was observed in 148/300 (49%) females and 162/298 (54%) males. 
 
Table 4. Cohort 1 relationship between smoking, RF and ACPA. 
 Median RF ACPA neg 
(%) 
ACPA pos (%) Odds ratio (95% 
CI) 
Never smoker, RF neg neg 56 (79) 15 (21) 1.0 (reference) * 
1-10 PY, RF neg neg 13 (87) 2 (13) 0.57  
(0.06-3.0) † 
11-20 PY, RF neg neg 13 (76) 4 (24) 1.2(0.2-4.5) ‡ 
>20 PY, RF neg neg 26 (68) 12 (32) 1.7(0.6-4.6) # 
 
    
Never smoker, RF weak 
pos 
22 (17-31) 21 (33) 43 (67) 7.6(3.3-17.9) * 
1-10 PY, RF weak pos 25 (19-29) 2 (12) 14 (88) 26.1(4.9-249.4) † 
11-20 PY, RF weak pos 25 (21-31) 4 (15) 22 (85) 20.5(5.6-90.8) ‡ 
>20 PY, RF weak pos 27 (17-30) 11 (27) 30 (73) 10.2(3.8-27.6) # 
 
    
Never smoker, RF strong 
pos 
115 (71-227) 12 (12) 88 (88) 27.4(12.6-59.3) * 
1-10 PY, RF strong pos 139 (76-277) 5 (13) 34 (87) 25.4(7.8-94.1) † 
11-20 PY, RF strong pos 153 (67-495) 4 (8) 46 (92) 42.9(12.3-182.0) ‡ 
>20 PY, RF strong pos 166 (92-283) 5 (4) 116 (96) 86.6(27.9-307.6) # 
 
Cochrane- Armitage test for OR trend: * P < 0.0001, † P < 0.0001, ‡ P < 0.0001, # P < 0.0001. 
 
Seventy one percent (425/598) of patients were ACPA positive, with 393/425 
(93%) demonstrating strong positivity as per ACR/EULAR criteria [4]. There was 
no significant difference in ACPA positivity between males and females (217/298 
(73%) vs. 208/300 (70%), p=0.32).  There was a significant trend of increasing 
ACPA positivity rates with increasing levels of RF without significant differences 
between patients who had never or ever smoked (never smoked: 15/71 (21%) 
RF-ve, vs. 43/64 (67%) RF weak +ve, vs 88/100 (88%) RF strong +ve. Ever 
smoked: 18/70 (26%) RF-ve vs. 66/83 (80%) RF weak +ve vs.196/210 (93%) RF 
strong +ve) (Table 1). There was no relationship between ACPA positivity and 
smoking in patients who were RF negative (OR (95% CI), 1.3 (0.4 – 5.1)). 
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Sixty one percent (363/598) of patients had ever smoked, and males were more 
likely to have ever smoked than females:  214/298 (72%) vs. 149/300 (50%), OR 
(95% CI) 2.6 (1.8 – 3.7), p < 0.0001. Smoking >20 pack years was observed in 
200/598 (33%), and was significantly different between males and females: 
130/298 (44%) vs. 70/300 (23%), OR (95% CI) 2.5 (1.8 – 3.7), p < 0.0001.  
Patients with >20 pack years demonstrated significantly increased risk of ACPA 
positive RA compared to patients who had never smoked (158/200 (79%) vs. 
146/235 (62%), OR (95% CI) 2.3(1.5-3.6), p < 0.0001).  
 
There was a significant difference in the proportion of strongly RF positive 
patients between those who had never smoked (100/235, 43%) and those who 
had smoked >20 pack years 121/200 (61%), (OR (95% CI), 2.1 (1.4 – 3.1), 
p=0.0002.  
 
No significant differences were seen in ACPA positivity amongst weakly positive 
RF patients who had never smoked (43/64) and weakly positive RF ever smokers 
(66/83), irrespective of smoking status or pack years smoked (OR (95% CI), 1.9 
(0.8 –4.3)).  
 
Strongly RF seropositive never smokers demonstrated ACPA seropositivity 
predominance (88/100, 88%), as did strongly RF seropositive smokers of >20 
pack years (116/121, 96%, Table 4). However, this numerically higher rate of 
ACPA positivity in strongly RF seropositive >20 pack year smokers is likely to be 
explained by significantly higher median RF titres of 166 (IQR 92-283), compared 
to a median RF in never smokers with a strongly positive RF of 115 (IQR 71-226), 
p=0.008.  
 
Given the above, and the dominant ACPA positive prevalence (88%) in RF 
strongly positive never smokers compared to just 32% of RF negative smokers 
of >20 pack years, odds ratio (OR) risk increases were calculated for both ever 
smokers (as a combined cohort) and never smokers, with RF negative, weakly 
positive and strongly positive titres (RF negative never smokers as referent). 
Amongst ever smokers (n=365), a stepwise increase in OR is seen, rising from 
1.3 (95% CI 0.6-3.1) for RF negative, to 14.5 (95% CI 6.2-34.2) for RF weakly 
positive, to 52.3 (95% CI 22.4-124.2) for RF strongly positive cases. Whilst not 
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as dramatic, the OR rise for never smokers (n=235) shows a similar trend; OR 
7.6 (95% CI 3.3-17.9) for RF weakly positive, rising to 27.4 (95% CI 11.2-68.7) 
for strongly positive cases (Figure 9). 
 
Figure 9. Odds ratio risk of ACPA positivity in RA 
 
 
From the strength of relationship seen for OR increases with RF titre irrespective 
of smoking, a further cohort (cohort 2, North Staffordshire) was analysed to 
determine whether ACPA was determined by increasing titres of RF with 
reference to SE status. 
 
3.4.2 Cohort 2 
 
Nearly 40% (162/409) of patients were RF negative in a second cohort of patients 
in which the SE status had been determined. Seventy five percent (307/409) of 
patients were ACPA positive (Table 5). There was no significant difference 
between males and females in the proportion of RF positive or ACPA positive 
patients.  Sixty one percent (235/386) of patients had ever smoked, with a 
significant difference between males and females (males, 123/150 (82%) vs 
females, 120/236 (51%), OR 4.3 (95% CI 2.6-7.4), p < 0.0001). As in cohort 1, 
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there was no relationship between ACPA positivity and smoking in RF negative 
patients (37/74 (50%) never smoked, v 45/73 (61.6%) ever smoked; OR 1.6 (95% 
CI 0.8–3.3).  
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Table 5. Cohort 2 relationship between RF levels, ACPA and shared epitope status (n=409). 
 
 SE=0 SE=1 SE=2 
 ACPA neg ACPA pos OR (95% CI) ACPA neg ACPA pos OR (95% CI) ACPA 
neg 
ACPA pos OR (95% CI) 
RF  n (%) n (%)  n (%) n (%)  n (%) n (%)  
   
 
  
 
  
 
Negative 23 (59.0) 16 (41.0) Referent 29 (43.3) 38 (56.7) 2.3(1.1-5.6) 15 (26.8) 41 (73.2) 4.8(2.0-12.8) 
Weak +ve 7(30.4) 16(69.6) 3.1(1.0-11.4) 7(11.9) 52(81.1) 10.0(3.5-33.8) 5(10.9) 41(89.1) 10.7(3.4-43.1) 
Strong  +ve 
 
6(37.5) 10(62.5) 2.3(0.6-9.4) 8(13.1) 53(86.9) 
 
9.0(3.3-28.8) 2(4.8) 40(95.2) 23.1(5.5-200) 
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We found that the proportion of ACPA positive patients increased with RF 
positivity in patients carrying 1 or 2 SE alleles but there was only a weak or no 
relationship in patients lacking a SE allele (Table 5). In RF positive patients the 
number of copies of the SE (either 1 or 2) was not significant in determining ACPA 
positivity. However, in RF negative patients, the rate of ACPA positivity appeared 
to have a greater dependence on number of SE copies, although it did not 
achieve significance (57% vs 73%, p=0.06). 
 
Multivariate logistic regression analysis confirmed that RF positivity was strongly 
associated with anti-CCP positivity (Table 6). Ever having smoked was only 
weakly associated with ACPA positivity, (Model 1) whereby RF positivity and the 
presence of the SE were significantly associated. Similar associations were seen 
in models in which having smoked for >20 years (Model 2) or accumulating >20 
pack years (Model 3) were compared with never having smoked, though the 
association with ACPA was not significant in Model 3. 
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Table 6. Cohort 2 multivariate logistic regression analysis of variables associated with anti-CCP positivity in RA (n=386). 
 Model 1  Model 2  Model 3 
 OR (95% CI) P  OR (95% CI) P  OR (95% CI) P 
Age 1.00 (0.98 -1.02) NS Age 1.00 (0.98 -1.02) NS Age 1.00 (0.98 – 1.02) NS 
Male sex 1.32 (0.74 – 2.34) NS Male sex 1.72 (0.80 – 3.68) NS Male sex 2.32 (1.05 – 5.12) 0.04 
Duration (per 
yr) 
1.03 (0.98 – 1.07) NS Duration (per yr) 1.03 (0.98 – 1.07) NS Duration (per yr) 1.03 (0.98 – 1.07) NS 
Shared epitope 3.00 (1.67 – 5.37) 0.0002 Shared epitope 2.26 (1.06 – 4.79) 0.03 Shared epitope 2.45 (1.16 -5.17) 0.02 
RF 4.23 (2.54 – 7.06) <0.0001 RF 6.09 (3.21 – 11.54) <0.0001 RF 4.41 (2.35 – 8.25) <0.0001 
Ever smoked 1.73 (1.01 – 2.94) 0.04 Years smoked >20 2.31 (1.15 – 4.68) 0.02 Pack years > 20 1.83 (0.90 – 3.69) 0.09 
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3.5 Discussion 
We have noted several interesting observations on the determination of ACPA 
positive RA. Smoking was associated with ACPA positivity only in RF positive 
patients, and especially in patients who were strongly RF positive.  Furthermore, 
there was a strong relationship between increasing RF levels and ACPA positivity 
in RA, irrespective of smoking (Table 2). Underpinning this relationship is carriage 
of the SE. In RA patients who did not carry the SE, we found only weak, or no 
relationship between RF levels and the frequency of ACPA positivity. This 
suggests that the co-existence of 2 RA-associated autoantibodies cannot be 
explained by a propensity for antibody production per se as the frequency of 
ACPA positivity in patients without the SE who were RF negative was not 
significantly different to those who were RF strongly positive.  
 
There appeared to be a difference in the importance of the number of SE alleles 
between RF negative and RF positive patients.  In those patients who were 
weakly or strongly RF positive, the number of copies of the SE (either 1 or 2) was 
not significant in determining ACPA positivity. However, in RF negative patients, 
the rate of ACPA positivity appeared to have a greater dependence on number of 
SE copies. If larger studies confirm a significant difference this may pave the way 
for investigating distinct SE-associated mechanisms giving rise to a positive 
ACPA in patients positive or negative for RF. 
 
The modest relationship between smoking and ACPA positivity appeared to be 
due to an increased propensity for smokers to be RF positive. In logistic 
regression analysis, one model suggested that smoking may be an independent 
risk factor for ACPA positivity in RA. However, this relationship was far less 
apparent than the dominant relationship between RF positivity and ACPA 
positivity. Smoking appeared to demonstrate a significant relationship between 
the development of both RF and ACPA in the patients studied. There was a clear 
relationship between smoking in terms of pack years and RF, and ACPA positivity 
in RA. There did not appear to be a relationship between smoking in terms of 
pack years smoked and positivity for ACPA alone.  Significantly fewer patients 
with >20 pack years and weakly positive RF were ACPA positive compared to 
never smokers with positive RF of any titre, further strengthening the argument 
that the principal determinants of ACPA positivity are RF and SE carriage rather 
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than smoking per se. However, these sub-groups were relatively small and larger 
studies are required to investigate these sub-groups further.  
 
We excluded 58/658 patients who had ceased smoking >20 years prior to RA 
onset.  Previous studies have demonstrated no increased risk of RA in individuals 
who have stopped smoking before this time point [11,12]. This cohort 
demonstrated similar seropositivity trends to RA patients who had never smoked 
(data not shown).  We excluded these patients so that the calculated association 
between smoking and ACPA positivity was not under represented.  
 
It is noteworthy that the prevalence of RF negative RA was low in cohort 1 (24%). 
Cornwall has been noted as the poorest region of England [13] and the low 
prevalence of RF negative RA may reflect a high proportion of socially deprived 
individuals in this cohort; the majority of the patients were in the most deprived 
40% of UK society as 180/300 (60%) females and 173/298 (58%) males had an 
IMD decile score of 4 or lower. RF positivity associates with social deprivation in 
other European RA populations [14,15].   
 
This study does have limitations due to its cross-sectional nature.  Different 
classification criteria were used for each cohort.  However, as both cohorts are of 
patients with established RA (median disease duration for cohort 1= 7yrs, cohort 
2= 9yrs), we do not feel that utilisation of the 1987 RA criteria for cohort 2 and the 
2010 criteria for cohort 1 of importance as it is well established that both 
classification criteria identify patients with established RA. The 2010 classification 
criteria identifies patients with RA at an earlier time point than the 1987 criteria, 
however at 5 years of disease duration the number of patients identified by either 
criteria are the same [16].   
 
Patient notes were analysed to ascertain RF levels at the time of diagnosis in 
cohort 1.  There is the potential for RF titres to vary with disease duration and 
treatment. A study of 640 inflammatory polyarthritis patients from the Norfolk 
Arthritis Register demonstrated that over a five-year period, RF status changed 
in 17% of patients [17]. Critically, this change in RF status was strongly linked to 
baseline anti-CCP status in this study. The status of RF was 8 times more likely 
to change in patients with a discordant baseline autoantibody status (RF+/ACPA- 
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or RF-/ACPA+) than in those who were either double negative or double positive 
(OR 8.2; 95% CI, 4.9 to 13.7; p<0.00001). Thus, RF-negative individuals who 
seroconverted to RF positive were more likely to be ACPA positive at baseline 
than were those who remained RF negative (OR, 7.6; 95% CI, 3.8 to 15.3); 
similarly, those who converted from RF positive to RF negative were more likely 
to be ACPA negative at baseline than were those who remained RF positive (OR, 
7.4; 95% CI, 3.5 to 15.6). Ergo, we feel our data has the potential to have 
underestimated the relationship between RF and ACPA as the RF test was only 
undertaken once at the time of diagnosis as per usual clinical practice. ACPA 
positivity in the same study remained remarkably constant over 5 years of follow 
up, with only 2% of ACPA negative patients seroconverting to positive, and 4.6% 
ACPA positive individuals becoming negative between baseline and 5 years. We 
therefore believe that the cross-sectional nature of ACPA testing would not 
significantly influence the findings reported here. The authors suggested that 
repeated testing of ACPA or RF in inflammatory arthritis patients should not be 
undertaken in routine clinical practice, which also reflects our clinical practice.   
Established literature suggests that therapies that target the adaptive immune 
response, such as rituximab and abatacept, can significantly reduce anti-CCP2 
IgG levels [18]. No such reductions in anti-CCP2 IgG levels have been noted in 
patients treated with methotrexate, tumour necrosis factor inhibitors or 
tocilizumab. In cohort 1, 18/598 (3%) had an ACPA of below 140 U/ml, with a 
theoretical possibility of changing from a strongly positive to a weakly positive or 
negative ACPA through treatment with rituximab or abatacept. However, only 
5/598 (0.8%) patients had an ACPA test after treatment with such agents. Whilst 
we acknowledge that treatment in a cross-sectional cohort may lead to possible 
misclassification bias due to the mechanism of action of specific disease 
modifying therapies, the numbers affected in this study are insignificant. 
 
We feel these results can be reconciled with a landmark Swedish study identifying 
smoking and carriage of the SE alleles as risk factors for ACPA positive RA [1]. 
In this study carriage of the SE was significantly associated with ACPA positive/ 
RF negative RA rather than RF positive/ ACPA negative RA. Consequently, the 
authors suggested that the primary process in RA involved anticitrulline immunity 
influenced by an interaction between smoking and carriage of the SE. However, 
in this study only a very small proportion of the ACPA positive RA cases were RF 
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negative (13%) and the clear majority (87%) were double positive for both RA 
autoantibodies (far more than would be expected by chance alone). Ergo, given 
the overall strong association between the carriage of SE alleles and ACPA 
positivity it follows that the SE is principally associated with ACPA positive / RF 
positive RA. Likewise, the observation that smoking interacts with the SE to 
generate ACPA positivity overall in RA is factually correct; more precisely this 
interaction is between smoking, the SE and both RA autoantibodies. This has 
recently been proven to be the case as pooled analysis of 2234 RA patients has 
suggested that smoking interacts with the SE to generate multiple RA associated 
antibodies rather than ACPA alone [6].   
 
We have suggested that the citrullinated heavy chain of immunoglobulin G (IgG) 
is the dominant antigen in RA and generated by B cells in the lungs of smokers; 
a process facilitated by SE alleles with the B cell acting as both an antigen 
presenting cell and the source of the antigen [19]. This process need not be 
exclusive to the lung as the rheumatoid joint could be the host for B cell activation 
and therefore could theoretically occur in both smokers and never smokers.  
 
Citrullination of the Fc region of IgG may generate an antibody response specific 
to RA, consequently generating both a strongly positive RF and ACPA response. 
This hypothesis is supported by the recent finding of citrullinated IgG in the 
synovial tissues of RA patients, with IgG as a target of peptidylarginine deiminase 
(PAD) 2 and PAD4 activity in RA synovial biopsy tissues [20]. Another recent 
study observed over 80 different citrullinated peptides in the RA synovial fluid 
including the heavy chain of IgG. [21]. Furthermore, the demonstration of 
bispecific antibodies against cyclic citrullinated peptides and IgG in RA suggests 
that citrullinated IgG may generate both a RF and ACPA response [22].  
 
We do not consider that ACPA positivity is likely to have given rise to a 
subsequent RF response in the RA patients studied here as a study of the RF 
isotypes (IgM, IgG and IgA) in individuals who subsequently developed RA were 
more likely to be present before the development of various ACPAs (fibrinogen, 
α-enolase, triple helical collagen type II, filaggrin and vimentin). Previous data 
suggests the frequency of ever being positive for IgM-RF in individuals who 
developed RA, but were negative for the above ACPA was 16–31% [23].  
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Recent analysis of specific immunoglobulin subtypes to ACPA, specifically IgG 
types 1-4 to anti-CCP, has been demonstrated [24]. It has been recently 
suggested that IgG1 and IgG4 anti-CCP antibodies associate with the shared 
epitope, and IgG2 associates with smoking. However, low patient numbers in 
analysis of individual subtype classes limit the applicability of this data. 
Furthermore, other evidence suggests that the shared epitope has been 
associated with elevated IgG3 and IgG2 ACPA titres. Selective support of the Th1 
response among RA patients homozygous for HLA-DRB1*04 has been 
suggested in IgG3 subtypes [25].  
 
Our study does not aim to address specific IgG subclasses [24] and IgA 
responses [26] to ACPA. This would be worthy of further study taking into account 
RF levels at diagnosis, and the smoking history of patients. 
 
3.6 Conclusion 
 
These results raise important questions about the relationship between RF and 
ACPA in RA and the potential mechanisms underlying this relationship. We feel 
that processes involving the simultaneous or sequential generation of both RF 
and ACPA need to be considered in further studies investigating RA pathogenesis 
irrespective of smoking.  
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Chapter 4.  Lysine carbamylation and arginine citrullination at the Fc region 
of immunoglobulin G potentiates a risk factor for rheumatoid arthritis 
development. 
 
Citation: Hutchinson D, Clarke A, Heesom K, Murphy D, Eggleton P. 
Carbamylation/citrullination of IgGFc in bronchiectasis, established RA with 
bronchiectasis and RA smokers: a potential risk factor for disease. ERJ Open 
Res 2017;3:0018-2017. 
 
4.1 Abstract 
 
Objective: To investigate the mechanisms by which bronchiectasis (BR) triggers 
rheumatoid arthritis (RA). BR strongly associates with concurrent rheumatoid 
factor (RF) and anti-cyclic citrullinated peptide antibody (anti-CCP) positivity and 
RA development. Anti-carbamylated protein antibodies (anti-CarP) have also 
been observed in BR patients. Given that immunoglobulin G (IgG) is the sole RF 
antigen, we hypothesize that post-translational modifications to IgG explain 
clustering of RA associated autoantibodies in both RA and BR. 
 
Methods: Protein analysis was undertaken on 22 individuals. Four individuals had 
a diagnosis of BR and subsequently developed RA up to 18 months following 
blood sampling. Four individuals had a diagnosis of RA and four individuals with 
both BR and RA. Ten were healthy controls. The distribution of lysine (Lys) 
carbamylation and arginine (Arg) citrullination within the heavy chain of IgG 
(IgGH) from individuals was undertaken by mass spectrometry and 
immunoblotting. 
 
Results: This is the first report of citrullinated IgG. Citrullination and carbamylation 
of IgG appeared to be universal. However, citrullination of Arg and/or 
carbamylation of Lys in the RF binding site of IgG CH2 domain was observed in 
5/12 (41.6%) patients (1 BR, 2 RA and 2 BRRA), but in no control subjects (0/10, 
0 %). 
 
Discussion: These results suggest that post-translationally modified IgGHFc is a 
potential universal antigen in RA. This may explain the clustering of RA 
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associated autoantibodies in RA and in individuals at risk of RA. Furthermore, 
post-translational IgGHFc modifications affect polarity, altering the binding to the 
Fc receptors of inflammatory cells in RA. 
 
4.2 Introduction 
The lung is now considered a site for RA development. Bronchiectasis (BR) is a 
particularly strong risk factor for RA. We prospectively followed 122 BR patients: 
four developed RA over an 18 month period [1]. The presence of both RF and 
anti-CCP in the sera of patients with BR was significantly more prevalent than in 
healthy controls and predicted the development of RA. Interestingly, a significant 
association between the two RA autoantibodies was observed. We noted that 
4/31 (13%) RF positive BR patients were strongly anti-CCP positive, versus 0/91 
(0%) RF negative BR patients [1]. These results demonstrate a significant 
clustering of RF and anti-CCP in those BR patients who later develop RA. 
 
BR provides a non-smoking model of RA development given the absence of 
smoking in the majority of the patients studied (.  A pathological characteristic 
shared between BR and RA is the presence of tertiary lymphoid structures. 
Bronchial associated lymphoid tissue (BALT) was first described in BR [2] and 
identical lymphoid tissue is also present in the synovium of RA patients [3]. 
Smoking, another important risk factor for RA development, associates with BALT 
development and the presence of BALT is associated with both RF and anti-CCP 
in established RA with pulmonary disease [5]. 
  
A study of early RA (<1 year) observed lymphocyte infiltration more frequently in 
anti-citrullinated peptide antibody (ACPA) positive patients (9/18, 50%), 
compared to ACPA-negative patients (1/6, 17%), on mucosal lung biopsy [5]. 
Furthermore, germinal centres, B cells and plasma cells were exclusive to ACPA-
positive patients. This suggests that BALT development potentially initiates RA 
and is not necessarily a secondary consequence of disease activity in established 
RA. Recently, anti-CarP were described as a third autoantibody system in RA. 
Again, these RA specific autoantibodies are more frequent in BR (3/80, 3.8%) 
compared to healthy controls (0/36, 0%) [6]. 
  
Given this evidence, we have recently suggested that the potential antigenicity of 
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the heavy chain of immunoglobulin G (IgGH) is triggered by B cell activation in 
the lung. This process involves post-translational modification to IgGH 
orchestrating a local (lung) and distant (joint) immune response that involves the 
production of RF, ACPA and anti-CarP, triggering RA [7]. Accordingly, we have 
studied the sera of 22 individuals: four BR patients prior to RA development, eight 
RA patients (four with BR and four without), and 10 healthy controls, analysing 
individual IgGH for sites of potential citrullination and carbamylation.  
 
4.3 Methods 
 
4.3.1 Patient population 
 
Sera from patients and controls were selected from the BRACRA (Bronchiectasis, 
Asthma, Control, Rheumatoid Arthritis) study: a prospective, multicentre, case–
control, observational study, conducted to determine the relationship between 
bronchiectasis and RA development. The overall study design, including assays 
used for the determination of RF and anti-CCP levels and approval has been 
previously reported [1]. All the RA patients fulfilled the ACR 2010 classification 
criteria for RA and the definition of a negative, low positive and high positive RF 
and anti-CCP is as per the above classification criteria [8]. 
 
4.3.2  Study design 
 
Serum samples from four BR seroconverts (anti-CCP positive prior to developing 
RA), four RA smokers without overt lung disease, four BRRA never smokers and 
ten control subjects (five never smokers and five current/ever smokers) were 
studied.    
 
Equal serum protein loads as determined by nanodrop spectrometry were 
separated on 8-16% SDS-PAGE gradient gels.  A protein band identified by 
immunoblotting with anti-human citrulline antibody, contained numerous 
citrullinated proteins in the region of 37-50 kilodaltons (KDa). The bands were 
excised from Bio-safe™ Coomasie stained gradient gels and subjected to in-gel 
tryptic digestion using a DigestPro automated digestion unit (Intavis Ltd.). The 
resulting peptides were fractionated using an Ultimate 3000 nanoHPLC system. 
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Tandem mass spectra were acquired using an LTQ- Orbitrap Velos mass 
spectrometer controlled by Xcalibur 2.1 software (Thermo Scientific) and 
operated in data-dependent acquisition mode. The raw data files were processed 
and quantified using Proteome Discoverer software v1.4 (Thermo Scientific) and 
searched against the UniProt Human database (131351 entries) using the 
SEQUEST algorithm. Search criteria routinely included carbamidomethylation of 
cysteine (+57.0214) as a fixed modification and oxidation of methionine as a 
variable modification. In addition, citrullination (+0.984Da) at Arg, Asn and Gln 
and carbamylation (+43.006Da) at Lys, Met, Arg, Ser, Thr and Tyr, were included 
as variable modifications in two separate searches. Only peptides where 
citrullination at Arg and carbamylation at Lys were ranked 1 in the respective 
searches (indicating that those residues were the most likely sites of modification) 
were considered. This identified IgG heavy chain as one of the most abundant 
proteins identified as being citrullinated and carbamylated. The amino acid 
sequence of IgG was obtained from the Uniprot database and then submitted to 
a phyre2 search (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) to 
obtain models in 3D. The UCSF Chimera protein viewing software 
(http://www.rbvi.ucsf.edu/chimera/) was used to annotate the amino acid 
modifications of interest to highlight the citrullinated and carbamylated sites on 
each IgG molecule.  
 
To confirm the presence of citrullination and carbamylation in the light and heavy 
chains of IgG from our test subjects, IgG was purified from individual sera by 
protein G affinity chromotography using an AKTA FLPC system (GE healthcare) 
employing unicorn 5.1 software. Protein aliquots of IgG were run on SDS-PAGE 
under reducing conditions to separate the 25 kDa light (IgGL)  and 50 kDa heavy 
chain (IgGH),  then immunoblotted and probed with primary anti-citrulline 
(ab100932) or anti-carbamyl-lysine (ab175132) specific antibodies. Post-
translational modifications were detected by probing the blot with 1:15000 
dilutions of IR Dye800-labeled anti-rabbit secondary antibody (Li-Cor P/N 925-
32213) followed by infrared imaging (Li-Cor Odyssey infra imaging system).  
 
4.4 Results 
 
Identification of citrullination and carbamylation residues of IgG in the blood of 
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BR, RA and BRRA patients and controls.  We examined the degree of 
carbamylated Lys (hcit) and citrullinated Arg (cit) residues in the proteins 
recovered from the blood of our patient and control subject cohorts (Table 7).  
 
Table 7. Demographics of individual subjects and identification of 
individual post-translational modifications in the RF binding site in the CH2 
domain of the Fc region of their serum IgG 
ID Cohort Age Gender Smoking 
Anti-
CCP 
Actual 
Result 
ACR Anti-
CCP 
Interpretation 
RF 
Actual 
result 
(IU/ml) 
ACR RF 
Interpretation 
1* BR 72 F Never 522 High +ve 56.2¶/§ High +ve 
2* BR 67 F Ex 43 High +ve 16 Low +ve 
3* BR 77 M Never 340 High +ve 22 Low +ve 
4* BR 71 F Ex 92 High +ve 130 High +ve 
5 BRRA 75 F Never 88 High +ve 27.5§ Low +ve 
6 BRRA 81 F Never 600 High +ve 130 High +ve 
7 BRRA 60 F Never 229 High +ve 130¶ High +ve 
8 BRRA 66 F Never 340 High +ve 130 High +ve 
9 RA 52 F Current 197 High +ve 74.6§ High +ve 
10 RA 38 F Current 6.9 Negative 78.1¶ High +ve 
11 RA 44 F Current 340 High +ve 130 High +ve 
12 RA 62 F Current 1.5 Negative 8.4 Negative 
13 Control 53 F Never 1 Negative <7.0 Negative 
14 Control 80 F Never 1 Negative <7.0 Negative 
15 Control 68 F Never 1 Negative <7.0 Negative 
16 Control 40 F Never 1 Negative <7.0 Negative 
17 Control 80 F Never 1 Negative <7.0 Negative 
18 Control 37 F Current 1 Negative 7.8 Negative 
19 Control 54 F Current 1 Negative <7.0 Negative 
20 Control 52 F Current 1 Negative <7.0 Negative 
21 Control 81 M Ex 1 Negative <7.0 Negative 
22 Control 56 F Current 1 Negative <7.0 Negative 
*Bronchiectasis patients who went on to develop RA 12-18 months - post 
sampling. 
Key to post translational modifications observed:- §hcit of Lys at RF 
binding site; ¶cit of Arg at RF binding site 
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We focussed on the distribution of hcit and cit modifications relevant to IgG, 
especially the CH2 domain that contains the RF, C1q and FcR binding peptides 
(Fig. 10A). Using mass spectrometry, we found 8/34 Lys carbamylated and 3/12 
Arg citrullinated (Fig. 10B) in the IgGH region. We identified modified arginines 
most frequently in the variable region and CH3 domains of IgG in patients and 
control subjects alike, but only observed citrullinated Arg and/or carbamylated Lys 
modifications (Fig. 10B) in the RF binding site of IgG CH2 domain of 5/12 (41.6%) 
patients investigated (1 BR, 2 RA and 2 BRRA), but in no control subjects (0/10, 
0%) see Table 7.  Furthermore, the degree of carbamylation of the CH2 domain 
varied between cohorts with BR>BRRA>HC>RA (Fig. 10C). In contrast, the 
degree of carbamylation in other IgGH domains was very similar for all cohorts 
(Fig. 10D).   
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Figure 10. Lysine carbamylation and arginine citrullination in IgGH.  
 
 
 
A. Schematic model of IgGH dimer showing RF binding sites (red). 
B. IgGH fragment showing post-translational modification of Lys (blue – left 
model) or Arg (blue – right model), detected at the RF binding site (red- 
both models) in individual patients.  Green- other unmodified Lys (left 
model) or Arg (right model). Orange- other modified Lys (left model) or Arg 
(right model). 
C. Proportion of LYShcit peptides (n = 66) found in the CH2 domains of 
individual cohorts of patients and control subjects.  
D. Proportion of LYShcit peptides (n = 63) found in the IgG VR, CH1 & CH3 
domains of individual cohorts of patients and control subjects.  
 
The presence of citrullination and carbamylation IgGH and/or IgGL was tested by 
immunoblotting the sera with anti-citrulline and anti-carbamyl-lysine antibody 
(Fig. 11A and C). The presence of citrullination was confined only to the 50 kDa 
IgGH of all subjects (Fig. 11B). Similarly the IgGH in all subjects were 
carbamylated, but we also observed some carbamylation in some patient and 
control IgGL (Fig. 11D).  
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Figure 11.  SDS-PAGE and immunoblots of purified IgG for 
citrullination and carbamylation. 
 
A. Representative Coomassie blue stained isolated total IgG from patients 
and control sera used to blot for citrulline.  
B. Immunoblot of IgGs probed with anti-citrulline.  
C. Representative Coomassie blue stained isolated total IgG from patients 
and control sera used to blot for carbamylation.  
D. Immunoblot of IgGs probed with anti-carbamyl-lysine. 
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4.5 Discussion 
 
This study has demonstrated for the first time that citrullinated and carbamylated 
IgGH is present in the sera of RA patients and also a pre-RA BR patient. We 
suggest our findings extend the findings of carbamylated IgG in synovial fluid of 
RA patients [9]. Citrullinated IgG was observed in healthy subjects and RA 
patients. However, specific citrullination and carbamylation of the RF binding site 
in the IgG CH2 domain was only observed in patients with seropositive RA (4/8) 
with or without apparent lung disease and a patient with BR who subsequently 
developed seropositive RA (1/4).  This would suggest that post-translational 
modifications of the RF binding site of the region of IgG are of importance in the 
development of RA. This study is limited by the small sample size and only 
represents a snap shot in time of IgGH in the sera of patients and healthy controls. 
However, an antibody response is a legacy of exposure to a particular antigen. 
The development of an antibody against the post-translationally modified Fc 
region of IgG may be of value as a specific diagnostic marker.  
 
These findings are of importance as they suggest that IgG is a potential universal 
antigen in RA. The association between the Fc region of IgG and RF has long 
been recognised. However, evidence is emerging that a citrulline antibody 
response against IgG exists in RA as bispecific antibodies against cyclic 
citrullinated peptides and IgG have been observed in RA [11]. The specific post-
translational changes noted at IgGHFc in this study could explain the clustering 
together of the three known RA autoantibodies in RA [12]. 
 
An animal study demonstrated that citrullinated filaggrin is highly arthritogenic, 
but only with co-exposure to carbamylated lysine residues [11]. This suggests a 
“double hit” of citrullinated and carbamylated antigen is required to trigger 
immune-mediated arthritis. We suggest that an antigen such as IgG that is both 
citrullinated and carbamylated could also elicit RA by the mechanisms described 
in the above study [11]. Supporting this, IgG complexes isolated from RA synovial 
fluid have triggered arthritis in an animal model [12].  
 
The relative abundance of IgG in RA serum (mean 8.9mg/ml [13]) compared to 
other putative RA associated autoantigens such as calreticulin (median 10.3 
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ng/ml [14]), is likely to be of significance in breaching immune tolerance.  
 
Post-translationally modified IgGH is not necessarily exclusive to the BR lung; it 
could potentially arise in BALT as a result of smoking, in other mucosal surfaces 
and in the joint. The importance of post-translational modification of IgGHFc is 
not only in the development of a neo-antigen, but in a fundamental change to the 
polarity of the Fc region and a potential enhanced interaction with the Fc receptor. 
Citrullination of arginine and carbamylation of lysine at the Fc region will change 
the electrical charge (from positive to neutral). This may alter binding and/or 
signalling with the FcγRIIB1 of B cells and FcγRIIIB receptors of follicular dendritic 
cells, stimulating development of autoimmune disease via tertiary lymphoid tissue 
development. We suggest that post-translationally modified IgGHFc enhances 
the ligand activity of IgGH by permitting binding to specific Fc receptors 
containing positively charged amino acids at critical sites of the Fc receptor [15]. 
Ergo, post-translationally modified IgGH has the potential to be an autoantigen 
and an enhanced ligand, which sets it apart from other citrullinated autoantigens. 
 
4.6  Conclusion 
 
Further, larger studies are needed to confirm if post-translational modifications to 
the Fc region of IgGH are present in the sera of individuals who have developed 
RA to determine if the presence of a specific antigen and ligand is unique to RA. 
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Chapter 5. Vapour, gas, dust and fume occupational exposures in male 
rheumatoid arthritis patients resident in Cornwall (UK) and their 
association with rheumatoid factor and anti-cyclic protein antibodies: a 
retrospective observational study. 
Citation: Murphy D, Bellis K, Hutchinson D. Vapour, gas, dust and fume 
occupational exposures in male rheumatoid arthritis patients resident in Cornwall 
(UK) and their association with rheumatoid factor and anti-cyclic protein 
antibodies: a retrospective clinical study. BMJ Open 2018;8:e021754 
5.1 Abstract  
Objectives: To quantify exposure to vapour, gas, dust and fumes (VGDF) and 
smoking in male rheumatoid arthritis (RA), and investigate impact on rheumatoid 
factor (RF) and anti-citrullinated protein antibody (ACPA) levels.  
Design: A retrospective observational study.  
Setting: The Royal Cornwall Hospital Trust, UK. A single university hospital 
setting. 
Participants: 726 males followed up between February 2015 to August 2016, 
fulfilling RA diagnostic criteria.  
Main outcome measures: Prevalence of VGDF exposure and smoking prior to 
RA diagnosis. Determination of association between VGDF, smoking and 
autoantibody levels. 
Results: 546/726 (75%) had been exposed to VGDF for >1 year. 561/726 (77%) 
had been smokers. Only 58/726 (8%) had no exposure to VGDF and had never 
smoked. A significant difference in RF levels was observed between unexposed 
and VGDF exposed never smokers (median RF 24 vs. 36, p=0.03), more marked 
when comparing unexposed to ≥2 VGDF exposures (median RF 24 vs. 57, 
p=0.02). A significant difference in RF levels was also observed between 
unexposed and VGDF exposed smokers (median RF 71 vs. RF 95 p=0.04), more 
marked when comparing unexposed to ≥2 VGDF exposures (median RF 71 vs. 
RF 113 p=0.01). A significant difference in RF titre was observed between never 
smokers >2 VGDF exposures and smokers with >2 VGDF exposures (RF 57 vs 
RF 113, p=0.02). No association of ACPA seropositivity rates or titres with VGDF 
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exposure was observed. Smokers with >2 VGDF exposures had a significantly 
lower age of RA diagnosis than smokers with no VGDF exposure (53 years vs 57 
years p=0.03). All results remained similar when corrected for social class. 
Conclusions: VGDF exposure increases RF levels.  Combination exposure to 
smoking and VDGF results in higher RF levels, particularly with multiple 
exposures. These compelling findings demonstrate the importance of combined 
inhaled exposures in RF generation.  
5.1.1 Strengths and limitations of this study 
• Methodology allowed follow up of an entire male RA cohort, with fixed 
diagnostic criteria applied and non-response minimised. 
• Rheumatoid factor titres were reported rather than seropositive or 
seronegative status. 
• Adjustment for social deprivation and educational level was made. 
• Heterogeneity was noted between the cohorts studied with regard to 
education and social deprivation. 
• As a single centre retrospective study, it is subject to a range of possible 
biases, with further study necessary to confirm the results in a population 
of wider demographic diversity. 
 
5.2 Introduction 
Rheumatoid arthritis (RA) is an inflammatory disease which primarily targets the 
small joints of the hands [1]. Individuals with RA develop debilitating fatigue, joint 
inflammation, resulting in weakened grip and the subsequent development of 
joint deformities impairing physical function and dexterity [2].   
The estimated global prevalence is 0.3–1.0% [3]. A UK study of RA patients with 
disease duration of 10-15 years reported an annual cost of approximately £3000 
per patient (2013 prices) for direct health care alone [4]. The overall direct health 
cost estimated to be £700 million in 2010 in the UK, with a further £8 billion lost 
to the UK economy when work productivity loss and state benefit requirements 
are considered [5].    
Identifying the underlying causes for progressive RA has centred on a 
combination of environmental and genetic risk factors that stimulate inflammation 
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via autoantibody production. The RA associated autoantibodies rheumatoid 
factor (RF) and anti-citrullinated protein antibodies (ACPA) are both associated 
with progressive joint damage in RA [6], and with mortality [7]. Smoking is a risk 
factor for the presence of the combination of RF and ACPA in RA and the number 
of pack years smoked is proportional to the RF titre, but not ACPA titre in RA [8]. 
Given the multifactorial basis for disease development, it is surprising that the 
effect of combined environmental exposures on autoantibody development has 
not been more widely investigated. 
Case-control studies have observed an association independent of smoking 
between occupational dust and fume inhalation and the risk of male RA. This 
relevant to RA as in the UK approximately 28% of RA patients are male (reviewed 
in [9]).   
Recent studies investigating the relationship between occupational exposures 
and chronic obstructive airways disease (COPD) have utilised self-report of any 
occupational inhalational exposures together and considered these exposures as 
an entity that can trigger COPD. Reported exposure to vapours, gas dust and 
fumes (VGDF) are independently, but modestly associated with COPD 
development [10].  VGDF exposure greatly increases the risk of chronic 
obstructive pulmonary disease (COPD) particularly in smokers, with an OR 14.1 
(9.33-21.2) compared to never smokers with no such work exposures [10]. The 
combined risk of VGDF and smoking was far higher than the OR of 6.71 (4.58-
9.82) in those smokers without such exposures. 
The lung is considered an initiating site for RA development [11] and the 
occupational inhalational insults associated with male RA development and 
COPD are concordant [9]. Considering grouped inhalational exposures as the 
potential risk for RA development (rather than “last occupation” only), has not 
been previously undertaken.  
We aimed to study the occupational and smoking histories of all male RA patients 
attending the rheumatology department in Cornwall, UK, to test a hypothesis that 
combinations of inhalational insults would interact to increase autoantibody levels 
in RA.  
5.3 Materials and methods  
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5.3.1 Subjects 
The data in this study was collected as part of project IRAS ID 194833, approved 
by South West Regional Ethical Committee (UK). The cohort consisted of males 
attending routine rheumatology clinics at the Royal Cornwall Hospital, Cornwall, 
UK from February 2015 to August 2016. Data was anonymised at source. 
Patients reviewed in clinic with a new or existing diagnosis of RA during the study 
period were included for analysis, initially invited to complete a written 
questionnaire. Data was recorded by clinicians in a standard questionnaire via 
face-to-face interview to determine current occupation, former occupation if 
retired, and previously held employments for >1 year.  Answers to open questions 
on occupation and main duties for each response were recorded, to be coded 
using SOC 2010, The current standard occupational classification for the UK [12]. 
As in previous COPD literature [10], an item used in the European Community 
Respiratory Health Survey (ECRHS II) main questionnaire was utilised, with each 
case asked about self-reported exposures to vapours, gas, dust or fumes (VGDF) 
in the line of their work [13]. Missing data was obtained by follow up telephone 
administration of the same questionnaire. Written consent was obtained for 
patients enrolled as part of the IRAS ID 194833 project investigating the role of 
cadmium inhalation and the development of RA. Individuals were stratified for the 
number of self-reported VGDF exposures in each occupation held for >1 year (0, 
1,>2). Age, age of RA onset, disease duration, smoking history prior to disease 
development, RF levels at disease onset and subsequent ACPA levels were 
recorded as part of routine clinical practice. All patients fulfilled 2010 ACR/EULAR 
RA criteria at diagnosis [14].  
726 patients were included for initial analysis.  Of these, 22/726 (3%) had 
incomplete smoking data and were excluded from linear regression analysis. 
3/726 (0.4%) had no verifiable RF data, and were excluded from RF analysis. 
54/726 (7%) had no ACPA data and were excluded from ACPA analysis. 16/726 
(2%) were excluded from occupational analysis; 5/16 died during the study period 
and therefore had incomplete occupational data, 3/16 did not want to disclose 
occupation in writing or on subsequent interview. 8/16 did not return initial 
questionnaires and were lost to follow up (Figure 14). Prevalence analysis of 
VGDF and smoking was analysed as a proportion of the entire identified cohort 
(n=726) to bias towards the null hypothesis. 
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Category Included Reason/s for exclusion 
Occupational status710 
 Anti-citrullinated protein antibody672 
 Smoking status707 
 Rheumatoid factor723 
 Smoking pack years704 
 Total cohort726 
Died, unable to gather data n=3 
Died, unable to gather data n=5 
Unwilling to disclose n=3 
Lost to follow up n=8 
Conflicting data on patient recall n=20 
Unwilling to disclose n=2 
Unable to recall status at diagnosis n=11 
Lost to follow up n=8 
Died, unable to gather data n=30 
ACPA test result unavailable n=24 
Figure 12. Flow diagram of patients included for analysis with reasons 
for exclusion 
121 
 
5.3.2 Patient involvement 
The initial concept of this research was developed from detailed histories of 
individual patient experiences of RA in Cornwall, UK. Initial hypotheses were 
presented at a local meeting of the National Rheumatoid Arthritis Society, 
attended by over 100 members, the majority of whom were RA patients.  
Subsequent interest following the meeting led to further discussion as to the 
development of a protocol that would be acceptable to patients in terms of its 
design and acceptability.  From initial ideas, this was refined and presented to 
the committee of the Cornwall Arthritis Trust, a local charity supporting arthritis 
patients.  Specific feedback was offered on wording of consent forms, 
questionnaire design and arrangements for follow up on patients who may not 
have been able to complete written questionnaires.  Patient involvement in this 
process was invaluable for how best to manage and undertake the research in a 
way that was minimally intrusive for patients in their regular clinical care.  
Dissemination of results to patients will take place via departmental displays post 
publication. 
5.3.3 Autoantibody measurement 
RF was measured with Tina-quant Rheumatoid Factors I1 Test System (Roche 
Diagnostics Corporation), with a value of < 14 IU/ml considered as negative as 
per manufacturer guidelines. ACPA was measured by Second Generation E170 
Anti-CCP analysis (Roche Modular Analytics), with a negative value of <17 U/ml 
as per manufacturer guidelines. 
5.3.4 Social deprivation analysis 
Social deprivation analysis was undertaken through the UK government validated 
Index of Multiple Deprivation (IMD) [15], a deprivation rank score of 32,844 
neighbourhoods weighted by income, health/disability, education, 
housing/service access, crime and living environment, converted to equal 
deciles. 
5.3.5 Statistical analysis 
Values are expressed as a median (interquartile range (IQR), or number (%). The 
Mann-Whitney U test was used for non-parametric comparisons of continuous 
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data of differing sample group sizes. All data were analysed using commercially 
available software (Microsoft Excel (Microsoft Corp) and Number Cruncher 
Statistical System for Windows (NCSS60)). 
5.4 Results 
546/726 (75%) had been exposed to VGDF for >1 year, with 254/726 (35%) 
having 2 or more identified VGDF exposures. 561/726 (77%) had been smokers, 
with 349/726 (48%) having accumulated 20 pack years or more at the time of 
diagnosis. 58/726 (8%) had never smoked and had no exposure to VGDF (Table 
8). No significant difference was seen in deprivation analysis (IMD) between 
VGDF and smoking exposed or unexposed cohorts, even when comparing never 
smokers with no VGDF exposure to smokers with >2 VGDF exposures (median 
IMD decile 4, IQR ranges 3-5 to 4-6, p=0.29). 
Table 8. Patient characteristics for whole cohort n=726 
 
Median age at diagnosis 
(IQR) 
55 (45-64) 
Median RF (IQR) 69 (17-201) 
Median ACPA (IQR) 200 (1-428) 
Median IMD (IQR) 4 (3-5) 
Ever smoker 561/726 
(77%) 
>20 pack years smoked 349/726 
(48%) 
VGDF exposure >1 year 546/726 
(75%) 
>2 VGDF exposures >1 year 254/726 
(35%) 
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545/710 (77%) had occupations with VGDF. In never smokers and ever smokers 
there was a significant dose response in terms of number of VGDF exposures 
and RF levels (Never smoker/ no VGDF, RF 24 vs never smoker/ VGDF, RF 36, 
p=0.03; Never smoker/ no VGDF, RF 24 vs never smoker/ >2 VGDF, RF 57, 
p=0.02, and smoker/ no VGDF, RF 71 vs smoker/ VGDF, RF 95 p=0.04; smoker/ 
no VGDF, RF 71 vs smoker/ >2 VGDF, RF 113, p=0.01, Figure 13).  
 
Figure 13. Median RF (IQR) by exposure group 
 
 
ap=0.03 bp=0.02 cp=0.04 dp=0.01 
 
No titre trends or significant additive relationship was seen in ACPA titres with 
VGDF exposure (Figure 14), but smoking cohorts all had significantly higher 
ACPA titres than non-smoking counterparts with similar VGDF exposure (Table 
9). No significant association was found in ACPA seropositivity rates amongst 
VGDF exposed or unexposed groups; ACPA for never smokers with 0, 1 and >2 
VGDF exposures 50.9% v 52.0% v 58.7%, p (trend) = 0.44, nor in ever smokers 
70.8% v 68.4% v 66.4%, p (trend) = 0.72. 
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Figure 14. Median ACPA (IQR) by exposure group   
 
ap=0.34 (not sig) bp=0.33 (not sig) cp=0.41 (not sig) dp=0.22 (not sig) 
 
Only 58/726 (8%) had never smoked and had no exposure to VGDFs, and had 
the lowest median RF titres (24, IQR 8-62). In never smokers with >2 VGDF 
exposures the median RF titre levels at RA diagnosis reflected ever smokers 
without VGDF exposure (57 vs 71). Smokers with a history of >2 VGDF 
exposures had the highest median RF titres (113 IQR 27-240), and had a 
significantly lower age of RA diagnosis than smokers with no VGDF exposure (53 
years IQR 44-61 vs 57 years IQR 42-68 p=0.03, Table 9).  
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Table 9. IMD, age, RF and ACPA by smoking and VGDF exposure 
 Median 
IMD 
(IQR) 
Median age 
at diagnosis 
(IQR) 
Median RF 
(IQR) 
Median 
ACPA (IQR) 
Never smoker, no VGDF exposure 
n=58  
4 (3-5) 58 (42-68) 24 (8-62) b,c 
 
47 (0-250)f 
 
Never smoker, VGDF exposure 
n=105 
4 (4-6) 54 (43-66) 36 (11-114)b 96  (0-351)g 
Never smoker, 2 or more VGDF 
exposures 
n=51 
4 (4-6) 54 (42-63) 57 (20-142)c 100 (0-361)h 
Smoker, no VGDF exposure 
n=120  
4 (3-5) 57 (42-68) a 71 (16-
177)d,e 
 
219 (15-
363)f 
Smoker, VGDF exposure 
n=443 
4 (3-5) 54 (46-63) 95 (22-245) d 
 
225 (29-
471)g 
Smoker, 2 or more VGDF exposures 
n=203 
4 (3-5) 53 (44-61) a  113 (27-
240)e 
228 (44-
473) h 
a p=0.03, b p=0.03, c p=0.02 d p=0.04, e p=0.01, f p=0.02, g p<0.01, h p=0.03 
  
Further analysis by multivariate linear regression on the effect of pack years 
smoked and cumulative VGDF exposures on RF levels demonstrated 
significance (R2 <0.03, p<0.0001). 
In analysis of occupations listed, 33/726 (4%) had an occupation that required an 
educational level greater than standard UK secondary education with a school 
leaving age of 15 or 16 years. 10/33 (30%) were teachers or lecturers, 1/10 (10%) 
of which was a never smoker with no reported dust or fume exposure.  7/33 (21%) 
were engineering or surveying professionals with a range of reported VGDF 
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exposures. 7/726 (<1%) were professionally occupied never smokers with no 
dust or fume exposures. 
By broad exposure types, construction dust (a mixed group of combinations of 
wood, cement/concrete, fine sand/rock, and gypsum, incorporating both silica, 
non-silica inorganic, and organic dusts) was the most common type of VGDF 
exposure, with 330/726 (45%) reporting such exposure.  More prevalent 
exposures included diesel fumes (239/726, 33%), and oils including mineral oil 
exposure (207/726, 28%). Other exposures that were less prevalent but still 
existed in >10% of the total cohort included those reporting fume exposure as 
part of plastics manufacturing (98/726, 13%), metal fumes from electrical work 
(103/726, 14%), and specific dust exposure involved with rock mining (98/726, 
13%), metals extraction (196/726, 27%), and wood related trades such as 
carpentry and boatbuilding (155/726, 21%,). 
5.5 Discussion 
5.5.1 Principal findings 
We believe this is the first study to link occupations in combination with smoking 
to RA autoantibody development. Strikingly high numbers of cases in this study 
had been exposed to VGDF (75%) or had been smokers (77%). VGDF exposure 
combined with smoking leads to RA development at a significantly younger age. 
Whilst these findings are unique in an RA population, they reflect a trend of 
exposure risk as seen in COPD [10].  
We have found compelling evidence that a combination of environmental 
exposures influences RF levels, more than observed in individual exposure. RF 
levels were highest in those with smoking and multiple VGDF exposures.   
5.5.2 Strengths and weaknesses of this study 
There is a relative lack of comparable RA cases that are unexposed to VGDF 
and smoking, giving limited ability to provide statistical significance via an 
adequate control group to analyse specific occupational exposures in which self-
report of VGDF exposure was found. The relative homogeneity of educational 
levels and social depravation indices between groups in our study may explain 
why no significant differences were found here, though this may reflect how 
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inhalational exposures manifest in a male RA cohort. A wider unexposed RA 
population and a similarly matched, non- RA cohort would both be useful for 
further study. 
Face to face interview with telephone follow up was designed to minimise non-
response.  At termination, only 8/726 (1%) were non-responders. Non-response, 
particularly in postal studies, is strongly correlated with low levels of formal 
education. Established literature links RA to low levels of formal education [16-
18], with two UK studies observing a functional illiteracy rate of 15% [19,20].  
Perhaps unsurprisingly, divergence in occupations related to literacy scores has 
been noted, with lower scores recorded in agriculture, construction, 
manufacturing and mining [21]. These occupations associate with male RA [9]. 
95% of occupations held by individuals in this study required no formal academic 
qualifications beyond secondary education, therefore it was not possible to 
compare lower and higher levels of formal education for RA autoantibody 
prevalence. We suggest that further studies investigating the impact of 
socioeconomic status or formal education levels on male RA susceptibility, 
severity, comorbidity and mortality consider an individual’s occupation as a 
confounding factor.  
Previous database referent studies have chosen to include patients under the 
age of 70 [22]. Occupational disease can have a long latency period; asbestos 
exposure and mesothelioma development is associated with a latency of 
between 14 and 72 years (median 51 years), with the majority of cases presenting 
in the 7th and 8th decade of life [23]. Though we found a significantly earlier age 
of onset in our most severely co-exposed cohort, 104/726 (14%) cases studied 
were diagnosed over the age of 70. The risk of smoking and RA is evident up to 
15 years after smoking cessation [24]. As polarisation of RA risk estimates occurs 
when a latency period is used in occupational exposures [25], using an age cut 
off of 70 does not allow an adequate latency period between exposure and 
disease development. 
Much of the literature investigating occupational risk and RA has been 
undertaken in Sweden, in the form of case control/ case referent or linkage 
studies from large dataset analysis (reviewed in [9]). Studies investigating 
occupation and RA risk may only consider the last occupation undertaken by the 
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respondent [22], or occupation noted on the database studied. It is not uncommon 
for individuals with low literacy levels to move from one casual job to another, 
accruing different occupational exposures over time. The last recorded job may 
not reflect these exposures. In poorer populations, trade sub-specialisation and 
health and safety legislation adherence may be less evident. Throughout an 
occupational career, unskilled workers may have multiple exposures. 
Construction labourers, for example, may be co-exposed to silica dust, inorganic 
non-silica dusts, wood dust and diesel fumes.  
We suggest that studies investigating individual occupational risk and RA via 
single job title analysis may be confounded by multiple inhalational insults, even 
when correcting for smoking and quantifying single job exposure risk through the 
use of job exposure matrices. In a well conducted analysis of silica vs. non-silica 
dust exposed construction workers, Blanc et al. [26] demonstrated that in ever 
smokers, both silica and other inorganic dust exposure were associated with 
increased risk of RA (RRs 1.36, 95% CI 1.11-1.68 and 1.42, 95% CI, 1.17-1.73, 
respectively), whilst in never smokers, neither exposure was associated 
significantly with an increased risk of RA. This large, longitudinal cohort registry 
study contained detailed information on occupations and exposure types.  
40645/240983 cases were excluded due to co-exposure to wood dust, gas or 
fumes to reduce confounding. It would be interesting to study these types of 
multiple exposures to investigate enhanced RA risk.  
5.5.3 Possible explanations and implications for clinicians and 
policymakers, unanswered questions and directions for future research 
We suggest potential reasons why VGDF may associate with RF and not ACPA. 
Newkirk et al [27] described RF generation via upregulation of IgG-heat shock 
protein 70 complexes stimulating production of IgA and IgM RF. Both cigarette 
smoke [27] and harsh working environments including exposure to dust [28] 
induce IgG-heat shock protein 70 complexes, with potential synergistic action on 
the same pathway to induce an enhanced RF response. An ACPA response is 
clearly related to smoking, but the mechanism by which this occurs is unclear. 
We acknowledge that VGDF exposure appears to have less of an influence on 
this process.  
129 
 
Furthermore, there appears to be a discordant RA autoantibody response in 
COPD. This is important as COPD is related to VGDF exposure and smoking in 
combination [10], and may be pertinent to the population studied here. Newkirk 
et al [27] observed that 20/20 COPD cases were IgA RF positive (20/20), but 0/14 
tested ACPA positive. Yang et al [29] found 29/70 COPD cases positive for RF, 
but 0/70 were ACPA positive. We suggest that COPD individuals either have an 
increased propensity for RF generation but not ACPA, or that the COPD lung 
differentially sequesters ACPA rather than RF.  
This study cannot address if multiple work exposures to VGDFs increase the risk 
of developing RA. Further studies are needed to address this important question. 
An increasing titre of RF in the general population increases the incidence of RA 
development by 20-fold when comparing the lowest vs highest titre of RF [30]. 
We suggest that studies of RF in the general population and the risk of developing 
RA not only consider the smoking history, but also occupational inhalations. 
It is well established that smoking blunts clinical response to RA treatment with 
both methotrexate and tumour necrosis factor (TNF) inhibitors [31,32], and higher 
levels of RF in RA patients with established disease receiving TNF inhibitors are 
much less likely to be in remission at 12 months follow up [33]. We suggest that 
RA patients exposed to VGDF will have a more pronounced blunting of response 
to conventional treatment due to high RF levels, generated by sequential 
inhalational insults. 
Prospective, large scale multi-centre studies of RA patients utilising occupational 
classification criteria and job exposure matrices may help to determine if 
occupational exposures in never smokers increase RF levels, increase disease 
activity and affect treatment response. Cohort studies using similar detailed 
exposure classification criteria may compare respiratory mortality rates amongst 
RA and non-RA cases with the same exposures, as it has been demonstrated 
that exposures to both smoking and VGDF greatly increase the risk of COPD in 
the general population with an OR of 14.1 (9.33-21.2) compared to never 
smokers with no such work exposures [10]. If our findings are representative, this 
is likely to be highly relevant to the co-morbidity and mortality of male RA. 
Given the single centre nature of this study, we cannot comment on how 
representative this male RA cohort compares to a wider RA population and 
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suggest that wider study is needed. We suggest that rheumatologists undertake 
a detailed occupational and smoking history when assessing patients with RA. 
5.6 Conclusion 
The overwhelming majority of RA men is this analysis of an entire University 
hospital male RA cohort had exposure to vapours, gas, dust or fumes and had 
been smokers before diagnosis. Men who had such exposures combined had 
significantly higher RF titres and were diagnosed at a significantly younger age.  
Given the prevalence of these exposures in an RA male cohort, further study is 
needed to uncover the pathophysiological mechanisms underlying these 
compelling findings as the environmental exposures driving the autoantibody 
generation seen here may affect response to treatment. 
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Chapter 6. Nodular rheumatoid arthritis (RA): A distinct disease subtype, 
initiated by cadmium inhalation inducing pulmonary nodule formation and 
subsequent RA–associated autoantibody generation.  
 
Citation: Murphy D, Sinha-Royle E, Bellis K, Harrington C, Hutchinson D. Nodular 
rheumatoid arthritis (RA): A distinct disease subtype, initiated by cadmium 
inhalation inducing pulmonary nodule formation and subsequent RA–associated 
autoantibody generation. Med Hypotheses 2018: submitted awaiting decision. 
 
6.1 Abstract 
 
Nodular rheumatoid arthritis (RA) patients have raised rheumatoid factor (RF) 
and anti–citrullinated protein antibody (ACPA) levels, and are more likely to 
smoke than RA patients without nodules. Subcutaneous and pulmonary 
rheumatoid nodules (granulomas) frequently co–exist. Pulmonary rheumatoid 
nodules develop prior to RA development and have the immunological machinery 
to generate RF and ACPAs. Pulmonary granulomas have been observed in 
animal models exposed to cadmium (Cd) inhalation. Cigarette smoke increases 
pulmonary Cd exposure. It has been suggested that dust and cigarette smoke 
co–exposure increases localised pulmonary Cd adsorption.  We hypothesise that 
subcutaneous nodular RA represents a distinct disease subtype induced by 
pulmonary rheumatoid nodule formation and the generation of high levels of RA 
associated autoantibodies initiated by Cd inhalation via cigarette smoke.  
 
Cohorts of RA patients attending rheumatology clinics in Cornwall, UK (total 
n=504) were studied to determine the prevalence of nodular RA, with matched 
analysis (age, gender and social class) to compare urinary Cd, RF and ACPA 
levels stratifying for nodular disease and smoking.   
 
In cohort 1 45/303 (14.9%) of the RA patients under regular follow up had nodular 
disease. Of the RA smokers, 30/155 (19%) were nodular and of the RA non–
smokers 15/148 (10%) were nodular. Smoking was significantly associated with 
nodular RA, odds ratio (OR) = 2.48 95% confidence interval (CI) 1.26–4.88, 
p=0.008.  Raised urinary Cd levels were significantly associated with nodular RA 
in non–dust exposed individuals, OR 2.26 (95% CI 1.08–4.73), p=0.03 compared 
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to dust exposed individuals, OR 0.78 (95% CI 0.35–1.76), p=0.557, despite fewer 
pack years (py) at diagnosis (16 vs 20 py). Nodular RA smokers had significantly 
raised RF levels compared to RA smokers without nodular disease (median RF 
171.5 (interquartile range (IQR) 48–394) vs median RF 31.7 (IQR 10.3–170.3), 
p<0.00001). RF positivity was significantly more prevalent in nodular RA smokers 
compared to RA smokers without nodular disease (84/89 (94%) vs. 141/199 
(71%), OR=6.9 (95% CI 2.66–17.91), p<0.00001). ACPA levels were also 
significantly raised in nodular smokers compared to non–nodular smokers 
(median ACPA 250 (IQR 145–426) vs 116 (1–257.5), p<0.00001), as were ACPA 
positivity rates (83/89 (93%) vs 123/191 (64%), OR=7.65 (95% CI 3.17–18.4), 
p<0.0001).  
 
These pilot results support the hypothesis that nodular RA represents a distinct 
disease subtype initiated by cadmium inhalation, which we suggest induces 
pulmonary rheumatoid nodule formation and generation of RA–associated 
autoantibodies. 
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6.2 Introduction 
 
Rheumatoid arthritis (RA) is a relatively contemporary disease having been first 
described in early 19th century Paris [1]. Florid classical RA is a characteristic 
disease with the development of ulnar deviation, swan neck deformities and 
subcutaneous nodules [2]. However, even in untreated disease, these features 
do not always develop, suggesting distinct RA subtypes. Classical features of RA 
strongly associate with erosive disease [3] which has not been observed in 
extensive studies of European skeletal remains prior to the 19th century [4], 
suggesting that classical RA is triggered by a set of relatively contemporary 
environmental risk factors. Cigarette smoking is the most important identified 
environmental risk factor for seropositive RA development and accounts for a 
third of cases [5], associating with erosive and nodular disease when compared 
to RA without these classical features [6]. However, the association between 
smoking and subcutaneous nodular RA appears to be dependent on rheumatoid 
factor (RF) positivity [7].  
 
Rheumatoid nodules are pathognomonic for RA. The presence of rheumatoid 
nodules previously formed part of the 1987 classification criteria for RA [8]. This 
is not altogether surprising given that in the 1960s nodules occurred in 30% of 
RA patients (n=516) in the UK [9]. Over time the prevalence of nodules in RA in 
the UK (1991–1993) has declined to 6% with established disease of 3 years 
duration [10]. Consequently rheumatoid nodules are no longer included in the 
updated 2010 classification criteria for RA [11].  
 
Rheumatoid nodules can either be located subcutaneously and are usually 
apparent over the extensor surfaces of the elbow, over the dorsum of the hand 
and fingers [2] or develop in the lung and are referred to as pulmonary rheumatoid 
nodules [12]. Pulmonary rheumatoid nodules were initially thought to be rare in 
RA as a case series of RA patients (n=253) failed to identify a single case [13], 
however, in retrospect, chest X–rays have a marked insensitivity with regards to 
identifying such nodules.  Subsequently, computed tomography (CT) imaging has 
identified a relatively high prevalence of pulmonary rheumatoid nodules (22–
30%) in a number of RA case series [14–17].  
 
138 
 
There is a striking association between cigarette smoking and the development 
of pulmonary rheumatoid nodules. Walker [9] observed a high rate of smoking in 
RA patients with pleural effusion (pleural effusion is recognised to be one of the 
sequelae of pulmonary rheumatoid nodules). Seventy six per cent of the RA 
patients studied with pleural effusion were smokers compared to 55% of the total 
RA cohort studied.  Subcutaneous nodules appeared to be associated with the 
development of pulmonary rheumatoid nodules as the pleural effusion cohort had 
an increased prevalence of subcutaneous nodules of 10/19 (53%) compared to 
the prevalence of subcutaneous nodule in the RA population without a pleural 
effusion 146/497 (29%). Interestingly it was observed that RA associated pleural 
effusion on occasions preceded the development of RA or presented 
simultaneously with RA [9]. 
 
Prior to this description of a high prevalence of subcutaneous nodules in 
association with pleural effusions in a non–mining RA cohort in Northern England 
[9], Caplan described pulmonary nodules in Welsh coal miners [18]. In stark 
contrast to subcutaneous rheumatoid nodules, it was apparent that pulmonary 
rheumatoid nodules occurred frequently without RA as a study of miners with 
pulmonary rheumatoid nodules observed that 82/168 (49%) did not have RA. 
Furthermore of these men, 71 were tested for the then contemporaneous RA 
latex test and 25 (34%) were positive. This compares to 0/32 control miners with 
no lung disease or simple pneumoconiosis [19]. Caplan observed the same 
phenomenon as Walker in that pulmonary rheumatoid nodules often preceded 
the development of RA [18]. Unsurprisingly coal mining has been observed to 
increase the risk of male RA with an odds ratio of 8.47 (95% CI 2.59 to 27.66) 
[20]. The prevalence of smoking was high in miners with pulmonary rheumatoid 
nodules; a study of lung function observed that 18/23 (78%) of miners with a 
documented smoking history were current smokers [21].  
 
These historic studies are of contemporary relevance as it has been suggested 
that RA can be initiated in the lung via local RA associated autoantibody 
generation [reviewed in 22]. A highly relevant, important observation of the nature 
of pulmonary rheumatoid nodules has been made by Highton et al [23].  . 
Pulmonary rheumatoid nodules have the immunological “machinery” to generate 
RA associated autoantibodies, evidenced by the presence of B lymphocytes and 
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ectopic lymphoid follicles.[23]. Such histological changes have not been 
observed in subcutaneous rheumatoid nodules [24]. 
 
It has been suggested that cadmium (Cd) exposure may be implicated in the 
pathogenesis of seropositive RA as Cd associates with cigarette smoking, social 
deprivation, living within 30 metres of a main road, residency in certain 
geographical locations of the United States of America and a plethora of 
occupations associated with RA development [25]. This hypothesis is specifically 
relevant to pulmonary rheumatoid nodule (granuloma) formation as a number of 
animal studies have observed that Cd nanoparticles nebulised into the lung can 
initiate the development of pulmonary nodules [26–28]. Cigarette smoking is 
strongly associated with an increased lifelong exposure to Cd and this is reflected 
in raised urinary Cd levels [29]. Median, gender specific UK levels for urinary Cd 
have been determined [30]. 
However, the relationship between measurable bodily Cd levels and disease is 
complex. For example, chronic obstructive pulmonary disease (COPD) is 
associated with raised lung tissue levels of Cd, but not necessarily raised urinary 
Cd levels [31]. As COPD is more strongly associated with co–exposures to both 
inhaled dust and cigarette smoke rather than either alone [32] we have suggested 
that lung Cd adsorption by the inhaled dust results in highly localised lung Cd 
levels and triggers disease [33].  As we hypothesise that enhanced  adsorption 
of Cd onto intra–pulmonary inhaled substrates will stimulate granulomatous 
nodule formation, this may result in a reduced systemic absorption and therefore 
reduced blood and urinary level of Cd despite high local lung levels. Given that 
dust inhalation is common in RA populations [34], it is essential that the 
occupational history in relation to dust exposure is accounted for when 
considering urinary Cd levels as a marker of Cd exposure. 
 
Accordingly, we hypothesised that RA nodular disease represents a distinct 
subset of RA with elevated RF, ACPA and appreciably raised urinary Cd levels 
(>95th centile as determined for UK populations) specifically in those RA patients 
unexposed to occupational dust exposure.  
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6.3 Methods 
 
6.3.1 Subjects 
 
Two cohorts of RA patients were studied. Cohort 1 (n=303) consisted of all RA 
males and females attending routine rheumatology clinics at the Royal Cornwall 
Hospital, Cornwall, UK from  August 2017  to February 2018 to determine 
prevalence of nodular RA, as part of Departmental Audit. Cohort 2 consisted of 
prospectively gathered nodular RA males and females (n=92),  matched for age 
(+/– 2 years), sex, and smoking history (+/–2 pack years),  to patients previously 
collected as part of project IRAS ID 194833, approved by South West Regional 
Ethical Committee (UK) as previously described [34] (n=133). Specifically more 
males were recruited to this arm of the study as our unit were actively 
investigating the relationship between occupational exposures and the 
development of male RA. Cohort 2 (n=225) was stratified for nodular disease and 
smoking with comparison made for urinary cadmium. 3 cases were excluded as 
extreme outliers with cutoff value of >3 µmol/mol creatinine used to bias towards 
the null hypothesis. 
 
Both cohorts were amalgamated (Cohort 3) with duplicate records excluded 
(n=24). RF and ACPA levels were compared between all RA patients (n=504) 
stratified for nodular disease and smoking. 
 
18 patients were excluded from ACPA analysis due to incomplete data (n=6 RF 
negative, n=3 RF weak positive, n=9 RF strong positive), Figure 15. 
 
Data was anonymised at source. Age, age of RA onset, disease duration, 
smoking history prior to disease development, RF levels at disease onset and 
subsequent ACPA levels were recorded as part of routine clinical practice. Patient 
occupational histories were recorded as part of ongoing clinical audit using 
methodology previously described [34]. All patients fulfilled 2010 ACR/EULAR RA 
criteria at diagnosis [11], Table 10. 
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Figure 15. Flow diagram of patients included for analysis with reasons for 
exclusion  
142 
 
 
Table 10. Demographic data for each cohort 
 Cohort 1 
n= 303 
Cohort 2 
n=225 
Cohort 3 
n=504 
Age at diagnosis (years, median (IQR)) 54  
(43–63) 
54  
(45–61) 
54  
(44–63) 
Male sex (%) 99/303 
(32.7%) 
129/225 
(57.3%) 
221/504 
(43.8%) 
Female sex (%) 204/303 
(67.3%) 
96/225 
(42.7%) 
283/504 
(56.2%) 
Disease duration (years) 9  
(3–16) 
11.5  
(6–22) 
10  
(4–18) 
Median RF at diagnosis (IQR) 38.4  
(1–169.5) 
70.4  
(19.4–
215.1) 
51 (14.9–
181.5) 
Prevalence RF + (%) 219/303 
(72.2%) 
184/225 
(81.8%) 
381/504 
(75.6%) 
Median ACPA at diagnosis (IQR) 161  
(1–260)** 
186.5 (25.6–
366.5) 
180  
(1–
319.8) 
Prevalence ACPA + (%) 211/285 
(74.0%)** 
176/225 
(78.2%) 
349/486 
(71.8%) 
Smoking prevalence: smoker or ex–
smoker (<20 years) at diagnosis 
151/303 
(49.8%) 
147/225 
(65.3%) 
288/504 
(57.1%) 
Median pack years smoked (IQR) 30  
(15–40) 
11  
(0–26) 
17 
(0–27.8) 
*Removed from combined cohort as record duplicated n=24 
**Incomplete ACPA data (RF– n=6, RF weak + n=3, RF strong + n=9) 
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6.3.2 Autoantibody measurement  
 
RF was measured with Tina–quant Rheumatoid Factors II Test System (Roche 
Diagnostics Corporation), with a value of <14 IU/mL considered as negative as 
per manufacturer guidelines. ACPA was measured by Second Generation E170 
Anti–CCP analysis (Roche Modular Analytics), with a negative value of <17 U/mL 
as per manufacturer guidelines. 
 
6.3.3 Social deprivation analysis 
 
Social deprivation analysis was undertaken through the UK government validated 
Index of Multiple Deprivation (IMD), a deprivation rank score of 32 844 
neighbourhoods weighted by income, health/disability, education, 
housing/service access, crime and living environment, converted to equal deciles 
[35]. 
 
6.3.4 Statistical analysis 
 
Chi square tests and multivariate logistic regression analysis was used to 
examine relationships between smoking, nodularity and urinary Cd levels, 
adjusted for gender. The Mann–Whitney U test was used for non–parametric 
comparisons of continuous data of differing sample group sizes, with values are 
expressed as a median (IQR) or number (%). All data were analysed using 
commercially available software (Microsoft Excel (Microsoft Corp) and Number 
Cruncher Statistical System for Windows (NCSS60)). 
 
6.3.5 Urinary Cadmium analysis 
 
Patients supplied first pass morning mid–stream urine samples into 13ml sterile 
polystyrene urine sample tubes (Thermo–Fisher, Newport, UK). Samples were 
posted within 72 hours to the Supra–Regional Assay Service Trace Elements 
Laboratory, Guildford, Surrey. Urinary cadmium was analysed by inductively 
coupled plasma mass spectrometry (ICP–MS), using a fully validated method 
previously described [30]. An appreciably raised urinary Cd was defined as a 
urinary Cd level above the 95th centile as determined for UK populations 
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unexposed to occupational Cd, equating to 0.65 mmol/mol creatinine (females), 
and 0.42 mmol/mol creatinine (males). The median levels were reported as 0.19 
mmol/mol creatinine and 0.16 mmol/mol creatinine respectively for females and 
males [30]. 
 
6.3.6 Smoking history 
 
Pack years smoked was recorded prior to the diagnosis of RA. One pack year is 
deemed equivalent to smoking 20 cigarettes daily for a year.  A smoker was 
defined as an individual that had smoked in a period up to 20 years before RA 
diagnosis and > 5 pack years total. A non–smoker was defined as an individual 
who had either never smoked or had smoked in the distant past (>20 years prior 
to the diagnosis of RA) and < 5 pack years total. 
 
6.3.7 Subcutaneous rheumatoid nodules 
 
Individuals were examined in clinic to determine the presence of characteristic 
rheumatoid nodules on the hands, forearm, elbow and feet. Patients who had 
undergone surgical removal of nodules and histological examination had 
confirmed the diagnosis, were considered to be a rheumatoid nodular patient 
irrespective of the presence of rheumatoid nodularity at the time of the 
examination. No  radiological evidence of pulmonary rheumatoid nodules was 
collected. 
 
6.4 Results 
 
6.4.1 Demographics 
 
The median age, age of RA onset, disease duration, smoking history prior to 
disease development, RF levels at disease onset and subsequent ACPA levels 
are recorded in Table 1 for cohorts 1–3. There was an increased prevalence of 
males in cohort 2 as a result of our particular interest in risk factors associated 
with male RA development [34]. The prevalence data in cohort 1 in terms of age 
and gender are broadly in line with other UK RA populations [3]. 
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6.4.2 Risk factors for rheumatoid nodularity (cohort 2) 
 
Current smoking was significantly associated with rheumatoid nodules (OR 2.74 
(CI 1.29–4.72)), p=0.006. Former smokers were not at an increased risk of 
rheumatoid nodules, OR 1.14 (CI 0.56–2.28). However, when account for pack 
years smoked was undertaken the principal association was between pack years 
smoked and rheumatoid nodularity (data not shown). 
Dust exposure alone was not associated with rheumatoid nodularity, OR 1.11 (CI 
0.64–1.94) when corrected for pack years smoked (data not shown). 
 
6.4.3 Gender and Cd levels 
 
Both males and females displayed higher median Cd levels than unexposed, 
non–disease UK median data [30]. In men (n=128) the median Cd levels were 
0.38 (IQR 0.16–0.42) and in women (n=95) the median Cd levels were 0.57 (IQR 
0.19–0.65), p< 0.00001.  
 
6.4.4 Nodularity, gender and Cd levels 
 
Overall, nodular RA patients (n=92) had median Cd levels of 0.54 (IQR 0.31–
0.82) mmol/mol creatinine compared to non–nodular (n=131) RA patients of 0.43 
(IQR 0.28–0.67) mmol/mol creatinine with no significant difference (p=0.13) in 
median Cd levels observed.  
 
In female nodular RA (n=38) the median Cd level was 0.64 (IQR 0.43–0.91) 
compared to a median Cd level of 0.5 (IQR 0.35–0.74) mmol/mol creatinine in 
female non–nodular RA (n=57), p=0.06, Figure 2. In contrast, in male nodular RA 
(n=54) the median Cd level of 0.385 (IQR 0.25–0.68) mmol/mol creatinine was 
very similar to the Cd levels of 0.37 (IQR 0.26–0.57) mmol/mol creatinine in non–
nodular male RA (n=74), p=0.6, Figure 16. 
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Figure 16. Significantly elevated urinary cadmium (mmol/mol creatinine) in 
female nodular patients, but not in males  *p= 0.06, **p= 0.6 
 
 
Subsequent analysis of occupations as previously described [34] revealed that 
the majority of the men (90/128, 70.3%) were dust exposed. Given that very few 
females had such exposures (8/95, 8.4%),  we analysed Cd levels in relation to 
dust exposure and the risk of rheumatoid nodularity given that female nodular 
patients had the highest Cd levels of any group studied (almost twice as high as 
male nodular smoking RA patients).  
 
In non–dust exposed individuals an appreciably raised Cd level was significantly 
associated with nodular RA, OR 2.26 (95% CI 1.08–4.73), p=0.03. In dust 
exposed individuals an appreciably raised Cd level was not associated with 
nodular RA, OR 0.78 (95% CI 0.35–1.76), p=0.557. 
 
In non–smoking, non–nodular patients 1/19 (5.26%) had appreciably raised Cd 
levels compared to 3/10 (30%) of the non–smoker nodular patients. Amongst 
smoking non–nodular patients 39/79 (50.6%) had appreciably raised Cd levels 
compared to smoking nodular patients 36/67 (46%). 
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6.4.5 Nodularity and RA–associated autoantibodies 
 
Nodular RA smokers had significantly raised RF levels of compared to RA 
smokers without nodular disease (median RF 171.5 (IQR 48–394) vs median RF 
31.7 (10.3–170.3), p<0.00001), Figure 17. 
 
Figure 17. Significantly elevated median RF (IQR) levels in nodular RA 
smokers and non–smokers *p<0.00001, **p=<0.00001 
 
 
RF positivity was significantly more prevalent in nodular RA smokers compared 
to RA smokers without nodular disease (84/89 (94%) vs. 141/199 (71%), OR=6.9 
(2.66–17.91), p<0.00001). 
 
ACPA levels were also significantly raised in nodular smokers compared to non–
nodular smokers (median ACPA 250 (IQR 145–426) vs 116 (1–257.5), p<0.0001) 
as were ACPA positivity rates (83/89 (93%) vs 123/191 (64%), OR=7.65 (3.17–
18.4), p<0.0001), Figure 18. 
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Figure 18. Significantly elevated median ACPA (IQR) levels in nodular RA 
smokers and non–smokers *p=0.02, **p<0.0001 
 
 
RF levels were significantly elevated in nodular never smokers, median RF 118 
(62.6–267.3) vs. 30.5 (7–95.3) for never smokers without nodular disease, 
p<0.00001, Figure 3.  ACPA levels were similarly significantly higher in nodular 
never smokers, median ACPA 245 (69.3–385.1) vs. 147.5 (1–280.3) for never 
smokers without nodular disease, p=0.02, Figure 4.  
 
No significant differences were observed in RF (p=0.25), or ACPA (p=0.67) 
between nodular never smokers and nodular smokers. 
 
6.5 Discussion 
 
6.5.1 Nodular RA environmental exposures 
 
Rheumatoid nodules have been of great interest to rheumatology researchers for 
over a hundred years. Histologically, rheumatoid nodules are granulomas 
consisting of a fibrous tissue shell arranged around a centre of fibrinoid necrosis 
[36]. Granulomas have been reported to occur in individuals in association with a 
number of metals including aluminium, barium, beryllium, cobalt, gold, titanium 
and zirconium [37]. In addition, Cd has also been observed to induce the 
formation of granulomas when nebulised into the lung in animal models [26–28]. 
Autophagy has emerged as an important process by which antigen presenting 
cells generate and present citrullinated proteins/peptides [38]. This process is 
induced in vivo by Cd and zinc rather than other metals such as cobalt, iron, lead, 
mercury and selenium [39]. Given that Cd as opposed to zinc is significantly 
raised in smokers as opposed to never smokers [40] and the strong relationship 
between smoking and rheumatoid nodules as highlighted above, we have 
hypothesised that Cd exposure is associated with nodular RA. 
 
In this study we observed that an appreciably raised urinary Cd level in non–dust 
exposed RA patients was significantly associated with the presence of peripheral 
rheumatoid nodules. We suggest that inhaled Cd and the subsequent 
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accumulation of this metal in the lung triggers a granulomatous lung reaction as 
has been described with other inhaled metals such as beryllium [41]. As there is 
a striking concordance between pulmonary and peripheral rheumatoid nodule 
formation we suggest that smoking induces rheumatoid peripheral nodules as a 
consequence of Cd exposure. 
 
6.5.2 Peripheral and pulmonary nodule differences 
 
The central area of the rheumatoid nodule is necrotic and contains fibrinogen and 
in the peripheral part of the necrotic area is fibronectin [42]. Citrullination is noted 
to occur within the rheumatoid nodule as a study noted positive citrulline staining 
in the majority of 26 cases (70%) [43]. At the junction of the necrotic centre and 
the outer fibrous shell is a palisade of activated macrophages and fibroblasts.  In 
the outer layer clustered around blood vessels are T lymphocytes of both CD4 
and CD8 subtype and these tend to accumulate around vessels in the area 
immediately outside the palisade. In close proximity to T cells, dendritic cells have 
been observed [42]. Therefore there is the potential for antigen presentation in 
the peripheral nodule. However, peripheral rheumatoid nodules lack of organised 
lymphoid tissue containing plasma cells. Despite the abundance of citrullinated 
antigens such as fibrin and fibronectin, autoantibody generation within the 
peripheral rheumatoid nodule does not appear to be feasible primarily for this 
reason. 
 
In distinct contrast pulmonary rheumatoid nodules have been observed to consist 
of lymphoid aggregates containing both B lymphocytes and T lymphocytes and 
germinal centres containing follicular dendritic cells in addition to the typical 
histological findings of the peripheral rheumatoid nodule [23]. Supporting the 
hypothesis that pulmonary nodules generate RA autoantibodies to trigger RA 
development (rather than arise as a result of RF and ACPA generated by the 
peripheral RA disease process), is the finding by Caplan [18] that pulmonary 
rheumatoid nodules often precede the development of RA and occurred 
commonly in the absence of RF prior to the development of RA [19]. The 
appearance of pulmonary rheumatoid nodules in the miners described by Caplan 
appears to be the strongest risk factor ever described in the literature for RA 
development with an approximate 364–fold increased risk (51% developing RA 
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as compared to a prevalence of RA in the same era in males living in non–mining 
communities of 0.14%) [44]. 
 
6.5.3 How this hypothesis changes understanding on the pathophysiology 
of nodular RA 
 
Current dogma suggests that rheumatoid nodules develop as a result of the RA 
disease process generating RF and ACPA, and that immune complexes deposit 
in the subcutaneous tissues possibly enhanced by local pressure point areas at 
the elbow, facilitating a local inflammatory process with macrophage activation 
[reviewed in 24]. There has been great interest in the understanding of peripheral 
rheumatoid nodule formation as it has been suggested that the disease process 
that occurs in the rheumatoid nodule shares great similarities with the 
inflammatory process in the synovial tissue described in RA [45].  
 
We have hypothesised that pulmonary rheumatoid nodules generate RA 
associated autoantibodies. In this study we observed that nodular RA patients 
had markedly elevated levels of RA autoantibodies compared to non–nodular RA 
patients and this remained the case when nodular patients were stratified for 
smoking. Smoking is the most important environmental risk factor for the 
development of raised RF levels in RA and is related to pack years smoked [46]. 
However the pack years smoked were very similar between smoking nodular and 
non–nodular RA patients and therefore do not explain the marked difference 
reported here. Remarkably non–nodular RA smokers had very similar RF levels 
to RA non–smokers without nodules. This finding is the first to be reported in the 
literature and suggests that smoking per se does not increase RF levels. We 
hypothesise that  smoking may generate pulmonary rheumatoid nodule formation 
which in turn generate the rheumatoid associated autoantibodies and the 
subsequent development of peripheral rheumatoid nodules.  
 
6.5.4 Limitations 
 
A limitation of this study was to use the presence of peripheral rheumatoid 
nodules as a surrogate for the presence of pulmonary rheumatoid nodules. It is 
conceivable that in some patients with peripheral rheumatoid nodules that the 
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nodules developed as a result of RA associated autoantibody production in the 
joint as a result of longstanding RA. Further studies investigating the levels of RF 
and ACPA in newly diagnosed RA patients with or without peripheral rheumatoid 
nodules may consider undertaking CT chest scans to determine the presence of 
pulmonary rheumatoid nodules and correlate with levels of RA associated 
autoantibodies in order to predict disease progression and response to treatment. 
 
The relationship between measurable bodily Cd levels and RA is complicated. 
For example we have recently demonstrated a markedly increased prevalence of 
inhalational occupational exposures in 546/726 (75%) men with RA [34]. These 
exposures included potent Cd adsorbers such as kaolin, silica, bitumen tar and 
wood dust. Furthermore we have suggested that lung Cd adsorption by the 
inhaled dust results in high lung levels and triggers disease [33]. Accordingly an 
enhanced Cd lung adsorption will result in a reduced systemic absorption and 
therefore reduced urinary level of Cd despite high lung levels which would 
enhance the risk of pulmonary rheumatoid nodule formation.  
 
Interestingly in this study we found that urinary Cd levels were significantly lower 
in dust exposed nodular RA patients compared to non–dust exposed nodular and 
non–nodular RA patients. This highlights the importance of lung Cd adsorption 
and possibly suggests that measuring bodily Cd levels in terms of urine or blood 
levels may overlook high levels of Cd in the lung which may have the potential to 
initiate RA via the generation of rheumatoid nodule formation. We suggest that 
studies investigating the relationship between RA pathogenesis and Cd levels 
take into account the occupational history as well as the smoking history of the 
patient as blood or urine levels in Cd exposed individuals are likely to be reduced 
as a result Cd adsorption in co–exposed lungs. This is particularly relevant to 
men with RA as the majority of these individuals have been exposed to 
occupational dusts [34]. It is noteworthy that a large Korean epidemiological study 
of RA prevalence revealed a strong association between Cd blood levels in 
women, but not men [47]. 
 
6.6 Conclusions 
 
There does appear to have been a change in the natural history of RA over the 
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last 40–50 years in terms of expression of nodular disease. It would be easy to 
ascribe this change to better treatment strategies and more efficacious 
medications for RA. However, these changes would not affect the type of RA at 
presentation. For example a study of 102 early RA patients in London, UK in the 
mid– 1970s observed that 12/102 (12%) individuals had subcutaneous nodules 
at presentation rising to 32/102 (31%) at 3 years [48]. In contrast a study in 
Norfolk, UK (1990–1993) observed that 37/486 (7.6%) of RA patients had 
subcutaneous nodules at presentation and at 3 years follow up this had fallen to 
31/486 (6.4%) [10]. This stark change appears to have occurred before the 
advent of biologics therapies and before the routine first line use of methotrexate. 
We suggest that the natural history of nodular RA may reflect the marked drop in 
Cd exposure in UK society. The industrial revolution was associated with a 15–
fold increase in anthropogenic emissions of Cd in Western Europe [49] and since 
the 1960s there has been a 2.5–fold decrease in emissions of Cd [50]. 
Additionally the marked reduction in the prevalence of smoking is also likely to 
reduced individuals exposure to Cd [51]. This is not the first study to observe an 
association between raised bodily Cd levels [47, 52–54], however this study is 
the first to describe a particular RA phenotype that most strongly associates with 
an increased Cd exposure.  Additionally, this hypothesis has generated the first 
evidence of an environmental risk factor, other than cigarette smoking, for the 
development of nodular RA. 
 
As described above the rheumatoid nodule is a potentially important source of 
citrullinated proteins such as fibrin and fibronectin which can be presented to the 
immune system by resident antigen presenting cells such as macrophages, 
fibroblasts and dendritic cells. Pulmonary rheumatoid nodules also have the 
potential to generate RA associated autoantibodies. Given that a recent study 
observed intracellular citrullination of proteins in lung cells exposed to Cd [55], 
we hypothesise that Cd inhalation orchestrates the development of pulmonary 
rheumatoid nodules, intracellular citrullination and the subsequent formation of 
RA associated autoantibodies leads to immune complex formation and activation 
of various immune cells that trigger the development of nodular RA. However, Cd 
exposure may also predispose to non–nodular RA. In this study we noted 
appreciably raised Cd levels in non–nodular patients irrespective of their smoking 
history and it is conceivable that Cd accumulation in the bone marrow may result 
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in altered mesenchymal stem cell viability as described in an animal model [56]. 
Certainly mesenchymal stem cells have the potential to have a significant role in 
the pathogenesis of RA [57]. 
 
It is noteworthy that 27 years ago that Fischer in Medical hypotheses 
hypothesised that tobacco smoking was a risk factor for RA [58]. We have 
extended Fischer’s hypothesis further and suggest that specifically, it is Cd 
derived mainly from cigarette smoke that triggers RA disease development. We 
suggest that one potential mechanism by which Cd triggers RA is as a result of 
lung granuloma formation with a subsequent autoantibody response triggering 
seropositive RA. 
 
The pilot data from the limited study presented here supports this hypothesis. We 
would welcome wider study incorporating local tissue cadmium analysis to study 
lung granulomata in RA and pre–RA states, and the use of diagnostic imaging in 
assessing pulmonary nodularity prevalence and impact on RA disease 
development. 
 
 
  
154 
 
6.7 Chapter 6 references 
 
1. Landre–Beauvais AJ. The first description of rheumatoid arthritis. 
Unabridged text of the doctoral dissertation presented in 1800. Joint Bone Spine 
2001;68:130–143. 
2.  Khurana R, Berney SM. Clinical aspects of rheumatoid arthritis.  
Pathophysiology 2005;12:153–165. 
3. Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. 
Rheumatoid factor is the major predictor of increasing severity of radiographic 
erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, 
a large inception cohort. Arthritis Rheum 2002;46:906–912. 
4.  Rothschild BM. Rheumatoid arthritis at a time of passage . J Rheumatol 
2001;28:245–250. 
5.  Stolt P, Bengtsson C, Nordmark B et al. Quantification of the influence of 
cigarette smoking on rheumatoid arthritis: results from a population based case–
control study, using incident cases. Ann Rheum Dis 2003;62:835–841. 
6.  Saag KG, Cerhan JR, Kolluri S Ohashi K, Hunninghake GW, Schwartz DA. 
Cigarette smoking and rheumatoid arthritis severity.  Ann Rheum Dis 
1997;56:463–469. 
7.  Nyhäll–Wåhlin BM, Jacobsson LT, Petersson IF et al. Smoking is a strong 
risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis 
2006;65:601–606.  
8.  Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism 
Association 1987 revised criteria for the classification of rheumatoid arthritis. 
Arthritis Rheum 1988;31:315–324. 
9.  Walker WC, Wright V. Rheumatoid pleuritis. Ann Rheum Dis 1967;26: 467–
474. 
10.  Harrison BJ, Silman AJ, Wiles NJ Scott DG, Symmons DP. The association 
of cigarette smoking with disease outcome in patients with early inflammatory 
polyarthritis. Arthritis Rheum 2001;44:323–330. 
11.  Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification 
criteria: an American College of Rheumatology/European League Against 
Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569–2581. 
12.  Bennett GA, Zeller JW, Bauer WA. Subcutaneous nodules of rheumatoid 
arthritis and rheumatic fever: a pathologic study. Arch Pathol 1940;30:70–89. 
155 
 
13.  Aronoff A, Bywaters EG, Fearnley GR. Lung lesions in rheumatoid arthritis. 
BMJ;2:228–232. 
14.  Cortet B, Flipo RM, Rémy–Jardin M et al. Use of high resolution computed 
tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 
1995;54:815–819. 
15.  Remy–Jardin M, Remy J, Cortet B Mauri F, Delcambre B. Lung changes 
in rheumatoid arthritis: CT findings.  Radiology 1994;193:375–382. 
16.  Perez T, Remy–Jardin M, Cortet B. Airways involvement in rheumatoid 
arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med 
1998;157:1658–1665. 
17. Mori S, Cho I, Koga Y, Sugimoto M. Comparison of pulmonary 
abnormalities on high–resolution computed tomography in patients with early 
versus longstanding rheumatoid arthritis. J Rheumatol 2008;35:1513–1521. 
18.  Caplan A. Certain unusual radiological appearances in the chest of coal–
miners suffering from rheumatoid arthritis. Thorax 1953;8:29–37. 
19.  Caplan A, Payne RB, Withey JL.  A broader concept of Caplan's syndrome 
related to rheumatoid factors.  Thorax 1962;17:205–212. 
20.  Turner S, Cherry N. Rheumatoid arthritis in workers exposed to silica in 
the pottery industry. Occup Environ Med 2000;57:443–447. 
21.  Constantinidis K, Musk AW, Jenkins JP Berry G. Pulmonary function in 
coal workers with Caplan's syndrome and non–rheumatoid complicated 
pneumoconiosis. Thorax 1978;33:764–768. 
22.  Perry E, Kelly C, Eggleton P, De Soyza A, Hutchinson D. The lung in 
ACPA–positive rheumatoid arthritis: an initiating site of injury? Rheumatology 
2014;53:1940–1950. 
23.  Highton J, Hung N, Hessian P, Wilsher M. Pulmonary rheumatoid nodules 
demonstrating features usually associated with rheumatoid synovial membrane. 
Rheumatology 2007;46:811–814.  
24.  Highton J, Hessian PA, Stamp L. The rheumatoid nodule: peripheral or 
central to rheumatoid arthritis? Rheumatology 2007;46:1385–1387.  
25.  Hutchinson D. Cadmium, one of the villains behind the curtain: has 
exposure to cadmium helped to pull the strings of seropositive rheumatoid 
arthritis pathogenesis all along?  Int J Rheum Dis 2015;18:570–573. 
26.  Ho CC, Chang H, Tsai HT et al. Quantum dot 705, a cadmium–based 
nanoparticle, induces persistent inflammation and granuloma formation in the 
156 
 
mouse lung. Nanotoxicology 2013;7:105–115.  
27.  Coccini T, Barni S, Vaccarone R Mustarelli P, Manzo L, Roda E. Pulmonary 
toxicity of instilled cadmium–doped silica nanoparticles during acute and 
subacute stages in rats. Histol Histopathol 2013;28:195–209. 
28.  Kutzman RS, Drew RT, Shiotsuka RN, Cockrell BY. Pulmonary changes 
resulting from subchronic exposure to cadmium chloride aerosol. J. Toxicol 
Environ Health 1986;17:175–189. 
29.  Järup L, Åkesson A. Current status of cadmium as an environmental health 
problem. Toxicol Appl Pharmacol 2009;238:201–208.  
30.  Morton J, Tan E, Leese E, Cocker J. Determination of 61 elements in urine 
samples collected from a non–occupationally exposed UK adult population.  
Toxicol Lett 2014;231:179–193. 
31.  Ganguly K, Levänen B, Palmberg L Åkesson A, Lindén A.  Cadmium in 
tobacco smokers: a neglected link to lung disease?  Eur Respir Rev 
2018;27:170122. 
32.  Blanc PD, Iribarren C, Trupin L et al. Occupational exposures and the risk 
of COPD: dusty trades revisited. Thorax 2009;64:6–12. 
33.  Murphy D, Bellis K, Hutchinson D. Occupational dust and cigarette smoke 
exposure might link rheumatoid arthritis to COPD.  Lancet Respir Med 2018; 
https://doi.org/10.1016/S2213–2600(18)30188–72018, accessed 22nd July 2018. 
34.  Murphy D, Bellis K, Hutchinson D.  Vapour, gas, dust and fume 
occupational exposures in male patients with rheumatoid arthritis resident in 
Cornwall (UK) and their association with rheumatoid factor and anti–cyclic protein 
antibodies: a retrospective clinical study.  BMJ Open 2018;8:e021754.  
35.  Department for Communities and Local Government. The English Indices 
of Deprivation 2015 Technical Report. 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/att
achment_data/file/464485/English_Indices_of_Deprivation_2015_-_Technical-
Report.pdf accessed 23rd July 2018. 
36.  Ziff M, Kantor T, Bien E, Smith A. Studies on the composition of the fibrinoid 
material of the subcutaneous nodule of rheumatoid arthritis. Eur J Clin Invest 
1953;32:1253–1259.  
37.  Newman LS Metals that cause sarcoidosis. Semin Respir Infect 
1998;13:212–220. 
38.  Ireland JM, Unanue ER. Processing of proteins in autophagy vesicles of 
157 
 
antigen–presenting cells generates citrullinated peptides recognized by the 
immune system.  Autophagy 2012;8:429–430. 
39.  Chargui A, Zekri S, Jacquillet G et al. Cadmium–induced autophagy in rat 
kidney: an early biomarker of subtoxic exposure. Toxicol Sci 2011;121:31–42. 
40. Bernhard D, Rossmann A, Wick G. Metals in cigarette smoke. IUBMB life 
2005;57:805–809. 
41.  Kreiss K, Miller F, Newman LS, Ojo-Amaize EA, Rossman MD, Saltini C. 
Chronic beryllium disease—from the workplace to cellular immunology, molecular 
immunogenetics, and back. Clin Immunol Immunopathol 1994;71:23–129. 
42  Ziff M. The rheumatoid nodule. Arthritis Rheum 1990;33:761–767. 
43.  Bongartz T, Cantaert T, Atkins SR et al. Citrullination in extra–articular 
manifestations of rheumatoid arthritis. Rheumatology 2006;46:70–75. 
44.  Hargreaves ER. A survey of rheumatoid arthritis in West Cornwall: a report 
to the Empire Rheumatism Council. Ann Rheum Dis 1958;17:61–75.  
45.  Edwards JC, Wilkinson LS, Pitsillides AA. Palisading cells of rheumatoid 
nodules: comparison with synovial intimal cells. Ann Rheum Dis 1993;52:801–
805. 
46.  Wolfe F. The effect of smoking on clinical, laboratory, and radiographic 
status in rheumatoid arthritis.  J.Rheumatol, 2000;27:630–637. 
47.  Sang Hyun Joo, Dong Jin Go, Eun Young Ahn et al. A large survey data 
analysis of the prevalence of rheumatoid arthritis in relation to serum cadmium 
and other metal serum and urinary concentrations: A Study of the Korean National 
Health and Nutrition Examination Survey (KNHANES)  
BMJ Open 2018; awaiting publication. 
48.  Fleming A, Dodman S, Crown JM, Corbett M. Extra–articular features in 
early rheumatoid disease. BMJ 1976;1:1241–1243. 
49.  Van de Velde K, Boutron CF, Ferrari CP et al.  A two hundred years record 
of atmospheric cadmium, copper and zinc concentrations in high altitude snow 
and ice from the French-Italian Alps. Geophys. Res. Lett 2000;27:249–252. 
50. Boutron CF, Görlach U, Candelone JP, Bolchov MA, Delmas RJ. Decrease 
in anthropogenic lead, cadmium and zinc in Greenland snows since the late 
1960s. Nature 1991;353:153–156. 
51. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking 
cessation, and lung cancer in the UK since 1950: combination of national 
statistics with two case–control studies. BMJ 2000;321:323–329. 
158 
 
52.  Afridi HI, Kazi TG, Brabazon D, Naher S. Association between essential 
trace and toxic elements in scalp hair samples of smokers rheumatoid arthritis 
subjects. Sci Total Environ 2011;412–413:93–100.  
53.  Afridi HI, Kazi TG, Brabazon D, Naher S. Interaction Between Zinc, 
Cadmium, and Lead in Scalp Hair Samples of Pakistani and Irish Smokers 
Rheumatoid Arthritis Subjects in Relation to Controls. Biol Trace Elem Res 
2012;148:139–147.  
54.  Afridi H, Kazi T, Talpur F, Naher S, Brabazon D. Relationship between 
toxic metals exposure via cigarette smoking and rheumatoid arthritis. Clin Lab 
2014;60:1735–1745. 
55. Hutchinson D, Müller J, McCarthy JE et al. Cadmium nanoparticles 
citrullinate cytokeratins within lung epithelial cells: cadmium as a potential cause 
of citrullination in chronic obstructive pulmonary disease. Int J Chron Obstruct 
Pulmon Dis 2018;13:441–449.  
56. Mehranjani M, Mosavi M.  Cadmium chloride toxicity suppresses 
osteogenic potential of rat bone marrow mesenchymal stem cells through 
reducing cell viability and bone matrix mineralization. Indian J Med Sci 2011; 
65:177–186. 
57. De Bari C, Dell'Accio F, Tylzanowski P Luyten FP. Multipotent 
mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 
2011;44:1928–1942. 
58. Fischer KM. Hypothesis: tobacco use is a risk factor in rheumatoid arthritis. 
Med hypotheses 1991;34:116–117. 
  
159 
 
Chapter 7: Further discussion and conclusions 
 
The collection of published papers that comprise Chapters 2-6 of this dissertation 
are now related back to the original hypotheses detailed in Chapter 1, highlighted 
by the published case report therein. New findings, strengths, weaknesses, 
unanswered questions, and directions for future research are discussed. 
  
7.1 Principal findings on original hypotheses 
Hypothesis 1: RA is precipitated by inhaled environmental exposures, and 
patients with multiple inhalation exposures are more likely to have elevated 
autoantibody levels to both rheumatoid factor (RF) and anti-citrullinated protein 
antibody (ACPA).  
Specific RA cases exposed to vapours, gas dust and fumes have been analysed 
and published [1]. A literature search into inhalation exposures in RA with 
reference to occupation has been undertaken and published [2], with discussion 
and reflection into potential pathophysiological mechanisms by which inhalational 
exposures may trigger RA. Data have been collected, analysed and published on 
the smoking habits, occupational exposures and rheumatoid autoantibody levels 
of an entire cohort of male RA patients under follow up at the Royal Cornwall 
Hospital, UK [3]. Overwhelming over-representation of vapour, gas dust and fume 
(VGDF) exposure (546/726, 75%) and smoking (561/726, 77%), was observed. 
Significantly higher rheumatoid autoantibody levels were found in RA patients 
who have multiple inhalational exposures [3]. A positive correlation was observed 
between VGDF exposure and increased RF levels. Combining this with cigarette 
smoking resulted in significantly higher RF levels, particularly with multiple 
exposures. No association of ACPA seropositivity rates or titres with VGDF 
exposure was observed. 
Hypothesis 2:  There is a common autoantigen in many RA patients to explain 
autoantibody clustering of both RF and ACPA. 
Chapters 3 and 4 [4,5] explored the possibility that RF and ACPA co-exist. A study 
to analyse the relationship between RF, smoking, and HLA-DRB1 alleles coding 
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a “shared epitope” (SE) in relation to ACPA positivity in RA patients was 
conceived, completed and published [4]. It was found that ACPA positivity in RA 
strongly associates with increasing RF titre independent of smoking; and this 
relationship is dependent on carriage of SE alleles. No relationship was found 
between ACPA and smoking in RF negative patients. 
With the primacy of RF demonstrated above and given that immunoglobulin G 
(IgG) is the sole RF antigen, a hypothesis that post-translational modifications to 
IgG may explain clustering of RA associated autoantibodies such as ACPA was 
generated. Subsequent laboratory analysis suggested that post-translational 
modification processes such as citrullination and carbamylation, occurring at the 
Fc binding region of IgG heavy chain fragments, may be a potential universal 
antigen in RA. 
Hypothesis 3: The presence of nodular RA is associated with raised rheumatoid 
factor (RF) and anti-citrullinated protein antibody (ACPA) levels irrespective of the 
smoking history.  
Chapter 3 [4] was originally conceived as an interim analysis of evidence 
gathered; and revealed a striking pattern that was at odds with the current dogma 
on the relationship between smoking and autoantibody generation.  It was 
discovered that ACPA-postive RA is primarily determined by RF titre and the 
shared epitope, rather than smoking in its own right. Following this, analysis was 
completed on RA patients with rheumatoid nodules stratified for smoking.  
Nodular RA patients demonstrated higher rheumatoid autoantibody levels than 
non smoking comparable cohorts.  
Further analysis of the relationship between subcutaneous nodules, rheumatoid 
autoantibodies and smoking was undertaken. Nodular RA patients who were 
smokers had significantly higher RF levels than age, sex, and deprivation 
matched non-nodular RA controls when stratified for cigarette smoking (Chapter 
6) [6]. This may be due to rheumatoid autoantibody production from rheumatoid 
pulmonary nodules in the lung (discussed below). 
Hypothesis 4: RA smokers exposed to VGDF develop pulmonary nodules, 
adsorbing heavy metal toxins into lung granulomata rather than into the systemic 
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circulation.  
Comparing nodular and non-nodular RA patients, significantly increased RF and 
ACPA levels were observed irrespective of the smoking history of the patient. 
Existing dogma would suggest that raised levels of RF predispose to the 
development of subcutaneous rheumatoid nodules in RA patients. However, my 
literature review [2] pertaining to the development of pulmonary rheumatoid 
nodules in Welsh coal miners (Caplan's syndrome) indicated that pulmonary 
nodules can commonly occur in individuals without RA and were not associated 
with RF in many of these individuals. This important historical antecedent strongly 
suggested that pulmonary rheumatoid nodules are not triggered by the RA 
disease process nor RF.  
Interestingly in those individuals with pulmonary rheumatoid nodules described 
by Caplan, approximately 50% had a diagnosis of seropositive RA and peripheral 
rheumatoid nodules were highly prevalent [7]. This raises the possibility that 
pulmonary rheumatoid nodules triggered RA by local RF production in the lung 
and subsequently predisposed the men to subcutaneous nodules. I have 
hypothesised that subcutaneous nodular RA smokers have a high prevalence of 
pulmonary rheumatoid nodules and as such have higher RF levels than non-
nodular RA smokers. The RF levels in nodular RA smokers were remarkably 
higher than non-nodular RA smokers and interestingly the non-nodular RA 
smokers/non-smokers had very similar RF levels. I suggest the main mechanism 
by which RA smokers generate raised RF levels is via pulmonary rheumatoid 
nodule formation, given that pulmonary rheumatoid nodules contain germinal 
centres capable of autoantibody production [6]. Comparing nodular and non-
nodular RA patients, significantly higher urinary cadmium levels were seen in 
nodular RA patients who did not have exposure to vapour, gas dust or fumes. 
Despite comparable smoking histories, individuals with nodular RA who were 
VGDF exposed had significantly lower urinary Cd levels than individuals who 
were not VGDF exposed [6]. This intriguing finding strengthens the concept that 
adsorption onto inhaled dust particles may take place, potentially rendering 
urinary cadmium an ineffective measure of general Cd exposure; higher urinary 
cadmium levels are associated with the formation of peripheral rheumatoid 
nodules in RA patients unexposed to vapour, gas, dust and fumes (VGDF). 
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This has implications for the VGDF and cigarette smoke co-exposed RA patient.  
I have subsequently hypothesised that cadmium-laden dust complexes become 
“bound up” in localised granulomata forming rheumatoid pulmonary nodules 
which stimulate local rheumatoid autoantibody production and break immune 
tolerance. This hypothesis highlights the importance of taking into consideration 
the occupational history of an individual when considering the association 
between disease development and urinary Cd levels. It has recently been 
highlighted that measuring blood and urinary Cd levels may overlook the 
association between Cd exposure and diseases such as emphysema by lung 
retention [8], specifically triggering lung disease, suggesting that further studies 
investigating the relationship between Cd exposure and emphysema should 
specifically measure Cd lung tissue levels.  
Similarly, given that RA is initiated in the lung, studies investigating the 
association between RA and Cd exposure need to consider stratifying individuals 
for exposure to dusts known to adsorb Cd. A recent Korean study supports a 
strong association between blood Cd levels (19-fold increased prevalence in 
those in highest vs. the lowest quartile), observed in women [9]. However, in this 
study no association was observed in men. It would be interesting to know the 
prevalence of VGDF exposure in the men and how this related to blood Cd levels 
in this study population. 
7.2 New findings 
7.2.1 Inhalation exposures increase RA autoantibody levels 
Analysing the entire male RA cohort under follow up at the Royal Cornwall 
Hospital, it was found that VGDF exposure was associated with increased RF 
levels [3].  Combination exposure to smoking and VDGF resulted in higher RF 
levels, particularly with multiple exposures occurring in the workplace. These 
compelling findings demonstrate the importance of combinations of inhalational 
exposures in RF generation, and the consequent impact on RA disease 
development, more than observed in an individual exposure. This is the first study 
to focus on occupational exposures combined with smoking as risk factors for 
autoantibody development in male RA; and is the first study in RA to use 
combined analysis of vapour, gas dust and fume inhalation. 
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Over representation of certain trades has allowed for further subgroup analysis 
within this study. The granularity of the data and the ability to explore historical 
exposures via telephone questionnaire follow up of what a job entailed was a 
strength of this study. For example, of 155/726 (21%) wood dust exposed cases, 
44/155 (28%) identified wood dust as their primary occupational exposure as 
carpenters, approximately seven times higher than expected given UK 
employment census data [10]. However, limitations in exposure classification, 
both in terms of definition and assessment or grade of exposure have been 
acknowledged [2,3] 
My previously published data on this cohort have revealed significantly higher RF 
titres and ACPA seropositivity rates amongst woodworkers compared to matched 
controls [11]. Similarly, amongst rock miners, 54/98 (55%) had exposure to kaolin 
(china clay) dust, approximately 12 times higher than then expected from 
occupational census data for the population studied.  Again, previously published 
data have revealed significantly higher RF and ACPA seropositivity rates and 
higher RF titres that matched controls [12]. Furthermore, significantly more kaolin 
exposed workers demonstrated nodular disease than controls, independent of 
smoking [12]. 
7.2.2 Autoantibody associations 
Surprisingly, a literature search revealed no studies investigating the relationship 
between the presence and levels of a positive RF, cigarette smoking, carriage of 
the SE alleles, and the frequency of ACPA in RA. In analysing the relationship 
between RF titre, smoking and HLA-DRB1 SE alleles in relation to ACPA 
positivity, I discovered that ACPA positivity in RA strongly associates with 
increasing RF titre independent of smoking, with the relationship dependent on 
carriage of SE alleles. No relationship was observed between ACPA and smoking 
in RF negative patients [4]. Investigating the clustering RF and ACPA in both 
smokers and never smokers for the first time, this study addressed the co-
existence of rheumatoid autoantibodies in those strongly positive for RF 
irrespective of smoking. These findings deepen the understanding from 
established studies identifying smoking and carriage of the SE alleles as risk 
factors for ACPA positive RA [13].   
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Previously, it was suggested that carriage of the SE was significantly associated 
with ACPA positive/RF negative RA rather than RF positive/ACPA negative RA. It 
was suggested that the primary process in RA involved anti-citrulline immunity 
influenced by an interaction between smoking and carriage of the SE. However, 
the tiny proportion of ACPA positive/RF negative cases (13%) compared to the 
majority of ACPA positive/RF positive cases (87%) [13], suggested an association 
here as well. It is perhaps surprising that an association has not been analysed 
sooner.  
I would suggest that given the overall strong association between the carriage of 
SE alleles and ACPA positivity, it follows that the SE is principally associated with 
ACPA positive/RF positive RA. Consequently, the findings here [4] can be 
reconciled with previous research [13]; and can refocus the current 
understanding of autoantibody clustering in RA. Similarly, the previously held 
observation that smoking interacts with the SE to generate ACPA positivity overall 
in RA [13] is factually correct; my findings suggest that a more precise 
interpretation of this interaction is between smoking, the SE, and both RA 
autoantibodies. Furthermore, my findings have stimulated analysis in other 
groups looking at autoantibodies in RA such as the Karolinska Institute, Sweden, 
and planning to test my hypotheses in the wider “EIRA” case-control study 
population. 
In researching the common clustering of autoantibodies in Hypothesis 2, this 
thesis has added significantly to understanding how autoantibodies associate in 
RA; and identified particular inhalation exposures that predispose. This thesis has 
stimulated global interest in this area, discussed below (7.5.5.2).  
7.2.3 IgG as a common autoantigen 
An important finding of this dissertation, and significant addition to academic 
thought, is the revelation of IgG as a potential common antigen in RA. It is 
suggested that a post translationally modified, misfolded heavy chain fragments 
of immunoglobulin G (IgG) could be dominant antigen in RA [14]. Post 
translational modification of the Fc binding region of IgG may generate an 
antibody response specific to RA, generating both a strongly positive “clustered” 
RF and ACPA response.  
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Recent findings of citrullinated IgG in synovial tissue biopsies of RA patients 
support this, with IgG as a target of peptidylarginine deiminase (PAD) 2 and PAD4 
activity [15]. Bispecific antibodies against cyclic citrullinated peptides and IgG in 
RA have been demonstrated, suggesting that citrullinated IgG may generate both 
a RF and ACPA response [16].  Citrullinated heavy chain fragments of IgG have 
been demonstrated in RA synovial fluid [17], amongst other citrullinated peptides.  
Whilst a plethora of proteins of a comparable size have the potential to be 
citrullinated and/or carbamylated, RF only has one autoantigen; the heavy chain 
fragment of IgG. This can be generated by B cells in the lungs of smokers; a 
process facilitated by SE alleles with the B cell acting as both an antigen 
presenting cell and the source of the antigen [5]. Though described in the lung, 
both rheumatoid joints and other mucosal surfaces could be the host the same 
process of B cell activation through the development of tertiary lymphoid tissue.  
The explanation of a common autoantigen has been demonstrated for the first 
time as part of this research [5], with the finding that citrullinated and 
carbamylated IgG heavy chain fragments are present in the sera of RA patients 
and in a pre-RA bronchiectasis patient. Whilst citrullinated IgG was observed in 
healthy subjects and RA patients, specific citrullination and carbamylation of the 
RF binding site was only observed in patients with seropositive RA (4/8) and in a 
patient with bronchiectasis who progressed to develop seropositive RA (1/4).  The 
role of post-translational modification to the RF binding site region of IgG in the 
development of RA may prove to be significant and is worthy of further study; 
especially given the changing receptor polarity of the Fc region that occurs when 
it becomes post-translationally modified, affecting ligand interaction [18] and 
potentially stimulating tertiary lymphoid tissue development, which sets it apart 
from other citrullinated autoantigens. 
This aspect explored in my thesis is limited by the small sample size and its cross-
sectional nature: my dissertation research only represents a moment in time in 
the sera of patients and healthy controls. However, an antibody response is a 
legacy of past antigen exposure, persisting over time. The development of an 
antibody against the post-translationally modified Fc region of IgG may be of 
value as a specific diagnostic marker in the early detection of RA. 
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7.2.4 Adsorption 
Investigating my hypotheses in this thesis, I uncovered many interesting findings 
from historical analysis of literature, cutting edge analysis of proteomics, and the 
basic epidemiology of the cohort that I was studying.  I wanted to find a unifying 
theory, an explanation for why VGDF and smoking co-exposures leads to more 
severe RA.  From the literature searches and detailed patient histories conducted 
as part of this dissertation, I have presented information to support a novel 
hypothesis of heavy metal adsorption onto inhaled dust particles driving RA 
pathophysiology.  
 
Utilising the historical significance of Caplan’s syndrome seen in coal workers in 
the 1950s [7], I was struck by the prevalence in kaolin workers being highest of 
any occupation ever reported [19], given the over-representation of current and 
former kaolin workers found in the Cornish RA population [12]. 
I have suggested that the kaolinite mineral capacity for adsorption of heavy 
metals may explain the scale and pattern of Caplan's syndrome prevalence seen 
in global mining populations; and further explain the pronounced interaction seen 
in sequential dust exposure and heavy metal laden cigarette smoke, particularly 
with reference to cadmium. I believe this novel process of adsorption to be an 
overlooked factor in RA disease development, explaining the interaction of 
inhalational exposures and cigarette smoking seen in RA [3,4].  
As discussed in Chapter 2 [2], the adsorption process is not exclusive to Kaolin, 
although the chemical structure of Kaolin renders it exquisitely capable in this 
regard. The RA affected kaolin mining population of Cornwall’s unique exposures 
have highlighted what may be a widely applicable mechanism of disease 
development.  Whilst the socio-economic determinants of health discussed in 
Chapter 1 drive a lot of the co-exposure burden seen in the Cornish RA 
population, the snapshot provided by the surviving workers of the Kaolin industry 
may prove invaluable in the history of RA understanding.  
7.3 Strengths and weaknesses 
 
167 
 
7.3.1 Patient involvement 
Patient involvement was central in this research and dissertation.  The narrative 
of the patient case study detailed in Chapter 1 [1] was a typical example, 
providing the starting point from which the overall hypothesis and aims came 
from, developed from detailed histories of individual patient experiences of RA in 
Cornwall, UK. The initial hypothesis was presented at a local meeting of the 
National Rheumatoid Arthritis Society, attended by over 100 members, the 
majority of whom were RA patients.  Subsequent interest following the meeting 
led to further discussion as to the development of a protocol that would be 
acceptable to patients in terms of its design and acceptability. From initial ideas, 
this was refined and presented to the committee of the Cornwall Arthritis Trust, a 
local charity supporting arthritis patients.  Specific feedback around consent form 
wording, questionnaire design, and follow up arrangements enabled patients who 
may not have been able to complete or return written questionnaires to access 
the research.   
Patient involvement in this process was invaluable for how best to manage and 
undertake the research in a way that was minimally intrusive for patients in their 
regular clinical care. This process was greatly beneficial in writing the Health 
Research Authority (HRA) protocol in Appendix 1. Dissemination of results 
relating to this research continues to take place within the Rheumatology 
Department, Royal Cornwall Hospital, via poster presentation.  
The impact of such detailed patient involvement throughout the research process 
is demonstrated in the response rates seen; study design with face-to-face 
interviewing and telephone follow up was designed to minimise non-response.  At 
termination, only 8/726 (1%) of the entire male RA cohort under follow up were 
non-responders.  
Non-response, particularly in postal studies, is strongly correlated with low levels 
of formal education. This is particularly relevant to the investigation of RA as there 
is an established literature linking RA and low levels of formal education [20-22]. 
In the UK, RA patients have a high prevalence of functional illiteracy with 2 British 
studies observing an identical rate of 15% [23,24].  Perhaps unsurprisingly, a USA 
study observed that literacy was positively related to educational attainment. 
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College graduates recorded higher mean literacy scores than high school 
graduates, which were higher than “dropouts” [25].  A divergence in occupations 
related to literacy scores was noted. Agriculture, construction, manufacturing, and 
mining had the lowest scores [25].  
Unsurprisingly again, such occupations are all associated with male RA [2]. 95% 
of occupations held by individuals studied here required no formal academic 
qualifications beyond secondary education. It was therefore not possible to 
compare low and high levels of formal education for RA autoantibody prevalence 
in our male RA cohort. I suggest that it is imperative that further studies 
investigating the impact of socioeconomic status or formal education levels on 
male RA susceptibility, severity, comorbidity, and mortality consider an individual’s 
occupation as an important confounding factor. 
7.3.2 Literature search 
From the literature search in Chapter 2 [2], evidence was found for a variety of 
occupations demonstrated to be associated with an increased risk for RA. This is 
the first such review to evaluate published clinical reports related to occupations 
associated with RA development. As such is a worthwhile addition to the area of 
occupations and RA. However, heterogeneity between study populations, data 
collection methods, and occupational classification systems precluded 
systematic literature review. The existing evidence was primarily generated 
through Swedish case referent and linkage studies, and involved exposure to 
inhalational particles, in the form of dust, fumes or both. It is acknowledged that 
a future systematic database review in this important area is still required; and 
should be a priority for researchers in this area as further evidence emerges.  
 
The major limitation of the existing data lies in the extent to which it can be applied 
elsewhere; Swedish data may not adequately represent the occupational 
experiences of individuals in other countries. Global health and safety legislation, 
working patterns and smoking habits vary considerably. In addition to the reverse 
social class gradient amongst Swedish smokers discussed in Chapter 2 (making 
VGDF and cigarette smoking co-exposure less likely), Sweden has a long history 
of recognition of the potential occupational risks to its population, with consequent 
state intervention, since the Occupation Hazard Act of 1889 [26].  Occupational 
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health and safety in Sweden is regulated by state legislation, with the 
Occupational Safety and Health Act of 1949 and the Working Environment Act of 
1977 predating equivalent health and safety legislation elsewhere in the world 
[26].  There is also a history of concordance with policy between the Swedish 
Employers Confederation (SAF) and the Swedish Trade Union Confederation 
(LO), being reported until the early 1990s [27].  
 
I would argue that transposing the findings in this advanced western democracy, 
with a strong history of public health legislation and implementation to protect its 
population, would have limited applicability elsewhere. Risks highlighted in the 
Swedish population are likely to be underestimated, and further risks may well be 
missed.  
 
7.3.3 Occupational exposure classification 
 
This research does not contain a job exposure matrix to classify individual 
occupations. It was not intended to sub-stratify into occupational classifications, 
though the granularity of data collected does allow this; and the coding of 
occupations is ongoing as detailed in Chapter 5 [3]. Although the lack of a matrix 
may be interpreted as a weakness, the key argument against this is the finding 
that the most important determinant of autoantibody levels is the combination of 
inhalational exposures rather than the specific occupation itself. 
 
Much of the literature investigating occupational risk and RA takes the form of 
case control/case referent or linkage studies from large dataset analysis 
(reviewed in [2]). Studies investigating occupation and RA risk may only consider 
the last occupation undertaken by the respondent [28], or the main occupation 
recorded in the database studied. It is not uncommon for individuals with low 
literacy levels to move from one casual job to another; accruing different 
occupational exposures over time and the last recorded job may not reflect these 
exposures. In poorer populations, trade sub-specialisation and health and safety 
legislation adherence may be less evident. Throughout their working careers, 
unskilled workers will encounter multiple occupational exposures. Construction 
labourers, for example, may be co-exposed to silica dust, inorganic non-silica 
dusts, wood dust, and diesel fumes.  
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Furthermore, an individual’s occupation “title” does not always reflect the 
inhalational exposures the individual may have been exposed to, as well as 
missing factors such as hobbies, environmental residence, and primary and/or 
passive cigarette smoke. Job exposure matrices give a broad indication of what 
exposures may have occurred if one is to assume heterogeneity of tasks. 
However, subspecialisation with jobs is missed in such tools; e.g. in the case of 
a gardener, a job matrix would not identify the individual who specialises in 
building retaining walls (with consequent regular cement dust exposure), or the 
individual who primarily repairs garden machinery and is regularly exposed to 
welding fumes and oils. Therefore, we suggest that studies investigating 
individual occupational risk and RA via single job title analysis may be 
confounded by multiple inhalational insults, even when correcting for smoking. In 
an analysis of silica vs. non-silica dust exposed construction workers, Blanc et al. 
[29] excluded 40,645/240,983 cases who were exposed to wood dust, gas or 
fumes to reduce confounding. I would argue that this is precisely the type of 
multiple exposure that would benefit from further analysis to investigate RA risk.  
Additionally, database referent studies choose to include patients under the age 
of 70 [30]. Many occupational diseases, such as asbestos exposure [31], have a 
long latency period between the inhaled occupational insult and disease 
development. Though we found a significantly earlier age of onset in our most 
severely co-exposed cohort, 104/726 (14%) cases studied were diagnosed over 
the age of 70. The risk of smoking and RA is evident up to 15 years after smoking 
cessation [32]. As polarisation of RA risk estimates occurs when a latency period 
is used in occupational exposures [30], using an age cutoff of 70 years of age 
does not allow an adequate latency period between exposure and disease 
development; although one acknowledges the impacts that such latency may 
create in the development of other smoking-associated cardiovascular and 
respiratory comorbidities.  
I chose to minimise the potential limitations detailed above by making use of 
recent studies investigating the relationships between occupational exposures 
and chronic obstructive airways disease (COPD) [33], which utilised self-report 
of any occupational inhalational exposures together and considered these 
exposures as an entity that can trigger COPD. “Grouping” reported exposure to 
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VGDF in this way demonstrated an independent, modest association with COPD 
development [33].  Using a similar methodology in RA patients in my single centre 
study revealed the fascinating results described in Chapter 5 [3]. More detailed 
analysis of specific occupations and exposures for this and future studies in a 
wider population will be important to further investigate individual risks and test 
further hypotheses into pathophysiological mechanisms. 
7.3.4 Cornish population-based specifics 
Overall, this thesis suffers from a relative lack of comparable RA cases that are 
unexposed to VGDF and smoking, limiting the ability to provide statistical 
significance via an adequate control group to analyse specific VGDF exposures. 
The relative homogeneity of educational levels and social depravation indices 
between the patient groups in Chapters 3,5 and 6 [3,4,6] may explain why no 
significant differences were found here; although this may reflect the nature of 
how inhalational exposures manifest in a male RA cohort.  
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7.4 Unanswered questions 
 
7.4.1 Exposure prevalence and treatment implications 
 
The overwhelming majority of RA men in my analysis of an entire University 
hospital male RA cohort had exposure to vapours, gas, dust or fumes, and had 
been smokers before diagnosis [3]. Men who had such exposures combined had 
significantly higher RF titres, and were diagnosed at a significantly younger age 
compared to unexposed never-smoking RA cases.  Given the prevalence of these 
exposures in this specific RA male cohort, it would be interesting to see if 
prevalence was representative of wider RA populations elsewhere. However, 
many men in Cornwall are also exposed to VDGF and cigarette smoke, and do 
not have RA. Further study of a case-control nature in similarly exposed non-RA 
individuals to determine disease susceptibility, particularly with regard to known 
genetic risk factors such as the number of HLA-DRB “shared epitope” copies.  
A wider unexposed RA study population and a similarly matched non-RA cohort 
would both be useful for further analysis. Given that males who had such 
exposures combined had significantly higher RF titres and were diagnosed at a 
significantly younger age, further multi-centre study is required to confirm findings 
and further research pathophysiological mechanisms suggested, as the 
environmental exposures driving autoantibody generation seen here will affect 
response to treatment. Cigarette smoking reduces the clinical response to RA 
treatment with both methotrexate and tumour necrosis factor (TNF) inhibitors 
[34,35]; and higher levels of RF in RA patients with established disease receiving 
TNF inhibitors are much less likely to be in remission at 12 months follow up [36]. 
I suggest that RA patients exposed to VGDF and smoking will have a more 
pronounced blunting of response to conventional treatment due to higher RF 
levels. 
The evidence from this research suggests that environmental and occupational 
exposures drive autoantibody generation. I have hypothesised that cadmium may 
lead to post translational modification of IgG and antibodies against IgG (RF), 
from pulmonary rheumatoid nodule formation. It is conceivable that this process 
may lead to anti-TNF autoantibody development. Given that higher levels of RF 
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in RA patients with established disease receiving tumour necrosis factor inhibitors 
to treat their disease are much less likely to be in remission at 12 months follow 
up [36], further research to assess the effect of such exposures in relation to 
treatment response is needed.  In particular, CT chest radiography to look for 
pulmonary nodules and localised tissue Cd levels may help to guide treatment in 
poor responders. 
 
7.4.2 Local cadmium levels stimulating autoantibody development 
 
My research has strengthened the evidence that multiple inhalational insults are 
associated with higher autoantibody levels in rheumatoid arthritis [3,4,6].  
However, my hypotheses around the adsorption of heavy metals such as 
cadmium in the lung remain unproven. Adsorption may explain the pronounced 
interactions of multiple inhalational exposures and cigarette smoking [2-4,6].  
However, the direct analysis of lung tissue to analyse local cadmium levels has 
not been undertaken, due to the difficulty in obtaining sample tissue. 
 
I found that nodular RA smokers who were not exposed to VGDF had significantly 
elevated urinary cadmium levels compared to RA smokers without nodular 
disease. However, amongst never smokers, urinary cadmium levels were similar 
irrespective of nodularity. Detailed discussion around the potential 
pathophysiological mechanisms by which cadmium adsorption may drive nodular 
disease has been undertaken [6]; and urinary cadmium levels reflective of total 
body burden may not reflect localised levels in lung or tissue granulomata. Direct 
histological analysis of lung tissue to investigate this would be an interesting 
avenue; this could be pursued by post mortem of RA patients, exposure-based 
animal models, or by biotechnology-based bronchial “chip” analysis of sequential 
exposures to further the understanding of the pronounced interaction seen in 
sequential dust exposure and cadmium-laden cigarette smoke. 
 
7.4.3 Nodular disease 
 
Chapter 6 [6] analysed the complex relationship between inhalational exposures, 
rheumatoid autoantibodies and nodular disease.  I have demonstrated that 
nodular RA significantly associates with RF and ACPA, irrespective of smoking. 
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Furthermore, there appears to be relationship between urinary Cd levels and 
nodular RA only in nodular RA patients who have not had occupational VGDF 
exposure; this is an interesting finding and an addition to the academic thought 
in this area, given the findings of previous chapters regarding autoantibody levels 
and clustering [3-5]. VGDF-exposed nodular patients demonstrated significantly 
lower urinary cadmium levels compared with matched RA controls (without visible 
nodular disease), despite an increased cumulative exposure to cigarettes. At first 
glance this appears to refute the logical hypothesis that higher cadmium levels 
associate with formation of rheumatoid nodules in RA patients. This appears to 
be true only if their VGDF exposure is accounted for.  
 
From testing the hypotheses in this thesis, I developed the adsorption hypothesis 
which suggests that VGDF exposure may “trap” cadmium in the lung [33], 
whereby cadmium derived from cigarette smoke is adsorbed onto previously 
inhaled fine particulate matter, stimulating B-cell mediated local production of 
citrullinated proteins manifesting as rheumatoid autoantibodies. Crucially, the 
incorporation of cadmium-dust adsorption complexes into granulomatous tissue 
would not show elevated levels of toxins (such as cadmium) in the systemic 
circulation, and would not be reflected in total body measures such as urinary 
cadmium.  
It has recently been suggested that a focus on the total body burden of cadmium, 
estimated through urinalysis, may not reflect the local burden of cadmium as 
there is tissue-specific retention, particularly with lung levels [8].  As inhalation 
exposure affects lung tissue, assessing the local accumulation of cadmium in the 
lungs appears more relevant. Recent laboratory analysis has proven that 
cadmium oxide nanoparticle exposure facilitates protein citrullination in lung 
epithelial cells [37]. Furthermore, cadmium chloride combined with post-
combustion ultrafine carbon black particle matter demonstrated a synergistic 
effect on citrullination, strengthening the adsorption hypothesis [37].  
 
To prove this hypothesis, I would suggest that future studies analyse lung tissue 
directly.  Whilst radiological imaging such as high resolution CT can detect 
pulmonary nodules, the direct analysis of such nodules could analyse both 
cadmium levels and the immunological “machinery” capable of producing the 
type of immune response suggested. 
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In this regard, analysing nodular disease provides a useful surrogate in the 
overarching hypothesis of this research.  As smoking only associated with raised 
RF levels in nodular disease, I would argue that pulmonary rheumatoid nodule 
formation from inhaled VGDF particles, subsequently adsorbing cadmium from 
other environmental sources such as cigarette smoke, both generates RF and 
ACPA locally and stimulates RA disease development. 
 
Whilst this is not the only pathophysiological mechanism at work, in breaking 
immune tolerance to trigger disease in the spectrum of presentations that fulfil 
the classification criteria of clinical RA, the predominance of the patterns of 
exposure described here (particularly in male RA) suggest that cadmium 
adsorption stimulating autoantibody development is of paramount importance. 
Further work is needed into the underlying pathophysiological mechanisms 
driving nodular disease to identify distinct disease patterns, particularly given the 
finding that RA never smokers had a significantly younger age of onset when 
nodular disease was apparent. 
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7.4.4 Respiratory mortality 
 
The centrality of repeated insults to the lung is apparent in this research; and the 
subsequent analysis of mortality undertaken in the male RA cohort detailed in 
Chapter 5 has revealed a high respiratory implication in mortality. Of the 56/726 
(8%) deaths during the study period, 35/56 (62%) deaths were respiratory related. 
In particular, 21/56 (37%) deaths were recorded with COPD, bronchiectasis, or 
emphysema as a contributory to the cause of death [33]. This strikingly high 
respiratory mortality may be explained by the inhalational exposures found in the 
cohort; as described, 561/726 (77%) had been smokers and 546/726 (75%) had 
occupational exposure to vapour, gas, dust or fumes [33]. This aspect of my 
thesis has developed a very high level of scientific interest, and may yet be 
revealed as the highest impact finding.  
 
My review in Chapter 2 has highlighted the similarities in the interactive risks for 
COPD and male RA [2], with VGDF exposure combined with smoking showing 
an increased risk of COPD. Interactive risks for male anti–citrullinated protein 
antibody positive (ACPA) RA have also been highlighted [4].  An increased risk is 
seen when silica and cigarette exposure (>20 pack years) are combined (OR 
14.9; 95% CI 5.32–37.84), far higher than ever smoking alone (OR 2.53; 95% CI 
1.72 to 3.72) or silica exposure alone (OR 1.67; 95% CI 1.13– 2.48) [4].  
 
It would be interesting to explore the extent to which RA and COPD are linked by 
shared environmental and occupational exposures and the common processes 
of post-translational protein modification which drive lung citrullination. Wider 
datasets exist in which large-scale mathematical “mapping“ of the nature of two 
distinct disease entities to deepen understanding of the relationship between RA 
and COPD. Although the precise role of B cells in mediating lung inflammation is 
unknown, B-cell mediated citrullination of proteins in lung tissue has been 
observed in mice exposed to organic dust [38]. Further research into these 
processes is suggested. 
Although this may be the area of greatest interest arising from my thesis, given 
the applicability outside of the disease of RA and the impact of publications 
generated [33], it must be noted RA is becoming less evident in the UK 
population. In addition to evidence of reduced severity [39,40] predating the 
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routine use of disease modifying drugs as detailed in Chapter 6 [6], falling 
incidence and prevalence are noted [41].    
 
Reasons given for this include the fall in the incidence of cigarette smoking, 
though the authors point out that geographic variation is seen, with variation in 
the prevalence of RA possibly be related to socio-economic deprivation that may 
co-associate with primary and secondary smoking [41]. This would be particularly 
pertinent to the RA population of Cornwall, given the high prevalence of both 
smoking and social deprivation, as discussed in Chapter 1 and revealed in the 
evidence gathered in Chapters 3,5 and 6 [1,3-6].  
 
I have suggested that the natural history of nodular RA may reflect the marked 
drop in Cd exposure in UK society. The industrial revolution was associated with 
a 15–fold increase in anthropogenic emissions of Cd in Western Europe [42]; and 
since the 1960s, there has been a 2.5–fold decrease in emissions of Cd [43]. The 
findings in the socio-economically deprived, co-exposed RA population may not 
have wider applicability to wider UK trends, but show that acknowledgement of 
geographical variation is vital to plan public health services.  Furthermore, the 
lessons of exposure that this largely historical set of conditions bestow can be 
applied to similarly exposed populations throughout the globe, particularly in 
deprived, rapidly developing economies. 
 
Finally, one cannot help but be drawn back to the findings of Haldane in the 
machine rock drillers of Redruth on 1900-1902 [44]. His findings of excess 
mortality due the combination of TB (causing bronchiectasis) and dust exposure 
were a fine precursor to the findings detailed here. 
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7.5 Additional directions for future research 
 
7.5.1 Histological analysis of lung tissue to prove inhalational heavy metal 
adsorption.  
On the relationship between cigarette smoke and VGDF inhalation as a 
pathophysiological mechanism of RA initiation through the process of heavy 
metal adsorption and pulmonary nodule development; an animal model prone to 
rheumatoid nodule formation could be utilised to determine if the combination of 
cigarette smoke and dust nebulised in to the lung triggers pulmonary and 
subcutaneous rheumatoid nodule formation. The lung concentrations of heavy 
metals could be tested and compared with blood and urinary levels to test the 
Cd/VGDF adsorption hypothesis further. 
Central to this research is the proposed mechanism of adsorption of trace 
elements such as cadmium in vitro onto previously inhaled substrates. This 
process drives the increased interactive RA risk seen in sequential inhalational 
exposures, enhancing ACPA generation in the lung via inducible bronchial 
lymphoid tissue (iBALT) and RF generation via upregulation of IgG-heat shock 
protein 70 complexes stimulating production of immunoglobulin A (IgA) and 
immunoglobulin M (IgM) rheumatoid factor. However, no direct analysis of lung 
tissue has been undertaken.  Given the recent finding that lung epithelium is a 
site for citrullination when exposed to cadmium nanoparticles [37], it would be 
useful to develop an animal or advanced biotechnology “chip” model, by which 
the histological analysis of lung tissue could be undertaken when exposed to 
VGDF and cigarette smoke, to determine if sequential insults enhance this 
process. 
 
ACPA generation in the lung via inducible bronchial lymphoid tissue (iBALT) and 
RF generation via upregulation of IgG-heat shock protein 70 complexes stimulate 
the production of IgA and IgM RF [5]. Further research is needed to investigate 
the potential for combination of inhalational insults to stimulate iBALT and 
rheumatoid pulmonary nodule formation in the lung, with the consequent impact 
on immunoglobulin G misfolding in the endoplasmic reticulum and the 
upregulation of autoantibody generation. This is particularly pertinent given that 
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B cell mediated lung citrullination has already been demonstrated in response to 
organic dust in an animal model [45]. 
Using the autoantibody analysis generated in my research, I have suggested that 
the main mechanism by which RA smokers generate raised RF levels is via 
pulmonary rheumatoid nodule formation, given that pulmonary rheumatoid 
nodules contain germinal centres capable of autoantibody production. It has been 
demonstrated in an animal model that lung granulomata develop as a 
consequence of exposure to nebulised Cd [45]. It would be of interest to 
determine if these lung granulomata are RF and/or ACPA secreting. 
7.5.2 Autoantibody clustering in a wider population with non- RA controls 
 
This study did not use non-RA controls to analyse rheumatoid autoantibody levels 
or urinary cadmium analysis. As such, comparison cannot be made to determine 
risks around raised elevated autoantibody levels and urinary cadmium in 
developing RA; and therefore, we cannot address if multiple work exposures to 
VGDFs increase the risk of developing R. Further studies are needed to address 
this important question, which would have to include accurate occupational 
exposure history to allow factor analysis, and could potentially analyse different 
combinations and timings of mixed exposures. Given that RF levels in the 
general, non-RA population increases the incidence of RA development by 20-
fold when comparing the lowest vs highest titre of RF [46], it is essential that 
studies of RF in the general population and the risk of developing RA not only 
consider the smoking history, but also occupational exposures.  
 
Work in this area is ongoing with the study population outlined in this research, 
with ethical approval for recruitment of non-RA controls having been approved 
(Appendix 1), to be gathered from primary care data in Cornwall, UK, for urinary 
cadmium analysis.  Response to the wider findings on autoantibody patterns 
described here is expected. Wider RA population analysis with matched cases 
and controls will be of interest to confirm the findings that ACPA positivity in RA 
strongly associates with increasing RF titre independent of smoking; and that the 
relationship is dependent on carriage of SE alleles. Furthermore, the possible 
confirmation of the combination of VGDF exposure and smoking increasing RF 
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levels in a non-RA population, thereby increasing the risk of RA disease 
development with such exposures, would be fascinating.   
 
7.5.3 Wider investigation of a common autoantigen 
 
The findings in Chapter 4 [5] are of importance as they suggest that 
immunoglobulin G (IgG) is a potential universal antigen in RA, given that the 
association between the Fc binding site region of IgG and RF has long been 
recognised; and that a citrulline antibody response against IgG exists, with 
bispecific antibodies having been observed in RA. The specific post-translational 
changes noted at the Fc binding site region of Immunoglobulin G heavy chain 
fragments described in Chapter 4 [5] have only been described in a small pilot 
study.  
 
However, the collection of serum made in and stored as part of this research 
(Appendix 2), means that this can be studied more thoroughly.  Furthermore, a 
larger study, involving this collection and study elsewhere, is needed to confirm if 
the post-translational modifications to the Fc region of immunoglobulin G heavy 
chain fragments are present in the sera of individuals who have developed RA to 
determine if the presence of a specific antigen and ligand is unique to RA. 
 
7.5.4 Wider public health implications 
 
From a wider public health perspective, the results of this research would suggest 
that minimisation of inhaled occupational insults would help to minimise the 
potential development of RA. In January 2017, the UK Industrial Injuries Advisory 
Council undertook a review of the literature on cadmium and autoimmune 
diseases [47], including RA, as a direct result of a publication by myself prior to 
this thesis [48]. The Council concluded that the evidence base on Cd as a putative 
hazard was at a preliminary stage, though conceded that it was possible that 
cadmium can cause RA in at least some circumstances. The Council concluded 
that it would continue to keep this emerging literature under review, particularly 
with pertinence to a doubling or more of RA risk, as the usual threshold for 
prescription within the Industrial Injuries Disablement Benefit (IIDB) Scheme.  
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We have subsequently found that RA patients displayed higher median urinary 
Cd levels than unexposed, non–disease UK median data [6]. In men (n=128) the 
median Cd levels were 0.38 (IQR 0.16–0.42) and in women (n=95) the median 
Cd levels were 0.57 (IQR 0.19–0.65) (p< 0.00001).  Furthermore, in non–dust 
exposed individuals, an appreciably raised Cd level (>95th centile for UK 
unexposed population) [49] was significantly associated with nodular RA, OR 
2.26 (95% CI 1.08–4.73) (p=0.03) [6].  
 
I would agree that further research is needed to provide evidence on the risk that 
Cd poses for the development of RA , to enable the UK Government, via the 
Industrial Injuries Advisory Council, to recommend prescription under the IIDB 
scheme. This is particularly true for those patients co-exposed to VGDF and 
cigarette smoke in whom the relationship is not clear Current regulations such as 
the Control of Substances Hazardous to Health 2002 (COSHH) [50] exist to 
protect workers from hazardous substances such as cadmium and its 
compounds, that have the potential to cause harm if inhaled. The COSHH 
requires the employer to carry out a risk assessment, to establish the hazards 
associated with the substances being used, and to put processes in place to 
control those risks.  
 
However, this misses the potential for combinations of exposures, such as 
discussed here, to cause disease, especially over the life course: it is vital that 
further work is carried out to investigate the potential of dramatically increased 
intrapulmonary levels of Cd in those who are exposed to VGDF and who are 
exposed to high levels of Cd exposure from cigarette smoke.  
 
The COSHH regulations require employers to prevent exposure to toxins such as 
cadmium by substituting them with a safer substance, or by totally enclosing the 
process. Where this is not possible, COSHH requires exposure to be controlled 
to as low a level as reasonably practicable and for it to be adequately controlled 
by the use of appropriate work processes, systems, engineering controls and 
measures including local exhaust ventilation systems to control exposure at 
source. I would argue that such measures need to be considered in exposure to 
adsorbing VGDF substrates in addition to smoking reduction programmes to 
make a wider public health impact. 
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7.5.5 Next steps 
 
7.5.5.1 Non-RA controls 
 
Data collection is currently underway on 32,000 patients from primary care in 
Cornwall, to identify age, sex and IMD matched controls to the already collected 
RA patients in this study.  This has been approved and extended by the Health 
Research Authority and primary care practices involved, with a primary care 
research nurse in place to collect data as per Appendix 1. An approach has been 
made to Exeter University to fund further study. The advent of a new General 
Practice contract in April 2019, with explicit reference to Primary Care Networks 
(PCNs) becoming the “functional unit” of general practice on the UK, opens up 
exciting opportunities to better design the interface between primary and 
secondary care for patients with rheumatoid arthritis. Being at the forefront of 
research in this area allows for optimal service redesign potential, both for the 
data gathering and analysis, but perhaps more importantly, to use the research 
findings to deliver tailored healthcare to the population of Mid Cornwall from 
where this research arose.  
 
7.5.5.2 Analysis in other populations 
The publications in this thesis have driven global interest into the role of 
occupational exposures and autoantibody clustering in RA, evidenced by the 
wide online readership numbers seen for the published chapters, particularly 
Chapter 3.  The findings within Chapters 3 and 4 have forced a re-examination of 
the complex relationships between smoking, HLA genes and serology in wider 
literature [51], using the Swedish EIRA cohorts discussed earlier. Helping to 
shape this paper through peer review, I also suggested to the Editor of the journal 
in which it was published that this fundamental shift in understanding was worthy 
of an editorial article within the journal.  This has also now been published [52]. 
Both of these pieces of citing research work help to establish my thesis in 
fundamentally changing perceptions at the cutting edge of rheumatology 
research. 
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Furthermore, Californian researchers examining 266/973 men in the Appalachian 
Mountains, USA, exposed to coal mining, found significantly higher RA self-
reported prevalence (12%, odds ratio 4.4, 95% confidence interval 2.7-7.2), than 
in unexposed coal workers [53].  A further recent publication by the same 
research group found the  increased risk of RA in men exposed to coal mining, 
when adjusted for covariates, to have a odds ratio of 3.6 (95% CI 2.1-6.2) [54]. 
Contact with this research group is ongoing for collaborative future work, given 
the common interests identified through Chapter 2. 
Italian researchers have recently demonstrated that diesel fume exposure 
induces autophagy and citrullination in bronchial epithelium [55], strengthening 
the findings and discussion generated by Chapters 5 and 6. 
Interest in cadmium exposure has led to publications through collaboration with 
other wider cohorts globally [56]. Further collaborative efforts in wider populations 
are planned, pending publication. (personal communication to Dr. D. Hutchinson, 
publication pending). Professor Veena Antony of the University of Alabama, 
Birmingham, is looking in to kaolin and cigarette smoke co-exposure in an animal 
model. 
 
I look forward to collaborating in these global efforts to increase research in this 
area, both as a peer reviewer and investigator, given that this PhD thesis has 
stimulated such interest. The kind donation of serum and blood from RA patients 
studied as part of this thesis into the Exeter Clinical Research Facility, will allow 
further collaborations into autoantibody and genetic typing to continue. 
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Appendix 1.  Health Research Authority Protocol, IRAS ID 194833: Dust, 
Cadmium and Rheumatoid Arthritis. 
 
Full Title 
An investigation into the dust exposures of rheumatoid 
arthritis patients in Cornwall and correlation to 
cadmium content 
 
 
Short Title 
Dust, cadmium and rheumatoid arthritis 
 
 
 
 
 
 
 
 
 
• This protocol has regard for the HRA guidance and order of content;  
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FULL/LONG TITLE OF THE TRIAL 
An investigation into the dust exposures of rheumatoid arthritis patients in 
Cornwall and correlation to cadmium content 
 
 
SHORT STUDY TITLE / ACRONYM 
Dust, cadmium and rheumatoid arthritis 
 
SPONSOR: Royal Cornwall Hospitals NHS Trust  
 
 
PROTOCOL VERSION: Version 1.0 11.04.16 
 
 
Research Project 2016.RCHT.30 DM: 
 
IRAS project ID 19483  
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1. SIGNATURE PAGE 
The undersigned confirm that the following protocol has been agreed and accepted 
and that the Chief Investigator agrees to conduct the trial in compliance with the 
approved protocol and will adhere to the principles outlined in the Medicines for Human 
Use (Clinical Trials) Regulations 2004 (SI 2004/1031), amended regulations (SI 
2006/1928) and any subsequent amendments of the clinical trial regulations, GCP 
guidelines, the Sponsor’s SOPs, and other regulatory requirements as amended. 
I agree to ensure that the confidential information contained in this document will not be 
used for any other purpose other than the evaluation or conduct of the clinical 
investigation without the prior written consent of the Sponsor 
I also confirm that I will make the findings of the study publically available through 
publication or other dissemination tools without any unnecessary delay and that an 
honest accurate and transparent account of the study will be given; and that any 
discrepancies from the study as planned in this protocol will be explained. 
 
For and on behalf of the Study Sponsor: 
Signature:  
...................................................................................................... 
 Date: 
....../....../...... 
Name (please print): 
...................................................................................................... 
  
Position: 
...................................................................................................... 
  
 
 
 
Chief Investigator: 
Signature: 
...................................................................................................... 
 Date: 
....../....../...... 
Name: (please print): 
......................................................................................................
  
  
 
  
   
   
   
2.  
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3. KEY STUDY CONTACTS 
 
Chief Investigator Dr. D Hutchinson, Department of Rheumatology, Royal 
Cornwall Hospital Trust, Truro, Cornwall TR1 3LQ tel 
01872253798 email david.hutchinson5 @nhs.net 
Study Co-ordinator Dr. D. Murphy, Department of Rheumatology, Royal 
Cornwall Hospital Trust, Truro, Cornwall TR1 3LQ tel 
01872 254692 email daniel.murphy8@nhs.net 
Sponsor Dr. Clark Crawford, Research and Development, 
Knowledge Spa, Royal Cornwall Hospital, TR1 3LJ, tel 
01872 256424 email rcht.sponsor@nhs.net 
Funder(s) Cornwall Arthritis Trust, C/o Department of 
Rheumatology, Royal Cornwall Hospital Trust, Truro, 
Cornwall TR1 3LQ email  
Key Protocol Contributors As above 
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4. STUDY SUMMARY 
This study seeks to answer the hypothesis that inhalation of dusts and fumes in the 
work place is associated with RA independent of smoking and that this association is 
confounded by the simultaneous exposure to inhaled cadmium within the dusts/fumes 
at the work place. Unveiling a novel mechanism of cadmium stimulating RA 
development in dust exposed patents would link many known independent risk factors 
for RA could have implications for early identification of exposed workers for 
interventions to minimise risk of future disease development.  
 
1. To identify if occupational dust exposure is a risk factor for development of 
rheumatoid arthritis amongst Cornish males.  
2. To investigate if occupational dust exposure correlates with a raised urinary 
cadmium level.  
3. To identify if urinary cadmium level is an independent marker for disease activity 
(DAS 28, X-ray erosions) when controlling for smoking, social deprivation score, age, 
smoking and occupation. 
4. Cadmium levels and anti-citrullinated calreticulin antibody positivity in RA (lab 
based). 
 
Trial Title An investigation into the dust exposures of rheumatoid 
arthritis patients in Cornwall and correlation to cadmium 
content 
Internal ref. no. (or short title) Dust, Cadmium and Rheumatoid Arthritis 
Clinical Phase  Not applicable 
Trial Design Single centre case control 
Trial Participants All males with rheumatoid arthritis follow up in Cornwall 2016, 
age sex and social deprivation matched to controls from 
primary care 
Planned Sample Size Total cohort of RA males in Cornwall:  680.   
Dust exposure cohort expected to be approx.60% of this= 
408.  
Statistical model suggests a smaller sample size to gain 
significant results.  However, data collection on individual 
occupation groups would be pertinent to analyse for 
differences 
Treatment duration Not Applicable 
Follow up duration 24 Months 
Planned Trial Period Planned March2016 -Feb 2017 
 Objectives Outcome Measures 
Primary 
 
Is occupational dust 
exposure a risk factor for 
rheumatoid arthritis amongst 
Cornish males, and is this 
confounded by cadmium 
contained within the dust? 
Positive C-reactive protein 
measurements, elevated 
urinary cadmium levels and 
positive anti-calreticulin 
antibody serum testing, 
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correlated with answers from 
Questionnaires 
 
Secondary 
 
1. To investigate if 
occupational dust exposure 
correlates with a raised 
urinary cadmium level.  
 
2. To identify if urinary 
cadmium level is an 
independent marker for 
disease activity (comparing to 
commonly used and 
validated clinical scores that 
are used to map disease 
activity such as the DAS-28 
CRP measure) when 
controlling for smoking, social 
deprivation score, age, 
smoking and occupation. 
3. Cadmium levels and anti-
citrullinated calreticulin 
antibody positivity in RA 
 
 
 
 
Elevated urinary cadmium 
levels 
 
 
 
Questionnaire response 
 
 
 
 
Positive anti-calreticulin 
antibody serum testing 
Investigational Medicinal Product(s) Not Applicable 
Formulation, Dose, Route of 
Administration 
Not Applicable 
 
 
FUNDING AND SUPPORT IN KIND 
FUNDER(S) FINANCIAL AND NON 
FINANCIALSUPPORT GIVEN 
Cornwall Arthritis Trust £20000 financial support 
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Protocol contributors 
Dr. D Murphy: Design, conduct, data analysis and interpretation, manuscript 
writing, dissemination of results. 
Dr. D. Hutchinson: principal investigator and academic supervisor to Dr. D. 
Murphy, data guardian. 
Dr. P Eggleton: Academic supervisor to Dr. D. Murphy, specific responsibility 
for laboratory work on anti-calreticulin antibody. 
Dr. C. Crawford: Sponsor’s representative for governance purposes and 
protocol checking. 
 
KEY WORDS: Occupation, rheumatoid arthritis, cadmium, 
citrullination, heavy metals, dust 
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STUDY PROTOCOL 
An investigation into the dust exposures of rheumatoid arthritis patients in 
Cornwall and correlation to cadmium content 
 
7. 1 BACKGROUND 
Evidence for occupational exposures relating to rheumatoid arthritis is 
accumulating. Specific occupations have been associated with seropositive 
rheumatoid arthritis (RA),1,2,3,4 a mix of technical and mechanical occupations 
including mining, construction work and textile production.   The potential exists 
for particle inhalation via dust, fumes or aerosolisation in the workplace. Both 
silica and non-silica based inorganic dust inhalation are independent risk factors 
for RA amongst male construction workers.4 In addition to silica, other 
nanoparticles inhaled within the dust include cadmium (Cd). Cadmium is found in 
cement dust, wood dust, and coal dust and is associated with the finishing of 
textiles as a pigment and stabilising agent. Further RA risk factors include lower 
socio-economic class, a low level of formal education, exposure to tobacco 
smoke and residing close to main roads.5  Intriguingly, these risk factors and 
occupational risk categories also associate with high levels of cadmium 
exposure.6  These environmental triggers combined with pre-existing genetic 
factors (such as the HLA-DRB1 shared epitope (SE)), drive development of 
citrullinated antigens resulting in anti-citrullinated protein antibodies (ACPAs), 
which may further drive RA pathology. 
 
Wood dust exposure has long been linked with adverse health effects such as 
dermatitis, mucosal changes, neoplasia and a range of pulmonary conditions.7  
Pulmonary fibrosis has been noted in controlled animal studies,8 as have 
inflammatory changes such as lymphocytic aggregation and increase in 
pulmonary connective tissue components.9 A review of non-malignant respiratory 
diseases found an association between fresh wood dust exposure and asthma, 
coughing, bronchitis, and impairment of lung function.10  This is of particular 
relevance as established literature suggests that the initiation of seropositive RA 
occurs in the lung.11 Interestingly, occupational exposure to cadmium associates 
with chronic obstructive pulmonary disease independent of cigarette smoking.12 
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Association between malignant disease both of the lung13 and the nasopharynx14 
has been demonstrated. A disproportionally high lifetime risk of mesothelioma 
development of 5.9% has been shown in UK carpenters. Again, cadmium is an 
independent risk factor in the development of lung maligancy.15   
 
Further industrial exposure to cadmium dust may occur in those extracting raw 
materials.  Miners may well be particularly at risk, and a re-examination of the 
pathophysiology of Caplan's syndrome may well be needed. First described in 
1953 amongst Welsh coal miners, Caplan's syndrome classically occurs in 
patients with both rheumatoid arthritis and pneumoconiosis related to 
occupational dust (coal, asbestos, silica) exposure.16 First demonstrated on chest 
radiographs, it is characterised by development of multiple pulmonary nodules 
0.5-5cm throughout the lung field.  High rates of rheumatoid factor seropositivity 
and prevalence of rheumatoid arthritis amongst coal miners with classical chest 
x-ray changes of Caplan syndrome were demonstrated.17 Histologically similar to 
rheumatoid nodules, Caplan’s nodules may have a layer of dust surrounding a 
central necrotic area.  Dust-containing inflammatory cells such as macrophages 
and polymorphonuclear granulocytes surround the dust layer,18 distinguishable 
from silicotic nodules or progressive massive fibrosis. 
 
Within coal, kaolinite is a known contaminant across the South Wales coal fields 
in which Caplan’s patients worked, particularly in the anthracite-producing areas 
such as the Rhondda.  A fascinating correlation is the strong association between 
kaolinite mineral contamination of coal and cadmium content.19 The cadmium 
content of coal varies greatly, from 0.01-0.19 mg/kg.20 South Wales has areas of 
soil contaminated with cadmium of the order 3.8-11mg/kg, thought to be due to 
mobilisation from contaminated coalfields and historical zinc ore smelting.21 The 
worldwide toxic burden of cadmium from coal burning has been noted in arctic 
ice cores.22 
 
In terms of roadside dust, cadmium levels have been shown to markedly 
decrease within 20 metres from the roadside.9 Cadmium is a component of petrol 
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and diesel fuel and was previously used as a curing agent in tires, a component 
of brake pads, alloyed with copper in the production of car radiators and in car 
paints. Additionally, asphalt concrete road surfacing contains appreciable 
amounts of cadmium.10 We suggest that cadmium-laden ultrafine dust will occur 
in close proximity to busy roads as a result of both vehicular component and road 
surface wear, and vehicular fuel emissions. Working in such an environment 
would expose to this dust. 
 
Textile dust in the workplace has also been shown to increase the risk of 
developing RA.3 A review article of trace metal pollution in soils affected by 
industrial processes highlighted that the textile industry was associated with the 
discharge of very high levels of cadmium.23 Indian24 and Bangladeshi25 soils 
around textile plants demonstrated cadmium concentrations of 83.6 to 164  mg 
kg−1, 28-56 times higher than European Union recommended  levels.26 Cadmium 
based pigments are utilised in the dyeing and finishing of technical textiles and 
include colour index (CI) pigment yellow 35, orange 20 red 108.27  
 
Cadmium is a heavy metal, mobilised from geological matrices since the 
industrial revolution into biologically accessible forms, leading to a range of health 
effects in humans as described.28  5-35% of inhaled cadmium may be absorbed 
into the blood depending on particle size, site of deposition within the lung, and 
chemical form. Glomerular filtration and re-absorption at the proximal tubule 
results in free cadmium in the serum, with concomitant glomerular damage 
occurring at toxic levels.  Cadmium concentration in the kidney is reflected in 
urinary excretion, with urinary testing reflecting long-term cadmium levels as 
elimination half-life is up to 20 years.29 However, health effects are seen at sub- 
nephrotoxic levels, and it has been argued that urinary levels may not accurately 
reflect end-organ damage, particularly in the lung.9 
 
Further cadmium sources that the occupationally exposed construction trades 
encounter include the substrates they cut,30 their cutting blades,31 and their 
portable tool power sources (cadmium nickel batteries).32 It has recently been 
hypothesised that exposure to cadmium (cigarette smoke, occupational exposure 
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and residing close to main roads and in the northeast of the US) is implicated in 
RA development.6 Cadmium has the potential to cause citrullination within the 
lung as a calcium channel activator, significantly raising intracellular calcium 
levels.33 Interestingly, a number of nanoparticles (including silica and carbon, to 
which many of the occupational groups identified will be co-exposed), can induce 
lung citrullination via activation of cellular calcium channels with a subsequent 
rise in intracellular calcium and activation of peptidyl arginine deaminase.34  
 
A recent animal model demonstrated the potential for cadmium to drive an 
inflammatory arthritic process. Cadmium administered to Wistar rats exacerbated 
collagen induced disease development. Higher dose oral cadmium administration 
demonstrated immunohistochemical expression of pro-inflammatory cytokines, 
confirmed with histopathological analysis.35  
 
Exposure to cadmium links the longevity of risk conferred by smoking36 (the most 
important aetiological factor in RA development),37 to many of the other known 
contemporary risk factors for RA, including occupational exposures. It has a 
plausible biochemical mode of action, and efficacy to drive inflammatory arthritis 
demonstrated in animal studies. The carpenters with RA that we have 
investigated thus far have all had urinary cadmium levels higher than one would 
expect from never smokers.  From the established effects of cadmium on the 
lung, it has been suggested that variability in metabolic pathways relevant to 
absorption, storage, injury, and repair render some individuals particularly 
susceptible to cadmium even at low levels of chronic exposure, particularly if 
inhaled.9 
8. 2 RATIONALE  
We intend to examine the occupational histories of male RA patients in Cornwall, 
examining the records for potential industrial exposures to dust and cadmium. It 
is hypothesised that we may discover that cadmium is an important confounding 
factor with respect to RA development in those with dust exposure. We 
hypothesise this for the following reasons: 
• In conjunction with researchers at Trinity College, Dublin, we have 
demonstrated that cadmium is an independent citrullinating agent, and 
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that the resulting citrullinated proteins are distinct from those citrullinated 
by silica (unpublished). 
• Unlike carbon nanoparticles or silica, cadmium can enter enter the 
circulation, and a cumulative dose-exposure response is seen in bone 
marrow. 
• Cadmium is associated with a pro inflammatory state.35 
 
2.1 Assessment and management of risk 
The results of the investigations will be given to the participant, respective 
hospital consultant and general practitioner. In the event that a case or control 
demonstrates a urinary cadmium within the toxic range, chelation therapy will 
be offered. Should an occupationally exposed group or subgroup demonstrate 
statistically significant higher levels of urinary cadmium on interim analysis, 
appropriate steps will be taken to inform public health authorities of the risk 
uncovered. 
 
In order to obtain informed consent, potential participants will be provided with 
information about the study.  Following time for contemplation and 
understanding, this will be discussed in face to face consultation with a member 
of the rheumatology team. If the potential participant agrees to take part, written 
consent will be obtained. 
 
The risk of data confidentiality breaches will be minimised as data collected will 
be stored on a spreadsheet within the rheumatology file area on the Trust's 
password protected computer system.  Specific access has to be granted for 
access to this, via request from the "owner" of that area (Dr Alison Endean) to 
IT services.  Transfer of data from here once dataset complete will be permitted 
once all patient identifiable information is removed.  Control Cases to be 
recruited from St. Austell Healthcare group patient population.  Hence, all 
patient identifiable information will be kept on the host organisation's host areas. 
Password and training to be provided by the host organisation to members of 
the investigating team when needed (pre-agreed). 
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9. 3 OBJECTIVES AND OUTCOME MEASURES/ENDPOINTS 
This study will  answer the hypothesis that inhalation of Cd enriched dusts and 
fumes in “at risk” workplaces is associated with RA independent of smoking and 
that this association is confounded by the simultaneous exposure to inhaled 
cadmium within the dusts/fumes at the work place. Unveiling a novel mechanism 
of cadmium, a known citrullinating agent, stimulating RA development in dust-
exposed patents would link many known independent risk factors for RA could 
have implications for early identification of exposed workers for interventions to 
minimise risk of future disease development.  The background information 
provided highlights current evidence around dust exposure in the workplace and 
development of RA, and for the potential role of cadmium as a confounding factor 
within this.  
By analysing the association between dust exposure, cadmium, and RA disease 
activity, with controls matched for age, gender and social deprivation, and 
smoking habits corrected for by linear regression analysis, we hope to further 
research into the pathogenesis of RA. 
Furthermore, establishing a comprehensive database of occupational histories 
and smoking habits of RA patients, with details on disease activity, severity, and 
response to therapy, we hope to produce a source of information for future 
studies to improve diagnosis and management occupationally exposed patients 
with RA.  
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3.1 Primary objective 
To determine if Cd enriched dust exposure can trigger the development of RA 
autoantibody markers to drive the pathology of RA. 
 
3.2 Secondary objectives 
• To identify if occupational dust exposure is a risk factor for development of 
rheumatoid arthritis amongst Cornish males.  
• To investigate if occupational dust exposure correlates with a raised urinary 
cadmium level.  
• To identify if urinary cadmium level is an independent marker for disease 
activity (DAS 28, X-ray erosions) when controlling for smoking, social 
deprivation score, age, smoking and occupation. 
• Cadmium levels and anti-citrullinated calreticulin antibody positivity in RA 
(lab based). 
 
3.3 Outcome measures/endpoints 
 
Anti-citrullinated protein antibody (ACPA) measurement 
ACPA status will be assessed by using an anti-cyclic citrullinated peptide (anti-
CCP) second generation fully-automated fluoroenzyme immunoassay 
measurement.  Determination of IgG antibodies against CCP to be measured in 
patient serum, with response value is directly proportional to the specific IgG 
present in the specimen.  
Definition of results as per ACR/EULAR RA criteria: 
• negative: within normal range 
• low positive: > normal range, < 3 x upper normal range 
• High positive: > 3 x upper normal range 
• Very high positive: > upper limit of analytical range 
  
DAS-28 CRP measurement 
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The DAS-28 CRP is a validated measure of disease activity in RA, providing a 
number on a scale from 0-10:40   
• DAS-28 CRP > 5.1 indicates high disease activity  
• DAS-28 CRP ≥ 3.2 to ≤5.1indicates moderate disease activity  
• DAS-28 CRP < 3.2 indicates low disease activity  
• DAS-28 CRP < 2.6 indicates RA remission  
 
The following values are required for calculation: 
•  The number of swollen joints out of 28 (SJC28), of proximal 
interphalangeal joints (PIP) 1-5, metacarpo-phalangeal joints (MCP) 1-5, 
wrist, elbow, shoulder, knee, on  the right and left. 
• The number of tender joints out of 28 (TJ28), of proximal interphalangeal 
joints (PIP) 1-5, metacarpo-phalangeal joints (MCP) 1-5, wrist, elbow, 
shoulder, knee, on the right and left. 
• The CRP (measured in mg/L). 
• Patient’s general health (GH) measured on a Visual Analogue Scale (VAS) 
of  100mm. 
The following (usually pre-programmed computed) algorithm is then completed: 
DAS28-CRP = (0.56 x √[TJC28] + (0.28 x √[[SJC28]) + (0.36 x ln(CRP+1) + 
(0.014 x GH) + 0.96  
 
C-reactive protein (CRP) measurement 
Serological marker of inflammation will be measured in all disease group patients. 
Quantification via Modular P autoanalyzer (Roche/Hitachi) immunoturbidimetric 
assay using reagents from Roche Diagnostics GmbH, (Mannheim, Germany). 
CRP sample reacts specifically with anti-human CRP antibodies coated on the 
latex particles to yield insoluble aggregates. The turbidimetric absorbance of 
aggregates is proportional to the CRP concentration in the sample. The normal 
range considered to be below 5mg/l.  
 
Urinary cadmium measurement 
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Selected patients and controls to be provided with sterile urine sample pots to 
collect first pass morning urine samples.  To be processed by Royal Cornwall 
Hospital biochemistry laboratory, Analysis to be conducted by: 
SAS Trace Elements Laboratory, Surrey Research Park, 15 Frederick Sanger 
Road, Guildford, Surrey, GU2 7YD  
 
Laboratory analysis: Anti-citrullinated calreticulin antibody positivity in RA 
There is evidence to suggest that citrullinated calreticulin binds to the share epitope 
of individuals with HLA-DRB1-SE alleles and promotes proinflammatory events in 
bystander cells leading to RA pathology.41,42 Moreover it has been found that 
increased calreticulin and anti-calreticulin antibodies are found in patients with 
RA.43,44 However the presence of anti-citrullinated calreticulin antibodies have not 
been measured. The generation of such antibodies would indicate a) the existence 
of citrullinated calreticulin in patients sera that is known to bind to the HLADRB1 
shared epitope and b) may indicate the generation of a ‘protective’ antibody against 
citrullinated calreticulin that inhibits its interaction with the shared epitope. 
10.  
 
11. 4 TRIAL DESIGN 
4.1      Subject selection 
All RA disease cohort patients under secondary care follow up at RCHT. To be 
recruited from the results of a questionnaire completed during an internal audit. 
Healthy controls to be recruited from participating GP surgeries, matched for age 
+/-2 years, sex (male), and social deprivation. 
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4.2     Deprivation matching 
Patients to be matched using individual postcode data to controls from a postcode 
within same decile from English Index of Multiple Deprivation (EMD) 2015 data, 
derived from 2011 census.39 
 
4.3     Questionnaire design, physician assessment and data storage 
Cases: All cases of rheumatoid arthritis in males under current follow up identified 
through departmental records.  Dust exposed occupational groups have been 
identified by postal return questionnaire, registered as formal audit at Royal 
Cornwall Hospitals Trust.  All RA patients identified as potential participants by audit 
questionnaire on occupations and smoking history registered by Dr D Murphy 
20/5/2015. Data collation has been ongoing since, with the potential for further 
research highlighted to patients.   
 
Recruitment into case control study to take place via clinical appointments, Dr 
Hutchinson and Dr. Murphy, March 2016 to December 2016 for RA patients. 
 
Controls: age, and sex matched from GP records at participating practices, with 
postcodes referred to through government deprivation data to match for Indices of 
Multiple Deprivation. Dust exposed occupational groups have been identified via 
postal return questionnaire. These will be followed up by further questionnaire, 
telephone consultation, or clinical appointment. 
 
This will all be done by the direct care giving team at the Rheumatology Dept, Royal 
Cornwall Hospital, with assistance from trained medical students. Data recorded on 
Microsoft Excel spreadsheet for subsequent analysis. Personal data will be stored 
in a spreadsheet format in the rheumatology shared computer drive.  This is a 
password protected area on a secure server. Access granted via specific request 
to IT services. Only able to be accessed via NHS computer system, computers kept 
in a locked room only accessible to members of the clinical care team. 
 
Once the data set is complete, any data leaving the trust will be anonymised for 
export outside of NHS setting, with all patient identifiable information removed. Data 
will be stored at the Rheumatology dept, standard access and security 
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arrangements for research data as detailed above: secure server, password 
protected under custodian Dr. D. Hutchinson, which will be stored for 5 years. 
 
Anti-calreticulin antibody serum testing will be processed by Dr. Dan Murphy under 
supervision of Dr. Paul Eggleton at University of Exeter Medical School Laboratory. 
Patient identifiable information will be converted to unique patient identifier prior to 
transport and subsequent and analysis.  
 
Patient identifiable information will be converted to a unique patient identifier prior 
to transport and subsequent analysis, to be related back to individual patient record 
by direct care team.  
 
Clinician review will be undertaken at a follow up clinical appointment to ensure up 
to date clinical measures (ACPA, DAS-28 CRP), demographic data and smoking 
histories are present, and inclusion criteria are met. 
 
 
12. 5 STUDY SETTING 
A single centre, case control study comparing RA males with occupational dust 
exposure, RA alone, with control groups of non-RA with occupational dust 
exposure, non-RA unexposed. 
Cases selected from follow-up RA population at The Royal Cornwall Hospital Trust, 
Truro, Cornwall, UK (RCHT): RCHT serves a population of 400,000.  There are 
approximately 2250 RA patients under regular follow up, 680 who are male. 
 
Controls to be selected from existing GP records from practices in Cornwall, UK.  
Controls positively selected on basis for matching age, sex, and social deprivation 
indices of cases. St Austell group practices have given written permission to search 
their records to match controls and subsequently approach patients to be potential 
participants. 
Lab work will be carried out at UEMS Research Laboratories (St. Luke's Campus 
and RILD). 
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13. 6 ELIGIBILITY CRITERIA 
The patient population comprise male RA patients currently being followed up at 
the Royal Cornwall Hospital during the study period. Matching controls will be 
positively identified from participating GP practices.  
 
6.1 Inclusion criteria 
Generic inclusion criteria (all groups): 
• Age range 18-95 
• Gender: Male participants 
 
Inclusion criteria (RA, dust exposure): 
• Diagnosis of RA based on approved classification criteria38 
• Exposure to occupational dust via working in occupations as detailed by 
Hutchinson6 for >1 year 
 
Inclusion criteria (RA alone): 
• Diagnosis of RA38 
• Absence occupational dust exposure on occupational questionnaire 
 
Inclusion criteria (Dust exposed, non-RA): 
• Exposure to occupational dust via working in occupations as detailed by 
Hutchinson6 for >1 year 
• Absence of inflammatory arthritis or connective tissue disorder in past 
medical history 
 
Inclusion criteria (No dust exposure, non-RA): 
• No exposure to occupational dust via working in occupations as detailed by 
Hutchinson6 for >1 year over lifetime 
• Absence of inflammatory arthritis or connective tissue disorder in past 
medical history 
6.2 Exclusion criteria 
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It is expected that participants may have significant comorbidity. However, 
adults lacking capacity to consent. And those unable or unwilling to comply with 
the protocol will be excluded.  
 
 
14. 7 TRIAL PROCEDURES 
7.1       Planned recruitment start date 
Recruitment Expected to Start May 2016.  
15.   
7.2 Recruitment 
Participants for all groups identified through existing departmental and GP 
records, utilizing search criteria for males with rheumatoid arthritis via clinical 
coding for cases, cross-checked with laboratory records for anti-CCP testing 
since 2007 in Cornwall to identify potential missed cases not currently coded 
but under follow up.  
 
Participants will be informed of the study on clinical review with the 
rheumatology team with information of study provided on clinical review. Cases 
will then be approached with a telephone call for further information and 
expression of willingness to take part. If willing, further clinical review to be 
arranged for consent form signing and sample taking.  Written information will 
be provided on the day of consenting again to ensure participants have read 
and understood the information.  
 
For controls, to identify via age, sex and social deprivation index score 
dependent searches of existing data within GP practice. Controls will then be 
approached with a telephone call for further information and expression of 
willingness to take part. If willing, information will be sent out by post or email. 
Further clinical review to be arranged for consent form signing and sample 
taking.  Written information will be provided on the day of consenting again to 
ensure participants have read and understood the information.  
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All participants will be approached via telephone call from clinical team for 
potential involvement in research prior to written information being provided. 
Timings of intervals for each potential participant will vary, but all are expected 
to be >24 hours between each step.  Provision of information on the day will be 
used as a contingency in case information has not reached the patient, and/or 
information has been lost or forgotten. 
 
General information posters on occupation and rheumatoid arthritis are present 
in the rheumatology department, but this is not an overt recruitment tool and is 
for information only. 
 
Only a member of the patient’s existing clinical care team, working with medical 
students, will have access to patient records without explicit consent in order to 
identify potential participants, check whether they meet the inclusion criteria or 
make the initial approach to cases. Dr. Murphy will make the initial approach to 
potential controls following identification from records at participating GP 
practices.   
 
7.3     Consent 
Informed consent will be obtained prior to the participant undergoing any 
activities that are specifically for the purposes of the study. 
 
Following provision of information as described above, an understanding check 
will be performed on clinical review by member of direct clinical team.  Consent 
to be taken by Dr. Murphy or Dr. Hutchinson, or designated members of the 
direct clinical team of the rheumatology department following training and 
protocol guidance under direct supervision. 
The process of consent will provide: 
• presentation of written material  (information leaflet and consent 
document following approval by REC) 
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• the opportunity for potential participants to ask questions in face to face 
clinical meeting 
• discussion between the potential and an individual knowledgeable 
about the research about the nature and objectives of the study and 
possible risks associated with their participation 
• assessment of capacity. For consent to be ethical and valid in law, 
participants must be capable of giving consent for themselves. A 
capable person will:  
o understand the purpose and nature of the research  
o understand what the research involves, its benefits (or lack of 
benefits), risks and burdens  
o understand the alternatives to taking part  
o be able to retain the information long enough to make an effective 
decision. 
o be able to make a free choice  
o be capable of making this particular decision at the time it needs 
to be made (though their capacity may fluctuate, and they may be 
capable of making some decisions but not others depending on 
their complexity) 
o where participants are capable of consenting for themselves but 
are particularly susceptible to coercion, it is important to explain 
how their interests will be protected 
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7.4      Study Assessments 
Study participant will be invited to a routine clinic appointment where they will be 
provide a one off urine sample. A one off anti CCP blood test will be added to the list of 
routine blood tests if it has not been conducted previously. Participants will be asked 
questions regarding their occupation and dust exposure for correlation with the blood 
and urine results.  
 
7.5 Long term follow-up assessments 
Participants will be followed up according to their routine clinical follow up. Any positive 
blood tests in the controls will be follow up in clinic and a treatment offered accordingly. 
 
7.6 Withdrawal criteria  
Participants are free to withdraw from participation at any time.  
 
7.7 Storage and analysis of samples 
Urine and blood samples will be stored within the microbiology lab or dedicated 
refrigerators with the Research department until there are sufficient samples to batch 
send for analysis. The samples will be disposed of according to Laboratory’s waste 
product’s procedure. 
   
 
7.8 End of study 
The study is scheduled to end at completion of analysis expected February 2017. 
 
16.  
17. 8 STATISTICS AND DATA ANALYSIS 
Sample size calculations have been performed to determine sample sizes for 
specific questions related to the research.  However, it is our intention to collect 
urinary cadmium samples from all of our RA population.  Such data will be 
collected as little data currently exists in this area, and sample size calculations 
are based on assumptions that may not prove to be valid in clinical practice 
amongst the population studied.  Widening the sample size will allow for a more 
robust dataset to be gathered.  Furthermore, we expect to find interesting 
differences within certain occupational subgroups.  A wider sampling size will 
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allow for more thorough subgroup analysis.  For these reasons, we intend to 
sample our entire male RA follow-up population that meet the inclusion criteria. 
 
8.1 Sample size calculation 
Occupations in RA case-control study:  
RA males matched for age, gender, social deprivation score 
Defined groups:  
• RA males with occupational dust exposure 
• RA alone 
• Control groups of non-RA with occupational dust exposure 
• Non-RA unexposed 
 
Null Hypothesis: there is no association between occupational dust exposure and 
RA development.  
 
Prevalence of dust exposed occupational categories etc., in the background male 
population of Cornwall is thought to be in the region of 28%, summarised in Table 
1:45 
 
Table 1: Census data of male occupations in Cornwall 
Occupational group Male % 
Mining 1.1 
Manufacturing 11.3 
Construction 15.6 
Total 28 
 
Prevalence of dust exposed occupational categories in the male RA population 
of Cornwall studied is thought to be in the region of 57% (pilot data, n=385) 
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Sample size calculated as test of 1 proportion (p), 1 sample, 2 sided equality: is 
the proportion(p) equal to the reference value (p0)? Null hypothesis (H0): p=p0, 
Alternative hypothesis (H1): p≠p0 
 
n=p(1−p)[(z1−α/2+z1−β)/p−p0]2  
1−β=Φ(z−z1−α/2)+Φ(−z−z1−α/2),z=p−p0p(1−p)n  
where 
•n is sample size 
•p0 is the comparison value 
•Φ is the standard normal distribution function 
•Φ−1 is the standard normal quantile function 
•α is Type I error 
•β is Type II error (1−β is power) 
 
sample size =26 
 
If the hypothesis is correct we expect the dust exposed groups to demonstrate a 
stronger association of RA development. Using this proportionality method, we 
estimate that with 26 cases and 26 controls we have a 90% power (β type II error 
= 0.1) to detect a statistically significant increase in proportion of RA prevalence 
in dust-exposed workers. (2-sided test, p=0.05 α type I error = 0.05). 
 
Does occupational dust exposure correlate with a raised urinary cadmium 
level? Case control study with controls for smoking, social  deprivation 
score, age, and occupation. 
 
If the null hypothesis is true, (i.e. there is no association between dust exposure 
and urinary cadmium levels), we would not expect to find any significant 
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differences in urinary cadmium levels between to dust and non-dust exposed 
groups.  
 
Personal communication has indicated that urinary cadmium levels in RA dust 
exposed workers are 3-4 fold higher than the normal range found in healthy 
individuals. This correlates with the 3-4 fold higher levels of cadmium found in 
hair samples of RA patients by Afridi et al, irrespective of smoking.46  Morton et 
at al47 found a median urinary cadmium concentration of 0.15µmol/mol creatinine 
(n=82, 95th centile 0.42µmol/mol creatinine) in healthy males. From this, one 
would expect to find urinary cadmium values of  0.45-0.6µmol/mol creatinine in 
our dust exposed cohorts if our hypothesis is correct. For each group we would 
expect: 
 
RA and dust exposure = urinary cadmium 0.45 
RA alone = urinary cadmium 0.15 
Non RA, Dust exposure alone = urinary cadmium 0.45 
Non RA, unexposed = urinary cadmium 0.15 
 
No published data has been found to further quantify the reliability of this estimate 
in larger groups with respect to urinary levels in RA. Further subdivision may be 
possible to quantify differences based on seropositive (ACPA positive) vs 
seronegative RA depending on dataset. 
 
Whilst imperfect, attempting to utilise the average urinary cadmium concentration 
given47 as a mean average, with 95 % CI and SE of 2x1.96, we can estimate a 
SD of: 
SD= 9.055 x (0.42-0.15)/3.92 
SD= 0.63 
Therefore to calculate the difference of  2 “means” as an average of 2 expected 
datasets: 
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nA=κnB 
and 
nB=(1+1/κ)(σ[z1−α/2+z1−β/µA−µB])2 
1−β=Φ(z−z1−α/2)+Φ(−z−z1−α/2),z=(µA−µB)/ σ√(1/nA)+(1/nB)  
where 
κ=nA/nB is the matching ratio 
σ is standard deviation 
Φ is the standard Normal distribution function 
α is Type I error (0.05) 
β is Type II error, meaning 1−β is power (0.8) 
and 
Group A mean= 0.15 
Group B mean= 0.45 
Standard deviation= 0.62 
Sampling ratio= 1:1 
 
Sample size= 67 
 
If our hypothesis is correct we expect the dust exposed groups to demonstrate a 
higher level of urinary cadmium. Using this estimate of interpreted, expected 
average 2 value comparison with 2 sided equality,  we estimate that with 67 cases 
and 67 controls we have an  80% power (β type II error = 0.2) to detect a 
statistically significant increase in proportion of RA prevalence in dust-exposed 
workers. (2-sided test, p=0.05 α type I error = 0.05). 
 
Is urinary cadmium level an independent marker for disease activity? (DAS 
28, X-ray erosions) when controlling for smoking, social deprivation score, 
age, smoking and occupation. 
Further analysis of dataset is required to ascertain levels of disease activity in 
dust exposed and unexposed groups of RA males 
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Urinary cadmium levels and anti-citrullinated calreticulin antibody 
positivity in RA (lab based) 
Our previous published studies indicate that cohorts of 50 or more patients 
provide sufficient power. We will be consulting with statisticians with experience 
in calculating power of such studies to determine sample size for calreticulin 
testing. 
 
8.2     Sampling technique 
Cases selected using purposive sampling of male RA patients under follow up at 
Royal Cornwall Hospital, Truro, 2016-2017.  
Controls selected from GP records matched for age, sex, social deprivation 
Rationale: to enable most robust dataset possible for analysis of occupations, 
potential for subgroup analysis.  Controls selected from same geographical area 
as cases. 
Random sampling from cases for subset analysis of anti-calreticulin antibody 
levels.  
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9 DATA HANDLING 
9.1 Data collection tools and source document identification 
An occupational questionnaire has been used within an audit provides the 
baseline information for identifying potential participants. The answers provided 
for this audit will form the basis for comparison with the sample results. 
Potential participants who were not part of the audit and also the controls will be 
required to complete the questionnaire.  
 
9.3 Data handling and record keeping 
Personal data will be stored in a spreadsheet format in the rheumatology 
shared computer drive.  This is a password protected area on a secure server. 
Access granted via specific request to IT services to members of the 
investigatiing team on an individual basis. Only able to be accessed via NHS 
computer system, computers kept in a locked room only accessible to members 
of the clinical care team. No patient identifiable data will leave the Trust 
 
9.4 Access to Data 
Data will be stored by Rheumatology dept, standard access and security 
arrangements for research data as detailed above: secure server, password 
protected under custodian Dr. D. Hutchinson, stored for 5 years. 
 
Access will be limited to the minimum number of individuals necessary for 
quality control, audit, and analysis. A sponsor's representative may require 
access to all data for audit and governance purposes 
 
9.2 Archiving 
The study documents will be archived for 5 years. 
10 MONITORING, AUDIT & INSPECTION 
The study is subject to internal audit. 
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18. 11  ETHICAL AND REGULATORY CONSIDERATIONS 
11.1  Research Ethics Committee (REC) review& reports 
Ethical approval is to be obtained and appended in final review.  Study has been 
designed to protect the dignity and confidentiality of participants by the contact, 
acquisition, storage and dissemination of finding s as detailed in the proposal. 
 
This protocol has been prepared in line with relevant legislation for submission to 
HRA for approval. 
 
In patient terms: 
The possible disadvantages and risks of taking part  
The blood sample we need for the study is the same process as any blood test 
normally undertaken. To minimise discomfort, with consent, we will use some of 
the blood taken for normal monitoring blood tests. If no monitoring blood tests are 
undertaken, taking part in the study may mean we would need to take a blood 
test. We know that people who have special proteins (ACPAs) are more likely to 
have rheumatoid arthritis. Therefore if there is dust exposure and no rheumatoid 
arthritis, and we find the special proteins via a blood test taken at a later date, it 
does not mean the participant has rheumatoid arthritis or will get rheumatoid 
arthritis. What it does tell us is that they could be at increased risk of rheumatoid 
arthritis in the future. Some people may not want to know if they could be at higher 
risk of developing rheumatoid arthritis and may not wish to take part.  
If the amount of cadmium in your urine is very high to the point where your 
immediate health is at risk, we may call you for another appointment to offer 
medicine to lower your cadmium levels. 
 
The possible benefits of taking part  
We know that treating rheumatoid arthritis early is very important. By identifying 
people who are at increased risk of developing rheumatoid arthritis, we can then 
monitor these people more closely, so if they then develop rheumatoid arthritis 
we can start treatment earlier and try and stop people from suffering ill health.  
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11.2     Assessment and management of risk 
A risk assessment has been undertaken to identify potential risks associated with 
the study and factors in place to reduce harm to participants. (See table of risks 
and benefits below) 
 
Table 2  Identified risk and mitigation. 
Identified risk Management strategy 
Participant demonstrates ACPA positivity and 
does not have a diagnosis of rheumatoid 
arthritis,  
 
 
Participant will be reassured that a proportion 
of the normal population demonstrate such 
seropositivity, and it would be important to 
report any joint symptoms in the future. Their 
general practitioner will be informed of the 
result, and they may be offered a 
rheumatology appointment if they wish to 
discuss the results further. 
Participant demonstrates a urinary cadmium 
within the toxic range.  
chelation therapy with EDTA will be offered 
(method of removing cadmium from the body) 
Occupationally exposed group or subgroup 
demonstrate statistically significant higher 
levels of urinary cadmium on interim analysis,  
Appropriate steps will be taken to inform public 
health authorities of the risk uncovered, via 
contact to Public Health England South west 
tel 0300 303 8162 
Participant alludes to chronic health problem 
unrelated to area of study, needing review 
Signpost to General Practitioner for review 
and advice 
Participant alludes to  acute health problem 
unrelated to area of study, needing review 
Signpost to relevant healthcare professional 
depending on nature of problem: may include 
GP, specialist nurse, referral to hospital 
inpatient teams or emergency department 
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Identified risk Management strategy 
Participant alludes to  life-threatening health 
problem unrelated to area of study, needing 
review 
Immediate lifesaving measures as 
appropriate measures such as advanced life 
support, referral to relevant team: emergency 
department, critical care outreach, psychiatric 
liaison services.  In case of ongoing suicide 
risk, patient to be kept in a place of safety 
pending psychiatric review. 
Participant demonstrates worsening control of 
rheumatoid arthritis, such as flaring of 
disease or medication side effect 
Contact Dr. Murphy, who will arrange further 
clinical review and discussion of relevant 
treatment adjustments with Patient's 
consultant at earliest opportunity 
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11.3     Research Ethics Committee  
Before the start of the study, approval will be sought from a REC (researchers 
should check if they are required to gain NHS REC or other REC approval) for 
the study protocol, informed consent forms and other relevant documents  
Substantial amendments that require review by REC will not be implemented 
until the REC grants a favourable opinion for the study  
All correspondence with the REC will be retained. 
It is the Chief Investigator’s responsibility to produce the annual reports as 
required. 
The Chief Investigator will notify the REC of the end of the study. 
 
An annual progress report (APR) will be submitted to the REC within 30 days of 
the anniversary date on which the favourable opinion was given, and annually 
until the study is declared ended. 
If the study is ended prematurely, the Chief Investigator will notify the REC, 
including the reasons for the premature termination. 
Within one year after the end of the study, the Chief Investigator will submit a 
final report with the results, including any publications/abstracts, to the REC. 
 
11.4    Peer review 
The study and protocol has undergone expert and proportionate peer review 
process prior to commencement. The initial peer review was conducted by 
academic supervisors (Dr Hutchinson &  Dr. Eggleton). Subsequent review has 
been undertaken by the sponsoring NHS trust R&D team. 
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11. 5   Patient & Public Involvement 
From the outset, this research has been designed in conjunction with the 
rheumatoid arthritis population of Cornwall. The ideas behind this research were 
presented at a local meeting of the National Rheumatoid Arthritis Society, 
attended by over 100 members, the majority of whom were RA patients.  
Subsequent interest following the meeting of many RA sufferers led to further 
informal discussion as to the development of a protocol that would be 
acceptable to patients in terms of its design and acceptability.  From initial 
ideas, this was refined and presented to the committee of the Cornwall Arthritis 
Trust, a local charity supporting arthritis sufferers.   
 
In agreeing to fund the research, the board of Cornwall Arthritis Trust provided 
invaluable support in acting as a “sounding board” for how best to manage and 
undertake the research in a way that was minimally intrusive for patients in their 
regular clinical care.  
 
11.6  Protocol compliance  
Protocol will be conducted in accordance with the sponsor’s SOPs. Protocol 
non-compliance is not expected however, they can occur from time to time. A 
deviation log will be kept in the site file.  
 
11.7  Data protection and patient confidentiality  
All investigators and study site staff must comply with the requirements of the 
Data Protection Act 1998 with regards to the collection, storage, processing and 
disclosure of personal information and will uphold the Act’s core principles.  
 
11.7  Indemnity 
The NHS indemnity scheme will apply for this study.  No arrangements for 
compensation in the event of harm to participants where no legal liability arises.  
11.8  Amendments  
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Investigating team will be responsible for the decision to amend the protocol 
and the sponsor will be responsible for deciding whether an amendment is 
substantial or non-substantial. 
Substantive changes will be communicated to relevant stakeholders via the 
Chief Investigator. Amendment history will be tracked to identify the most recent 
protocol version, and it is expected that all substantial amendments will be 
submitted on the relevant notification template that can be accessed from IRAS, 
and sent in accordance with the instructions in IRAS as per guidance at: 
http://www.hra.nhs.uk/nhshsc-rd-uk-process-management-amendments/ 
 
11.9    Access to the final study dataset 
All members of the investigating team will have access to the final dataset.  As a 
single site investigation (with separate GP practice involvement for control 
matching) there is no recourse to restrict access for study investigators at any 
point during the study. 
 
 
12 DISSEMINIATION POLICY 
12.1    Dissemination policy 
• Data arising will remain under the ownership of the investigating team 
• On completion of the study, the data will be analysed and tabulated and 
a Final Study Report prepared 
• The full study report is aimed to be published as an MD thesis 
• Investigating team retain the rights to publish extracts of study data 
subject to peer review and with acknowledgement of other members of 
investigating team 
• Cornwall Arthritis Trust to be acknowledged as funder on subsequent 
publications.  Cornwall Arthritis Trust does not have any review or data 
access rights. 
• In-department poster presentation and in-department displays of 
published material will be used to disseminate findings.  Personal 
findings to be communicated with individual patients and GP 
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• The study protocol, full study report, anonymised participant level 
dataset, and statistical code for generating the results will be made 
publicly available via media as described above. 
 
12.2    Authorship eligibility guidelines and any intended use of 
professional writers 
The final study report will be under the authorship of Dr. D. Murphy, under the 
clinical and academic supervision of Dr. D Hutchinson and academic 
supervision of  Dr. P. Eggleton. 
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14.  APPENDICIES 
 
14.1 Appendix 1- CVs of investigating team 
CURRICULUM VITAE 
 
Name: Daniel Murphy  
 
Present appointment: (Job title, department, and organisation.) 
Trust Grade Doctor, Rheumatology Dept, Royal Cornwall Hospitals Trust 
Address: (Full work address.) 
Rheumatology Dept, Royal Cornwall Hospital, Treliske, Truro, TR1 3LJ 
Telephone number: , Direct line: 01872 
253978  Dept fax: 01872 252845 
Email address: 
Daniel.murphy8@nhs.net 
  
Qualifications: 
1996-1999: Loughborough University, BSc Physical Education and Sports 
Science 
2002-2003: College of St. Mark and St. John, Postgraduate Certificate in 
Education 
2007-2012: Peninsula Medical School, BmBs Medicine 
Professional registration: (Name of body, registration number and date of 
registration.) 
General Medical Council number 7280893, August  2012 
Previous and other appointments: (Include previous appointments in the last 5 
years and other current appointments.) 
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Aug 2014-Feb 2016: General Practice Trainee, Royal Cornwall Hospital 
Aug 2012-Aug 2014: Foundation Doctor, Royal Cornwall Hospital 
Research experience: (Summary of research experience, including the extent of 
your involvement.  Refer to any specific clinical or research experience relevant to 
the current application.) 
2015: Literature search and commentary analysis on occupational exposures in 
rheumatoid arthritis. 
2014: Designed and led retrospective cohort analysis into cases of reptile associated 
salmonellosis in children aged 5 or under in Southwest UK. Findings published 
internationally in academic and mainstream media. 
2012: Designed and led investigation into discharge summary preparation at Royal 
Cornwall Hospital as a medical student, leading to presentation at international 
conference and subsequent publication, changing practice. 
Research training: (Details of any relevant training in the design or conduct of 
research, for example in the Clinical Trials Regulations, Good Clinical Practice, 
consent or other training appropriate to non-clinical research.  Give the date of the 
training.) 
1997-1998: Training given as research assistant in postgraduate investigations into 
amino acid supplementation in endurance cycling performance: double blind RCT 
protocol administration 
2007-2012:  Research methodology as part of undergraduate degree 
2012: Statistical analysis training for methodology into discharge summary analysis 
investigation 
2013: In-house training given during secondment to Public Health England for 
research purposes 
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Relevant publications: (Give references to all publications in the last two years plus 
other publications relevant to the current application.) 
Murphy D, Mathew A, James B, Hutchinson D. Could the inhalation of cadmium and 
other metals in addition to textile dust account for the observed increased risk of 
rheumatoid arthritis in textile workers? Ann Rheum Dis 2016; Published online 9th 
February 2016. DOI:10.1136/annrheumdis-2016-209228 
 
Murphy D, Hutchinson D. Cadmium, road dust and rheumatoid arthritis: an alternative 
hypothesis to general air pollution. J Inflamm 2015;12:58. DOI: 10.1186/s12950-015-
0103-2 
 
Murphy D, Sinha A, Hutchinson D. Wood dust: a trigger for rheumatoid arthritis? Am J 
Med 2015;128(12):e35. DOI: 10.1016/j.amjmed.2015.06.054 
 
Murphy D, Oshin F. Reptile-associated salmonellosis in children aged under 5 years 
in South West England. Arch Dis Child. 201;100(4):364-5. doi: 10.1136/archdischild-
2014-306134 
Signature: Date: 
D. Murphy 21 March 2016 
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CURRICULUM VITAE 
 
Name: David Hutchinson  
 
Present appointment: (Job title, department, and organisation.) 
Honorary Senior Lecturer in medicine, University of Exeter . 
Consultant Rheumatologist Royal Cornwall Hospital Trust 
 
Address: (Full work address.) 
Rheumatology Department, Royal Cornwall Hospital Trust, Truro, TR1 3LJ 
; Fax +44 (0)1872 252845 e-mail:  
Telephone number: UK. Tel. + 44 
(0)1872253978 
Email address: 
david.hutchinson5@nhs.net 
  
Qualifications: 
1986–1991:  Leicester University. Leicester, England.  
  MB ChB  
1994:              MRCP  
2003:  MD                       
2005:              FRCP      
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Professional registration: (Name of body, registration number and date of 
registration. 
GMC 1991  
Previous and other appointments: (Include previous appointments in the last 5 
years and other current appointments.) 
House Officer Appointments 
Aug 1991 – Aug 1992 Six months medicine – Pilgrim Hospital, Boston 
Six months surgery – Pilgrim Hospital, Boston 
Senior House Officer Appointments: 
Aug 1992 – Feb 1993  Six months general medicine – Gibraltar, Southern 
Spain 
Feb 1993 – Aug 1993 General medicine – Stafford District General 
Aug 1993 – Aug 1994  General medicine – North Staffordshire Hospitals: 
Cardiology, Neurology, Diabetes and Endocrine, Renal 
Aug 1994 – Oct 1995 General medicine – Derby General Hospital: 
Gastroenterology, Hepatology,  
Specialist Registrar Rotation rheumatology: 
Oct 1995 – Oct 1997 Rheumatology – Whiston and St Helens hospitals, 
Merseyside 
Oct 1997 – Oct 1998 Full-time Rheumatology – University Hospital Aintree 
Oct 1998 – Oct 2001 Rheumatology Lecturer, University of Liverpool, University 
Hospital Aintree 
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Oct 2001- present Rheumatology Consultant Royal Cornwall Hospital,  Truro
 Cornwall, Honorary Senior Lecturer at the University of Exeter Medical School. 
Research experience: (Summary of research experience, including the extent of 
your involvement.  Refer to any specific clinical or research experience relevant to the 
current application.) 
• Overview of research experience:  
M.D THESIS:  Cigarette smoking and rheumatoid arthritis by Hutchinson, David, 
M.D., UNIVERSITY OF LEICESTER (UNITED KINGDOM), 2003, 221 pages; 
U181154. (314 Citations up until Oct 2014) 
Cigarette Smoking and Rheumatoid arthritis 
This thesis was undertaken whilst I was a clinical lecturer at University Hospital 
Aintree, 
Cigarette smoking is now acknowledged as the most important environmental risk 
factor for RA development. 
The principle aim of my thesis was to test the hypothesis that heavy smoking is an 
aetiological factor in RA and generates a distinct subgroup of the disease 
definable in terms of clinical phenotype, particularly severity. 
A second aim was to investigate possible molecular mechanisms linking smoking 
with RA and what I believed to be candidate mechanisms involving the glutathione 
S transferase Mu 1 (GST M1) gene and oxidative damage to the alpha 1 
antitrypsin protein (alpha1 PI).   
These studies involved a review of the literature regarding the link between RA 
and both smoking and alpha1 PI deficiency.  I investigated the relationship 
between heavy cigarette smoking and hospital based, more severely affected RA 
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patients.  Additionally the age of onset and smoking history was compared in 
familial and sporadic RA cases.  Regarding smoking and severity of RA, a cohort 
of RA patients were studied to determine if smoking was an independent risk 
factor for severe RA and whether this effect was influenced by polymorphisms of 
the detoxifying genotype GST M1.  Oxidative damage in RA to the alpha-1 PI 
protein was studied in relation to rheumatoid disease activity, GST M1 and 
cigarette smoking.  The oxidative damage to alpha-1 PI was measured in terms of 
serum levels of Immunoglobulin A- alpha-1 PI (IgA-alpha-1 PI). 
 
In summary, I demonstrated that heavy cigarette smoking is strongly associated 
with hospital based RA.  Secondly that familial RA presents at an earlier age than 
sporadic RA in individuals smoking at disease onset only and that sporadic RA 
patients are significantly more likely to smoke at disease onset than familial RA 
patients. I have confirmed previous findings that raised serum IgA-alpha-1 PI 
levels are associated with erosive as opposed to non-erosive RA cases and 
demonstrated that principally these raised serum complexes occur as a result of 
cigarette smoking and increased disease activity. 
   
It was also demonstrated that in RA patients attending hospital outpatients with 
longstanding disease, cigarette smoking is associated with a worse prognosis in 
terms of joint damage (Larsen score) and disability (HAQ score).  Potentially 
underlying this association was the finding of a greatly increased prevalence and 
concentration of rheumatoid factor in smokers.  A correlation between the number 
of years smoked and pack years smoked by the patient and rheumatoid factor 
levels was observed. 
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• Post graduate Students  - I have supervised 1 MD student (Exeter).  
Research training: (Details of any relevant training in the design or conduct of 
research, for example in the Clinical Trials Regulations, Good Clinical Practice, 
consent or other training appropriate to non-clinical research.  Give the date of the 
training.) 
I have spoken at national meetings regarding lung disease and rheumatoid arthritis. 
Teaching and Research- Medical Students, Peninsula Medical School/University of 
Exeter Medical School. Lead consultant for rheumatology teaching at the Royal 
Cornwall Hospital Trust. 6 students per year as part of rheumatology Special 
Study Unit culminating in student presenting posters or oral presentations at 
national and international meetings. Member of the Arthritis Research UK USER 
committee over 3 years until 2015 
Clinical Research Network lead for musculoskeletal disease SW Peninsula 2014 
onwards 
Relevant publications: (Give references to all publications in the last two years plus 
other publications relevant to the current application.) 
 
• Quirke, A.-M., Perry, E., Cartwright, A., Kelly, C., De Soyza, A., Eggleton, P., 
Hutchinson, D. and Venables, P. J. (2015), Bronchiectasis Is a Model for 
Chronic Bacterial Infection Inducing Autoimmunity in Rheumatoid Arthritis. 
Arthritis & Rheumatology, 67: 2335–2342. doi: 10.1002/art.39226 
• Perry, E., Eggleton, P., De Soyza, A., Hutchinson, D. and Kelly, C. (2015), 
Increased disease activity, severity and autoantibody positivity in rheumatoid 
241 
 
arthritis patients with co-existent bronchiectasis. International Journal of 
Rheumatic Diseases. doi: 10.1111/1756-185X.12702 
• Hutchinson, D. (2015), Cadmium, one of the villains behind the curtain: has 
exposure to cadmium helped to pull the strings of seropositive rheumatoid 
arthritis pathogenesis all along?. International Journal of Rheumatic Diseases, 
18: 570–573. doi: 10.1111/1756-185X.12673. 
• Dan Murphy, Aishwarya Mathew, Benjamin James, David Hutchinson. (2016), 
Could the inhalation of cadmium and other metals in addition to textile dust 
inhalation account for the observed increased risk of rheumatoid arthritis in 
textile workers? Ann Rheum Dis   doi:10.1136/annrheumdis-2016-209228 
• Daniel Murphy, David Hutchinson. (2015), Cadmium, road dust and 
rheumatoid arthritis: an alternative hypothesis to general air pollution. Journal 
of Inflammation201512:58 DOI: 10.1186/s12950-015-0103-2. 
• Daniel Murphy,  Alisha Sinha,  David Hutchinson. (2015), Wood Dust: A 
Trigger for Rheumatoid Arthritis? DOI: 
http://dx.doi.org/10.1016/j.amjmed.2015.06.054 
• Behçets- A man with multiple venous thrombosis .D Hutchinson, R Moots.  
Postgraduate journal of medicine  1999;75:254-255 
• Haloperidol  old drug , new tricks. Z Al-Saffar, D Hutchinson, RN Thompson, 
SP Golding, JP McLaughlin and RJ Moots. Ann rheum dis 1999; 58:  
• Devics Neuromyelitis optica A primary autoimmune condition. D Hutchinson, 
R Moots Rheumatology 2000 Feb;39(2):215-7.   
• Implementation of antithrombotic management in atrial fibrillation. McNulty SJ, 
Hutchinson D, Hardy KJ. Postgrad Med J. 2000 Dec;76(902):783-6. 
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• RA, poverty and smoking. Hutchinson D, Moots R. Ann Rheum 
Dis.2000;59:396-397. 
• Diagnostic evaluation of classification criteria for RA and reactive arthritis. 
Hutchinson D, Moots RJ. Ann Rheum Dis. 2000 May;59(5):396-7. 
• Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), 
particularly in patients without a family history of RA. Hutchinson D, 
Shepstone L, Moots R, Lear JT, Lynch MP. Ann Rheum Dis 2001;60:223-27. 
• The influence of current cigarette smoking on the age of onset of rheumatoid 
arthritis (RA) in individuals with sporadic and familial RA. Hutchinson D, Lynch 
MP, Moots RJ, Thompson RN, Williams E.  Rheumatology. 2001;40:1068-70. 
• Heavy cigarette smoking and rheumatoid arthritis: rheumatoid factor 
production may not be the primary contributing mechanism. Hutchinson D, 
Moots RJ. Ann Rheum Dis 2001;60:1154-5. 
• Coffee consumption, RF, and the risk of RA. Hutchinson D, Moots RJ. Ann 
Rheum Dis 2001;60:540-541. 
• Are cases of rheumatoid arthritis in smokers and lifelong nonsmokers 
representative of different rheumatoid disease processes? Hutchinson D. 
Arthritis Rheum. 2001;44:2942-3. 
• Cigarette smoking and severity of rheumatoid arthritis. D Hutchinson, RJ 
Moots. Rheumatology (Oxford). 2001;40:1426-7.  
• Late onset Raynaud's phenomenon, hypertension, deteriorating renal 
function, and a fit in a middle aged woman. Hutchinson D, Moots RJ. : 
Postgrad Med J. 2001 Dec;77(914):E10. 
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• Sigmoid diverticular abscess perforation in 2 patients with rheumatoid arthritis 
treated with high dose corticosteroids. A cautionary tale. Hutchinson D, Lynch 
M. : J Rheumatol. 2001 Aug;28(8):1935-6. 
• Smoking and disease severity in rheumatoid arthritis: association with 
polymorphism at the glutathione S-transferase M1 locus. Derek L Mattey, 
David Hutchinson, Peter T Dawes, Nicola B Nixon, Sheila Clarke, June 
Fisher, Ann Brownfield, Julie Alldersea, Anthony A Fryer, Richard C Strange. 
Arthritis Rheum. 2002;46:640-6. 
• Serum complexes of immunoglobulin A-Y1-proteinase inhibitor in rheumatoid 
arthritis: Association with current cigarette smoking and disease activity. David 
Hutchinson, Peter T Dawes, Nicola B Nixon, Derek L Mattey. Clin Exp 
Rheumatol 2002;20:387-391. 
• Association between bronchiectasis and smoking in patients with rheumatoid 
arthritis. Kaushik VV, Hutchinson D, Desmond J, Lynch MP, Dawson JK Ann 
Rheum Dis. 2004 Aug;63(8):1001-2.  
• Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular 
abscess perforation in rheumatic conditions. Mpofu S, Mpofu CM, Hutchinson 
D, Maier AE, Dodd SR, Moots RJ. Ann Rheum Dis. 2004 May;63(5):588-90. 
• Painful hips in a shipyard worker. Hutchinson D, Mascarenhas R. : 
Rheumatology (Oxford). 2004 Apr;43(4):524. 
• Primary synovial non-Hodgkin's lymphoma in association with ankylosing 
spondylitis. Khan SY, Hutchinson DG. Rheumatology (Oxford). 2004 
Mar;43(3):391. 
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• Smoking and HLA-DR shared epitope alleles in rheumatoid arthritis: Mattey 
DL, Hutchinson D. Arthritis Rheum 2005 Nov;52(11):3675-6. 
• Spontaneous pneumomediastinum secondary to refractory dermatomyositis 
successfully treated with rituximab. Lee MA, Hutchinson DG. Clin Rheumatol. 
2010 Aug;29(8):945-6. 
• HRCT-proven leflunomide pneumonitis in a patient with psoriatic arthritis and 
normal lung function tests and chest radiography. Lee MA, Hutchinson DG. 
Rheumatology (Oxford). 2010 Jun;49(6):1206-7. 
• Clinical images: rice body arthritis. Hauser B, Hutchinson D. Arthritis Rheum. 
2011 Apr;63(4):1158. 
• RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis 
bronchiectasis patients. Perry E, Stenton C, Kelly C, Eggleton P, Hutchinson 
D, De Soyza A. Eur Respir J. 2014 Oct;44:1082-1085. 
• The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury? 
Perry E,  
• Kelly C, Eggleton P, De Soyza A, Hutchinson D. Rheumatology (Oxford).2014 
May 15. pii: keu 195. 
• Cadmium the missing link between smoking and increased rheumatoid 
disease activity? Cates M, Hutchinson D. Ann Rheum Dis - 2014 Sep 23. pii: 
annrheumdis-2014-206538. doi: 10.1136/annrheumdis-2014-206538. 
 
Reviews 
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• Elizabeth Perry, Clive Kelly, Paul Eggleton, Anthony De-Soyza & David 
Hutchinson (2014) The Lung in ACPA-Positive Rheumatoid Arthritis: An 
Initiating Site of Injury? Rheumatology (Oxford) 53(11) 1940-50. IF 4.44. 
• 10.1517/14728222.2016.1164695 
 
Signature: Date: 
 
David Hutchinson 
21 March 2016 
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CURRICULUM VITAE 
Name: Paul Eggleton  
 
Present appointment: (Job title, department, and organisation.) 
Immunology Senior Lecturer in Immunology, Medicine, University of Exeter  
 
Address: (Full work address.) 
Institute of Biomedical & Clinical Science, University of Exeter Medical School, St 
Luke’s Campus, Room G09, Heavitree Road, Exeter EX1 2LU Devon.  
UK. Tel. + 44 (0)1392 722940 ; Fax +44 (0)1392 262926 e-mail: 
p.eggleton@exeter.ac.uk 
Telephone number: Email address: 
  
Qualifications: 
1981–1983:  Plymouth University. Plymouth, Devon, England.  
  B.Sc. Hons Biological Sciences – Upper second class (2.i).  
1985–1987:  University College London - Royal Free Hospital School of Medicine 
                        (RFHSM).  
 M.Phil. Medical Microbiology.  
1987–1991:  University College London - Royal College of Surgeons of England & 
RFHSM. 
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 Ph.D. Biochemistry  
Professional registration: (Name of body, registration number and date of 
registration.) 
None 
Previous and other appointments: (Include previous appointments in the last 5 
years and other current appointments.) 
University of Alberta, Edmonton, Alberta, Canada  
August 2012 – ongoing. Dept. Biochemistry, Faculty of Medicine & Dentistry  
Position: Visiting Professor (sabbatical). 
Laboratory Host: Professor Marek Michalak. Project A: Investigate the role of 
calnexin in multiple sclerosis pathology. Project B: Develop new therapeutic 
strategies to boost host immunity against cancer. 
Research experience: (Summary of research experience, including the extent of 
your involvement.  Refer to any specific clinical or research experience relevant to 
the current application.) 
a. Overview of research experience: My research interests are broad and varied, 
which has allowed me to work in many cross-disciplinary biomedical subject areas 
over the past 15-20 years in the fields of innate and adaptive immunity, cancer, 
inflammation, medical microbiology, neurology and hyperbaric medicine. I am a 
leading authority in the following areas:  
b. Post graduate Students  - I have supervised 5 D.Phil students (Oxon), 1 MSc 
student (Oxon), 9 PhD students (Exeter) and 1 MD student (Exeter).  
• Role of chaperones in ER stress, autoimmunity and tumour vaccination. 
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• Inflammatory mechanisms of musculoskeletal and autoimmune diseases 
(rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis).  
• Diagnostic biomarkers of autoimmune disease. 
• Mechanisms of Apoptosis/frustrated autophagy in colon cancer. 
• Co-discoverer of the role of CD20+ve T-cells in autoimmune diseases and 
cancer  
• Co-discoverer of components of the lectin (MBL) pathway of complement 
activation. 
• Co-discoverer of many innate immune functions of C1q, collectins and ficolins. 
• Co-discoverer of the extracellular immune roles of calreticulin (complement 
inactivation) in human disease 
• Proteomic and genomic analysis of proteins in autoimmune diseases. 
• Mechanisms of Hyperbaric Oxygen Therapy in wound repair 
Research training: (Details of any relevant training in the design or conduct of 
research, for example in the Clinical Trials Regulations, Good Clinical Practice, 
consent or other training appropriate to non-clinical research.  Give the date of the 
training.) 
• I have designed and conducted research trials for 30 years, written MREC and 
IRAS ethics for multi-centres. Sat on the Exeter and Plymouth Medical School 
Research Degree Committees for 14 years (2002-2016) and lectured at 
national and international events to medical trainees and patients.  
• Northcott Devon Medical Foundation Committee Member (2006-present). 
Scientific advisor for charitable Trust, funding local research within the 
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Universities and Hospitals of Devon, UK. Over the past 9 years, I have 
reviewed over 130 research grants and successfully lobbied for the support of 
pump-priming funding for approximately 50 research grants for researches at 
PCMD and UEMS.  
• Regional clinical and patient training lectures 
• Research for Patients Benefit Guest speaker at the Devon and Cornwall 
Lupus Group. Various venues (Exeter, Plymouth, Ashburton and Dartington), 
2008, 2009, 2011, 2012 and 2015.  
• ‘Development of new cancer therapeutics’ ‘Bridging the Gap’ Immunology 
Workshop, Exeter University, 29th July 2013. 
• Speaker: ‘Breakdown of immune tolerance by post translational modification of 
host proteins’ American College of Rheumatology/ARHP annual meeting, 
Boston, Nov 15-19th 2014. 
• Chair and speaker: ‘Chaperones and disease activity in Rheumatoid Arthritis’ 
11th Intl. Calreticulin workshop. New York City, May 8-11th 2015. 
• Speaker   ‘The generation of autoantibodies to C1q and their usefulness in 
diagnosing Lupus nephritis’ International Conference ‘Antibodies-2015’, 
Birmingham, UK, August 10-12 2015. 
• Speaker ‘Galectin-9 levels in bronchiectasis: a possible promoter of 
immunopathology in rheumatoid arthritis. West and Wales Regional Lung 
Meeting 19th Jan 2016.  
• Guest Speaker. The challenges of infection and immunity for medics in the 
21st century’.  Exeter Medics Society. March 2016. 
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• Guest Speaker ‘Bronchiectasis as a trigger of rheumatoid arthritis’ British 
Society of Rheumatology Training meeting. Birmingham, UK. April 2016.  
• King Faisal Prize for Medicine committee Member to select the winner of the 
2015 King Faisal International Prize for Medicine. Topic: ‘Intestinal Microflora 
and Human Health’. Riyadh, KSA and select the subject for the 2017 King 
Faisal International Prize for Medicine. Riyadh, KSA, March 2015.  
 
Relevant publications: (Give references to all publications in the last two years plus 
other publications relevant to the current application.) 
Books and book chapter 2014-2016 
1 Eggleton P, Bremer E & Michalak M. (2016) Endoplasmic reticulum and its 
role in tumour immunity. Frontiers/Nature Journals e-book. Switzerland. 101 
pages. ISBN-10: 978-2-88919-786-6 
2 Eggleton Paul, Javed Moazzam, Pulavar David and Sheldon Gemma (April 
2015) Immune Complexes. In: eLS. John Wiley & Sons, Ltd: Chichester. DOI: 
10.1002/9780470015902.a0001118.pub2  
3 P Eggleton, M Michalak & E Bremer Endoplasmic reticulum and its role in 
tumor immunity – Editorial Frontiers in Oncology e-book 
4  P Eggleton, G R. Smerdon, J Holley, & N J. Gutowski (2016) Manipulation of 
Oxygen and Endoplasmic Reticulum Stress Factors as Possible Interventions 
for Treatment of Multiple Sclerosis: Evidence For And Against. (Ed: F Al-
Khamis, A. A. Al-Sulaiman, P. Kaur and A. A. A. Asea) In: Multiple Sclerosis: 
Global Perspectives of a Silent Killer. Springer International Publishers 
(Netherlands). (To be published Spring 2016) 
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Research papers 2014-16 
1 Wiersma VR, He Y, Sampionus DF, van Ginkel RJ, Gerssen J, Eggleton P, 
Bremer E & Helfrich W (2014) A CD47-blocking TRAIL fusion protein with duel 
pro-phagocytic and pro-apoptotic activity. Brit J Haematol 164(2): 304-7. IF 
4.9. 
2 Brent J. Ryan & Paul Eggleton (2014) Detection and characterization of 
autoantibodies against modified self-proteins in SLE sera after exposure to 
reactive oxygen and nitrogen species. Methods Mol Biol 1134: 163-71. IF 1.3. 
3 Isabel Cottrell, Asma Khan, Sidra Maqsood, Jemma Thornes & Paul Eggleton 
(2014) Meta-analysis as a diagnostic tool for predicting disease onset and/or 
activity in systemic lupus erythematosus. Methods Mol Biol 1134: 249-59. IF 
1.3. 
4 Paul Eggleton, Obioha Ukoumunne, Isabel Cottrell, Asma Khan, Sidra 
Maqsood, Jemma Thornes, E. Perry & David Isenberg (2014) Autoantibodies 
against C1q as a diagnostic measure of lupus nephritis: systematic review and 
meta-analysis. J Clin Cell Immunol 5(2): 1-14. IF 5.6. 
5 Elizabeth Perry, Chris Stenton, Clive Kelly, Paul Eggleton, David Hutchinson, 
Anthony De Soyza (2014) A combination of positive rheumatoid factor and 
anti-cyclic citrullinated antibodies as a predictor of non-cystic fibrosis 
bronchiectasis patients developing rheumatoid arthritis. Eur Resp J.  44:1082-
5. IF 7.1. 
6 Holley JE, Bremer E, Kendall AC, de Bruyn M, Helfrich W, Tarr JM, 
Newcombe Jia, Gutowski NJ, & Eggleton P. (2014) CD20+ inflammatory T-
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cells are present in blood and brain of multiple sclerosis patients and can be 
selectively targeted for apoptotic elimination. Multiple Sclerosis and Related 
Disorders 3:5 650-658. 
7 M de Bruyn, VR Wiersma, W Helfrich, P Eggleton & E Bremer. (2015) The 
ever-expanding immunomodulatory role of calreticulin in cancer immunity. 
Frontiers in Oncology. 5:35. doi: 10.3389/fonc.2015.00035 
8 M de Bruyn, VR Wiersma, DF Samplonius, HG Klip, W Helfrich HW Nijman, P 
Eggleton & E Bremer. (2015) CD20+ T cells have a predominantly Tc1 effector 
memory phenotype and are expanded in the ascites of patients with ovarian 
cancer. Oncoimmunology 4(4):e999536 DOI:10.1080/2162402X.2014.999536  
IF 6.28. 
9 Quirke AM, Perry E, Kelly C, de-Soyza A, Eggleton P, Cartwright A, 
Hutchinson D, Venables P. (2015) Bronchiectasis: a model for chronic 
bacterial infection inducing autoimmunity in rheumatoid arthritis.  Arthritis and 
Rheumatology 2015 May 27. doi: 10.1002/art.39226. IF 7.8. 
10 VR. Wiersma, M de Bruyn,*, Y Wei, R J. van Ginkel, M Hirashima, T Niki, N 
Nishi, D F. Samplonius, J Gerssen, H W. Nijman, P Eggleton, W Helfrich, & E 
Bremer. (2015) Galectin-9 induces frustrated autophagy and cell death in K-
Ras mutant colon carcinoma. Autophagy Jun 18:0. IF 12.0. 
11 VR Wiersma, D Hendrike, E, Dudek, W-A Wang, Y He, P van Bommel, R van 
Ginkel, D Samplonus, J Gerssen, H Nijman, W Helfrich, M Michalak, P 
Eggleton & E Bremer. (2015) Calreticulin regulates anti-cancer innate 
immunity and activates T-cell responses. Cancer Immunology Research 
(Under review).  
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12 E Perry, P Eggleton, A De-Soyza & D Hutchinson & C Kelly. (2015) Increased 
disease activity, severity and autoantibody positivity in rheumatoid arthritis 
patients with co-existent bronchiectasis. Intl J Rheumatic Diseases doi: 
10.1111/1756-185X.12702. IF 1.7. 
 
Reviews 
1 Elizabeth Perry, Clive Kelly, Paul Eggleton, Anthony De-Soyza & David 
Hutchinson (2014) The Lung in ACPA-Positive Rheumatoid Arthritis: An 
Initiating Site of Injury? Rheumatology (Oxford) 53(11) 1940-50. IF 4.44. 
2 VR Wiersma, M Michalak, TM Abdulla, E Bremer & P Eggleton. (2015) 
Mechanisms of translocation of ER chaperones to the cell surface and 
immunomodulatory roles in cancer and autoimmunity. Frontiers in Oncology 
5(7); 1-14 doi:10.3389/fonc.2015.00007. 
3 Eggleton P, Bishop A and Smerdon G (2015) Safety and efficacy of hyperbaric 
oxygen therapy in chronic wound management: current evidence. Chronic 
Wound Care Management & Research 2:81-93 
4 Leslie Gold, David Williams, Jody Groenendyk, Marek Michalak, P Eggleton 
(2015) Unfolding the complexities of ER chaperones in health and disease: 
Report on the XI international calreticulin workshop Cell Stress and 
Chaperones 20:875-883 IF 3.16.  
5 P Eggleton, E Bremer, Elzbieta Dudek and M Michalak. (2016) Calreticulin: a 
therapeutic target in cancer? Expert Opinions on Therapeutic Targets. IF 5.14. 
DOI: 10.1517/14728222.2016.1164695 
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Signature: Date: 
 
 
21 March 2016 
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Appendix 2 - Text of participant information sheet. See separate document 
for version controlling on headed paper. 
 
Dust, Cadmium and Rheumatoid Arthritis. 
 
Participant Information Sheet  
 
RESEARCH INVITATION  
 
We would like to invite you to take part in our research study. Before you decide 
if you would like to participate we want to explain why this research is being done 
and what it would involve for you.  
 
One of our team will be available to go through the information sheet with you at 
next clinic appointment and answer any questions you have. Please take time to 
read the following information carefully and discuss it with friends, relatives and 
your GP if you wish. Take time to decide whether or not you wish to take part.  
 
If you would like to contact us before coming in to clinic to discuss the research 
in more detail our contact details are listed below:  
 
Dr. D Murphy 
Dr. D Hutchinson 
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Rheumatology Department 
Royal Cornwall Hospital 
Truro 
Cornwall 
TR1 3LJ 
Tel. 01872 254690 
Email: daniel.murphy8@nhs.net 
 
In this information sheet part 1 tells you the purpose of this study and what will 
happen to you if you take part. Part 2 gives you more detailed information about 
the conduct of the study.  
 
Please feel free to ask us at any stage if there is anything that is not clear.  
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PART 1  
 
What is the purpose of this study?  
 
Emerging research suggests that people exposed to dust in their workplace may 
be at higher risk of developing rheumatoid arthritis (RA).  This has been shown 
in groups of people exposed to silica, textiles, and mineral oils amongst other 
trades.  We have noticed that in Cornwall, particularly amongst men, we have 
strikingly high rates of dust-exposed trades with rheumatoid arthritis.  To date, 
no-one has put forward a reason to link these different occupations, or suggest 
how the dust may be triggering rheumatoid arthritis.    
 
Lots of other risk factors have been identified with developing rheumatoid arthritis. 
Interestingly, these also associate with high levels of cadmium exposure. 
 
The potential exists for cadmium (Cd) inhalation via dust, fumes or fine spray in 
the workplace. Cadmium is found in cement dust, wood dust, and coal dust and 
is associated with the finishing of textiles as a pigment and stabilising agent.  
These environmental triggers combined with pre-existing genetic factors result in 
the development of special proteins, called anti-citrullinated protein antibodies 
(ACPAs), which then drive RA pathology. 
 
By measuring the urine cadmium levels of people exposed to dust, we can see if 
they are higher than we would expect. If we find raised levels in certain 
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occupations, we may invite you back for a blood test to measure the special 
proteins. By measuring the special proteins (ACPAs) in the blood, we can see if 
the dust exposed people are at higher risk of developing rheumatoid arthritis. 
  
Why does this study matter to me?  
 
This has never been proven before and would mean that we could link cadmium 
exposure to the development of these special proteins (ACPAs) in people with 
dust exposure to see if they are at risk of developing rheumatoid arthritis. We can 
then monitor these people more closely to allow us to diagnose rheumatoid 
arthritis and dust exposure earlier, so we can start treatment earlier and try and 
stop people from suffering ill health.  
 
By measuring the cadmium levels, we can see if there is a link between inhaled 
dust, cadmium levels and RA development in Cornish workers. This will help us 
to understand the way in which RA develops in some people, and allow us to 
better identify which individuals are more at risk of future disease development 
than others. Better understanding of the roles played by dust and cadmium will 
also help us to develop new treatment options to treat rheumatoid arthritis and 
possibly in the future, to be able to stop some people from developing these 
conditions at all.  
 
Why have I been invited?  
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We are inviting all men in Cornwall with rheumatoid arthritis into the study, and 
men who are similar age but do not have rheumatoid arthritis. You have been 
chosen as you are between 18 and 95 years-old, have either rheumatoid arthritis 
or fit into one of the groups we need to study which are detailed below:  
Rheumatoid arthritis on its own  
Rheumatoid arthritis and dust exposure 
Dust exposure on its own  
No dust exposure or rheumatoid arthritis  
 
Do I have to take part?  
 
It is up to you to decide to join the study. We will describe the study and go 
through this information sheet. If you agree to take part, we will then ask you to 
sign a consent form. You are free to withdraw at any time, without giving a reason. 
This would not affect the standard of care you receive.  
 
What will happen if I agree to take part?  
 
The study in total should take no more than 15 minutes of your time and where 
possible will be performed alongside your normal clinic appointment to save you 
from having to make an extra journey. The points below detail what will happen 
if you would like to participate in the study. 
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1. You will be offered the opportunity to meet with one of the research team at 
your next clinic appointment to talk over the research in more detail and answer 
any questions you have.  
 
2. We will complete a short questionnaire to make sure we can include you in the 
study (you may have already done this as part of our departmental audit).  
 
3. If you are happy to participate in the research, we will ask you to sign the 
consent form which we have attached to this information sheet so you have time 
to read it before seeing us.  
 
4.  
a. If you are due routine blood tests we will use 10-20mls of this blood to test for 
the special proteins (ACPA’s).  
b. If you are not due routine blood tests we will take an extra blood test (10-20mls 
only, no more than a normal blood test). We will send the blood test away to test 
for special proteins (ACPA’s).  
c. If you do not currently have a diagnosis of rheumatoid arthritis but are taking 
part in the study, we will not routinely take a blood sample from you, but may 
invite you for a blood test at a later date 
 
5. We will give you a sample pot to collect some urine.  This should be from the 
first urine you pass after waking up in the morning.  
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6. We normally expect results to take around 3 months to process. We will write 
to you, your consultant and your GP (General Practitioner) explaining the results 
of your tests. Should you wish to discuss your results in more detail, we will 
include details in the letter of how to arrange this.  
 
What are the possible disadvantages and risks of taking part?  
 
The blood sample we need for the study is the same process as any blood test 
you would normally have, some people don’t like to have extra blood tests and 
so where possible with your consent, we will use some of the blood taken for your 
normal monitoring blood tests. If you are not having any monitoring blood tests, 
taking part in the study would mean we would need to take a blood test. We know 
that people who have special proteins (ACPAs) are more likely to have 
rheumatoid arthritis. Therefore if you have dust exposure and don’t have 
rheumatoid arthritis, and we find the special proteins via a blood test taken at a 
later date, it does not mean you have rheumatoid arthritis or that you will get 
rheumatoid arthritis. What it does tell us is that you could be at increased risk of 
rheumatoid arthritis in the future. Some people do not want to know if they could 
be at higher risk of developing rheumatoid arthritis and so may not wish to take 
part.  
 
If the amount of cadmium in your urine is very high to the point where your 
immediate health is at risk, we may call you for another appointment to offer 
medicine to lower your cadmium levels. 
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What are the possible benefits of taking part?  
 
We know that treating rheumatoid arthritis early is very important. By identifying 
people who are at increased risk of developing rheumatoid arthritis, we can then 
monitor these people more closely, so if they then develop rheumatoid arthritis 
we can start treatment earlier and try and stop people from suffering ill health.  
 
Will my taking part in the study be kept confidential?  
 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2. If the information in Part 
1 has interested you and you are considering participation, please read the 
additional information in Part 2 before making any decision. 
PART 2  
 
What if there is a problem?  
 
If you have a concern about any aspect of this study, you should ask to speak to 
the researchers who will do their best to answer your questions. If you remain 
unhappy and wish to complain formally, you can do this. The Patient Advice and 
Liaison Service (PALS) can be contacted on local team telephone number 01872 
252793, or email rcht.pals@nhs.net. 
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In the event that something does go wrong and you are harmed during research 
and this is due to someone‘s negligence, then you may have grounds for a legal 
action for compensation against your NHS Trust who is performing the research 
but you may have to pay your legal costs. The normal National Health Service 
complaints mechanisms will still be available to you.  
 
Will my taking part in this study be kept confidential?  
 
If you join the study, some parts of your medical records and the data collected 
for the study will be looked at by authorised persons from the research team. 
They may also be looked at by authorised people to check that the study is being 
carried out correctly. All will have a duty of confidentiality to you as a research 
participant.  
 
What will happen to any samples I give?  
 
Blood and urine samples taken for the study will be used only for this study and 
any monitoring bloods that your doctor has asked for from your clinic 
appointment. The samples will be looked at by only the research team and 
authorised laboratory team, any excess will be destroyed after 24 months. 
  
What will happen to the results of the study?  
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We will publish the results in the public domain in scientific journals and literature 
in order to increase international understanding of rheumatoid arthritis and dust 
exposure. You will not be identifiable in any way from the results.  
 
Who is organising and funding the research?  
 
The research is being funded by Cornwall Arthritis Trust, working with doctors in 
the Rheumatology Department and employed by the Royal Cornwall Hospitals 
Trust. The research team for this work is led by Dr D Murphy and includes Dr D 
Hutchinson, consultant rheumatologist Royal Cornwall Hospital. 
 
Who has reviewed the study?  
 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests. This study is to be 
reviewed and given favourable opinion by the local ethics committee before 
commencing.  
 
Many thanks for taking the time to consider participation in our study. I enclose a 
consent form for you to read, do not worry about completing the consent form. 
This is something we can do at your clinic appointment. 
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11.3 Appendix 3- Consent form.  See separate document for version 
controlling on headed paper. 
 
Participant Details: (please use hospital sticker if available) 
Name: ___________________  
NHS Number: ___________________  
Hospital Number: ___________________  
Date of birth: ___________________  
 
Title of Project: Dust, Cadmium and Rheumatoid Arthritis. 
 
Researchers: Dr Dan Murphy, Dr David Hutchinson (Royal Cornwall Hospital)  
 
 
1. I confirm that I have read and understand the information sheet for the above study and 
have had the opportunity to ask questions.  
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected.  
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3. I understand that sections of my medical notes may be looked at by authorised members 
of the research team. I give my permission for these individuals to have access to my 
records.  
 
 
4. I accept that I will donate 20 mls of blood for the study, and acknowledge that data from 
this will kept anonymous.  
 
 
5. I am happy for my urine to be tested for cadmium levels.  
 
 
6. I acknowledge that the samples I donate will be stored until analysed and for a maximum 
of 24 months and then disposed of without loss of confidentiality  
 
 
7. I agree to take part in the above study  
 
 
8. I would be happy to be contacted by the research team to be invited to participate in 
future research studies.  
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Signature __________________________________________ 
 
Print name________________________ Date ___________________ 
 
11.4 Appendix 4- GP information form.  See separate document for version 
controlling on headed paper. 
 
Dust, Cadmium and Rheumatoid Arthritis. 
 
General Practitioner Information Sheet Version 0.1 
 
We are writing to inform you that the following patient is participating in the above 
study: 
 
If you would like to contact us to discuss this research in more detail please 
contact:  
Dr. D Murphy 
Rheumatology Department 
Royal Cornwall Hospital 
Truro 
Cornwall 
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TR1 3LJ 
Tel. 01872 254690 
Email: daniel.murphy8@nhs.net 
 
What is the purpose of this study?  
 
Emerging research suggests that people exposed to dust in their workplace may 
be at higher risk of developing rheumatoid arthritis (RA).  This has been shown 
in groups of people exposed to silica, textiles, and mineral oils amongst other 
trades.  We have noticed that in Cornwall, particularly amongst men, we have 
strikingly high rates of dust-exposed trades with rheumatoid arthritis.  To date, 
no-one has put forward a reason to link these different occupations, or suggest 
how the dust may be triggering rheumatoid arthritis.    
 
Known RA risk factors include lower socio-economic class, a low level of formal 
education, exposure to tobacco smoke and residing close to main roads.  
Intriguingly, these risk factors and occupational risk categories also associate 
with high levels of cadmium exposure. 
 
The potential exists for cadmium (Cd) nanoparticle inhalation via dust, fumes or 
aerosolisation in the workplace. Cadmium is found in cement dust, wood dust, 
and coal dust and is associated with the finishing of textiles as a pigment and 
stabilising agent.  These environmental triggers combined with pre-existing 
genetic factors (such as the HLA-DRB1 shared epitope (SE)), drive development 
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of citrullinated antigens resulting in anti-citrullinated protein antibodies (ACPAs), 
which then drive RA pathology. 
 
 
What does the study involve?  
Our study is a single centre epidemiological, observational, case control study 
comparing four well defined cohorts: RA and dust exposure, RA alone, dust 
exposure alone and healthy unexposed individuals. To test our hypothesis we will 
collect samples of venous blood to measure ACPAs and urinary cadmium in each 
cohort. By comparing the groups we will be able to see if more people with dust 
exposure have high levels of urinary cadmium, and if this correlates with RA.  
  
What are the implications of the study to my patient?  
The study will be performed where possible during the patient’s routine follow-up 
appointment. A simple data collection form will be completed, written consent and 
venous blood sample taken for testing.  
We know that people who have ACPAs are more likely to have or to develop 
rheumatoid arthritis. Any patients who tests positive for ACPA in the dust 
exposure alone group or the healthy individuals control group will be informed of 
the result and given an opportunity to come to a rheumatology clinic to discuss 
the result further. We will also send notification to yourself so that a high index of 
suspicion for rheumatoid arthritis should they develop joint symptoms in the 
future. 
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Appendix 3 – Study Time lines 
Ethical and HRA approval (awaited, Apr 2016) 
 Submission of protocol and IRAS form 
 Following local R&D approval 
 
Commence research (awaited, Apr 2016) 
 Approach potential study group via telephone call 
 Provision of written information, invitation to clinical appointment 
 
Approach matched controls (Pending approval, expected May 2016) 
 Identify through GP records, approach via telephone call 
 Provision of written information, invitation to clinical appointment 
 
Consent and sampling (May-Dec 2016) 
 Formal clinical appointment for answering questions, consent and data 
gathering. Provision of urine sampling pot 
 
Urine sample batching (May-Dec 2016) 
 Urine samples to be batched and sent to lab as per protocol (cadmium) 
 Blood samples batched for lab processing as per protocol (calreticulin) 
 
Sample matching (May-Dec 2016) 
 Samples to be matched back to cases 
 PII removed for data analysis 
 
Data analysis (expected Dec 2016- Mar 2017) 
 Appropriate statistical methodology to be checked by independent 
statsitician 
 
Results (expected Dec 2016- Mar 2017) 
 Communication of personal results with GP and patient 
 
Final study report (expected Apr 2017) 
 Under authorship of Dr. D Murphy, Academic supervision: Dr. D 
Hutchinson,  
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Dr. P Eggleton 
 Dissemination of results via peer reviewed publication, potential MD 
thesis 
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Appendix 4 – Occupation Quesitonnaire 
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Appendix 5 – Amendment History 
Amendment 
No. 
Protocol 
version no. 
Date 
issued 
Author(s) 
of changes 
Details of changes made 
1 0.2 11.4.16 DM Proofreading following R&D input 
2 1.0 19.4.16 NM Transferred to correct template 
 
List details of all protocol amendments here whenever a new version of the 
protocol is produced. 
Protocol amendments must be submitted to the Sponsor for approval prior to 
submission to the REC committee. 
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Appendix 2. National Institute for Health Research, Clinical Research 
Facility (Exeter).  Application for a new collection: CRF 249.  
 
Cadmium and rheumatoid arthritis: could cadmium exposure break 
immune tolerance by stimulating post-translational modification and 
subsequent autoantibody development in genetically susceptible 
individuals? 
 
Introduction 
Subcutaneous nodule development is a common extra-articular manifestation of 
RA, found 20–25% of cases [1]. Rheumatoid nodules are associated with more 
severe disease progression and  joint damage. The exact mechanisms involved 
in the pathogenesis of rheumatoid nodules remain uncertain. It has been 
suggested that rheumatoid factor (RF),  smoking, and HLA-DRB1/TNF gene 
interaction have linked but separate roles in the development of rheumatoid 
nodules [2]. Nodular RA associates with both RF positivity and cigarette smoking 
in patients with RA [3-7]. Production of RF also associates with cigarette smoking 
in patients with RA and healthy individuals [5-10].  
 
Potential environmental triggers 
Nodules also occur in patients with RA who have never smoked. Other 
environmental factors have been suggested as a possible trigger [2].  Known risk 
factors for RA development include lower socio-economic class, a low level of 
formal education, exposure to tobacco smoke and residing close to main roads 
[11]. Intriguingly, these risk factors also associate with high levels of cadmium 
exposure [12]. We propose that cadmium inhalation is a plausible trigger for 
nodular RA development. Emerging literature suggests that RA is associated with 
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a number of occupations associated with cadmium exposure [12]. These include 
underground mining work (odds ratio (OR) 8.47 (95% CI 2.59 to 27.66),  
bricklaying and working with concrete (OR: 2.6, 95% CI: 1.3–4.9) , working with 
electrics and electronics (OR: 1.8, 95% CI: 1.0–3) , workers exposed to mineral 
oils (relative risk (RR): 1.4, 95% CI: 1.0–2.02) , workers exposed to hydraulic oils 
(RR: 1.7, 95% CI: 1.1–2.6), asphalters (OR: 14.0, 95% CI 1.2–799.0)  and 
conductors, freight and transport workers (OR: 4.7, 95% CI 1.4–16.3). Further 
studies demonstrate a link with smelting and working in metal foundries (OR 2.8, 
95% confidence interval (CI): 1.0–7.4)[13]. 
 
Rheumatoid autoantibodies 
Nodular RA development associates with high titres of rheumatoid 
autoantibodies.  Routine testing for rheumatoid autoantibodies consists of 
rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA). 
 
Rheumatoid factor is an autoantibody directed against the CH2 and CH3 areas 
of the Fc portion of human IgG.  The specificity of detection of RF is about 79%, 
with sensitivity of about 60% [14]. 
 
ACPA testing has been derived from cross-reactivity testing of endogenous 
antibodies to a synthetically derived form of citrullinated filaggrin acting as 
antigen. Citrullination is the process by which arginine residues are replaced by 
citrulline. Sensitivity and specificity are 65-70% and 96-98% respectively [15].  De 
novo, this process is referred to as post-translational modification.  However, the 
exact antigen to which the RA patient develops antibodies remains unknown.  
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In analysing citrullinated peptides found in the rheumatoid patient as potential 
autoantigens, researchers have looked at fibrin [16], fibrinogen [17], vimentin [18] 
and alpha-enolase [19]. Citrullinated alpha-enolase has been detected in the 
synovial tissue of patients with rheumatoid arthritis [20], and high levels have 
been found within rheumatoid nodules along with neurone-specific enolase 
[personal communication]. 
 
Additionally, antibodies against proteins that have undergone post-translational 
modification by carbamylation (whereby lysine residues are replaced by 
homocitrulline) have been described in RA patients' serum [21]. Homocitrulline is 
present in rheumatoid nodules alongside citrulline [22], and antibodies against 
carbamylated proteins were found to predict joint damage.  
 
Our own work has led to a recently published hypothesis that a post-
translationally modified heavy chain fragment of IgG, that has undergone both 
citrullination and carbamylation, would be the most obvious linking autoantigen 
to explain the presence of rheumatoid factor, anticitrullinated peptide antibodies 
and anti-carbamylated protein antibodies in the RA patient [23], given its relative 
abundance, size and ability to undergo post-translation modification. 
 
Genetic susceptibility 
In analysing HLA DRB1 genotypes in an RA population, it has been shown that 
DRB1*0401 homozygotes are associated with nodular disease development, 
independent of smoking and rheumatoid factor seropositivity [2].   
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Conclusion 
We wish to store samples of urine and serum on both nodular and non-nodular 
RA patients to enable further testing of specific rheumatoid autoantibodies, and 
specific HLA types for future use given our evolving interest in this area.   
 
We anticipate further applications to use the samples in collaboration with other 
researchers pending completion of our initial work on urinary cadmium testing via 
case-control of nodular vs. non-nodular RA patients.  
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Appendix 3. Data recording questionnaire and capture forms 
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Request Form for “Dust, Cadmium and Rheumatoid Arthritis” trial 
samples (CRF 261) 
 
*** For further instructions, please refer to Sample Management Work Instruction *** 
 
DETAILS:  REFERRER 
ID numbers: 
Name:  
              
 
 
Job title:    
 
 
Signed: 
 
 
Gender:  Date sample taken: 
Male                       Female  
Patient’s Date of Birth: Time sample taken: 
 
                                           (24h clock, e.g. 13:20) 
  
  
Contact Tel: 
____________________________ 
Additional Notes/Instructions:  
 
 
 
FOR LAB USE ONLY 
2x Purple EDTA tubes  
1x Gold Top Becton Dickinson SST tube  
3x Urine tubes  
 
2x EDTA to Exeter as whole blood for DNA analysis 
 
1x Urine to Guildford SAS Trace Elements Lab for Cadmium 
 
1x Urine to store in -80 Freezer 
 
1x SST – spin and separate serum into three labelled micro-tubes for storage in -80 freezer 
 
 
 
 
***CLINICAL TRIAL SAMPLE *** 
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Dust, cadmium and rheumatoid arthritis. IRAS ID: 194833 
Donor registration information and data capture form- primary care controls 
 
 
 
 
 
 
 
Samples donated 
Sample type Date Collaborating clinician 
   
   
 
Smoking history  1 pack year = 1 year at 20/day, equivalence calculator at: 
http://www.smokingpackyears.com/ 
Ever (E), Never (N), Current (C)- if E or C, if E or C please document 
pack years below 
 
Pack years up to date of contact  
Years since stopped smoking  
 
Occupational history (industry and job title, significant exposures) 
Current/ last occupation  
Other occupations involving dust or fume 
exposure greater than one year (continue 
below if necessary) 
 
 
Medical history (Type of condition and duration) 
Lung disease 
 
 
Inflammatory arthritis (NOT osteoarthritis) 
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Appendix 5. Overview of methods 
Each chapter as a separate peer-reviewed publication contains a methods 
section specific to that publication.  A more detailed description of the methods 
are collated here to link each chapter and describe a narrative arc into 
investigations around inhalational insults in RA. 
Appendix 5.1 Chapter 1 
Written consent for the clinical case report contained in Chapter 1 was obtained 
from the patient to use specific details and images from clinical history, and was 
recorded in the patient notes. The case in question was discussed with 
histopathological and laboratory colleagues as per author listings. Computed 
Tomography radiological images were obtained from the patient’s digital record.  
Macroscopic images of kaolinosis lung were donated from the personal archive 
of Professor Robert Marshall, University of Exeter Medical School. Exeter, UK. 
Urinary cadmium (UCd) analysis 
For the case report detailed in Chapter 1 and for urinary cadmium (UCd) 
measured elsewhere in this dissertation, UCd was analysed by inductively 
coupled plasma mass spectrometry (ICP-MS), using a fully validated method by 
the Supra Regional Assay Service Trace Element Laboratory, Guildford, Surrey, 
UK [1]. 
Equipment consisted of iCap-Q (ThermoFisher Scientific, Hemel Hempstead, 
UK) collision cell ICP-MS instrument, polyethylene tubes (8 mL Midi Vials, 
PerkinElmer). 
Reagents were reverse osmosis/deionised water (RO/DI) with >18.2 MΩ cm 
resistivity (Millipore, Elix/Synergy Water Purification System).  Instrument wash 
solution was concentrated trace element grade nitric acid (50mls); 5% (v/v) Triton 
X-100 (2.5 mls); made up in 5 L ultra-pure RO/DI. Concentrated nitric acid, trace 
analysis grade, (Fisher Scientific). Nitric acid 1% (v/v): dilute 10 mL concentrated 
nitric acid to 1 L with ultra-pure RO/DI water.  Cadmium standard solution, 1000 
mg L-1 ( BDH,Prolab). 
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Cadmium in urine was measured by ICP-MS in kinetic energy discrimination 
(KED) mode using helium as the collision cell gas. Samples were diluted 1 in 50 
with a diluent containing germanium (Ge), rhodium (Rh) and iridium (Ir) as internal 
standards added to a final concentration of Ge 15 µg/L-1 and Rh, Ir 1.5 µg/L-1.  
Samples were assayed against a calibration curve matrix matched with urine and 
containing the same internal standards as above. 
Analytical Performance was calibrated as accuracy (bias) 1.5%; repeatability 
(std. dev.), 0.8 nmol/L; intermediate precision (%RSD), 6%; expanded 
uncertainty, 1.9 nmol/L; calibration standards 5–40 nmol/L. 
Appendix 5.2 Chapter 2 
From the anecdotal evidence of case reports such as found in Chapter 1, it was 
hypothesised that RA should be considered an occupational disease as a 
consequence of dust and fume inhalation in the workplace, as such exposures 
may stimulate immune tolerance breakdown. 
A literature search was performed using Pubmed, Embase, and Cochrane 
databases and to cover all relative reports relating to RA and occupation.  Titles 
and abstracts of identified articles were screened for eligibility and relevance to 
the a priori hypothesis detailed above. Duplicates and reports generated that 
were not relevant to the study aims were removed. Reference lists of relevant 
articles were searched for further evidence by hand around mechanisms of action 
and further hypothesis refinement. (Figure 1). 
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Figure 1. Literature retrieval flowchart 
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Occupational exposure 
Initial searches were conducted using the following keywords: “occupation OR mining 
OR silica”, in combination with disease specific term “Rheumatoid arthritis”. 
Subsequent searches of disease and exposure detail were made using the terms 
“Rheumatoid factor OR anti-citrullinated protein antibody/ies”, AND “silica OR dust OR 
fumes OR metals OR cadmium OR asbestos OR mining”. A separate search was 
made using the combination terms “rheumatoid AND smoking AND occupation”. It 
became apparent that knowledge gaps were evident in the pathophysiological 
mechanisms by which inhalational insults may drive the process of immune tolerance 
breakdown. Such insults were found to be associated with the development of 
bronchial associated lymphoid tissue, and concurrent laboratory work/ hypothesis 
generation on the post-translational modification of IgG fragments suggested the 
implication of heat shock protein, specifically heat shock protein 70, as detailed in 
Chapters 2, 3.2, 5 and 6. Following hypothesis generation and in the process of 
refinement, further searches were made using the combination terms “Rheumatoid 
arthritis AND bronchial associated lymphoid tissue OR adsorption OR heat shock 
protein 70” (Figure 4). 
Appraisal 
For occupational exposures, studies were examined for information relevant to output 
fields of sex, country of study, follow up period and exposure type. Reported or 
calculable RA risk being statistically significant for increased RA risk (with lower 95% 
confidence interval greater than 1.0) was used for inclusion. Literature searching was 
undertaken by Dr. D Murphy under the supervision and guidance of Dr. D. Hutchinson. 
Relevant papers were discussed and agreed for inclusion or exclusion as appropriate. 
Integration 
For critical review purposes, statistically significant data pertaining to increased RA 
risk in male occupational exposures were integrated into a single table (Table 1, 
Chapter 2), for descriptive comparison. Data not reaching statistical significance were 
not included in the table, though elements of non-statistical significance of relevance 
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are included in the discussion. Heterogeneity in study populations, comparison groups 
and outcome measures precluded further pooled analysis or systematic review. 
Chapter 3 
In this paper, two cohorts of RA patients were studied to analyse the relationship of 
autoantibodies to the known inhalational insult of smoking. As a highly prevalent 
inhalational insult in other RA populations, it was felt important to have a firm 
understanding on the nature of the relationship between smoking and RA autoantibody 
generation. 
Cohort 1 subjects 
Cohort 1 consisted of males and females attending routine rheumatology clinics at the 
Royal Cornwall Hospital, Cornwall, UK from February 2015 to August 2016. The data 
were anonymised at source, collected as part of project IRAS ID 194833, approved by 
South West Regional Ethical Committee as detailed previously, and was undertaken 
as a form of interim analysis of data collected on male and female patients. This cohort 
was selected to achieve an intended total cohort size of six hundred gender matched 
patients for analysis. Patients reviewed in clinic with a new or existing diagnosis of RA 
during the study period were included for analysis, with 60 patients subsequently 
excluded (see below). 298 male and 300 female RA patients were included to provide 
a suitable cohort size for serological subgroup analysis, with approximately equal 
numbers of each gender selected to detect potential differences in smoking rates, age 
of onset, and serological status rather than to represent the overall male to female 
prevalence ratio.  
Recruitment for this analysis ceased when the target cohort size was reached. Data 
were recorded by clinicians in a standard questionnaire via face-to-face interview 
(Appendix 3).  Missing data were obtained by follow up telephone conversation. Age, 
age of RA onset, disease duration, smoking history prior to disease development, RF 
levels at disease onset and subsequent ACPA levels were recorded as part of routine 
clinical practice. Testing for SE status does not form part of routine clinical practice 
and was therefore unavailable.  All patients fulfilled the 2010 American College of 
Rheumatology/ European League Against Rheumatism (ACR/EULAR) RA criteria at 
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diagnosis [2].  
As per guidelines, a negative RF or ACPA was defined as a level within the normal 
range, a weakly positive RF or ACPA <3 times the upper limit of normal and a strongly 
positive RF or ACPA >3 times the upper limit of normal [2].  Six percent (18/318) of 
females and 12% (40/340) of males were excluded during the collection period due to 
>20 years between smoking and RA diagnosis. A further 2/340 males were excluded 
due to incomplete data on subsequent review. Social deprivation analysis was 
undertaken through the UK government validated Index of Multiple Deprivation (IMD) 
[3], a deprivation rank score of 32,844 neighbourhoods weighted by income, 
health/disability, education, housing/service access, crime and living environment, 
converted to equal deciles. 
Cohort 1 autoantibody analysis 
RF was measured with Tina-quant Rheumatoid Factors I1 Test System, by Roche 
Diagnostics Corporation. A value of < 14 IU/ml was considered as negative as per 
manufacturer guidelines.  ACPA was measured by Roche Modular Analytics Second 
Generation E170 Anti-CCP analysis, with a negative value of <17 U/ml as per 
manufacturer guidelines. 
Cohort 2 subjects 
Given the striking findings of autoantibody analysis in cohort 1, a collaboration was 
sought to verify findings in a different, pre-existing cohort dataset.   A second cohort 
(n=409) of RA patients consisted of 154 males and 255 females attending 
rheumatology clinics at the Haywood Rheumatology Centre in North Staffordshire, UK, 
in whom “shared epitope” (SE) status had been determined. Prevalent cases were 
recruited consecutively from a clinic established to monitor the effects of disease 
modifying anti-rheumatic drugs including hydroxychloroquine, sulfasalazine, D-
penicillamine, gold and methotrexate. Sample collection occurred from 1994 to 2002 
as part of a study to investigate the relationship between genetic factors and outcome 
in RA. Ethical approval was obtained from the North Staffordshire local research ethics 
committee and written informed consent was provided by all patients. All patients had 
established disease (median disease duration 9.2 years), fulfilling 1987 RA criteria at 
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time of diagnosis [4]. A full smoking history was obtained on 386/409 patients. 
Smokers were defined as smoking >1 cigarette (or equivalent)/day for >1 year, and 
categorised according to pack years smoked [5]. All patients had been genotyped for 
Human Leucocyte Antigen (HLA)-DRB1 [6].  
Cohort 2 autoantibody analysis 
In the Staffordshire cohort (cohort 2), IgM RF was measured by nephelometry at 
disease onset while ACPA was measured subsequently using a commercially 
available anti-CCP2 ELISA (Axis-Shield, Dundee, Scotland).  RF levels were reported 
in International Units (IU). An RF level > 60 -180 IU/ml was considered weakly positive 
and a level >180 IU/ml was strongly positive. ACPA measurements above 5 units/ml 
were considered positive as per manufacturer guidelines.   
Statistical analyses 
Chi square tests and multivariate logistic regression analysis were used to examine 
the relationships between ACPA, IgM RF, HLA-DRB1 shared epitope and cigarette 
smoking. Analyses were adjusted for age, sex and disease duration where 
appropriate. Mann-Whitney U testing was performed to analyse differences in RF titre. 
Given the heterogeneity between different cohorts, no pooled analysis was made. 
All analyses were carried out using the Number Cruncher Statistical System for 
Windows (NCSS60). 
Chapter 4 
Given the findings in chapter 3, formal conferences were held within the study group 
to discuss how autoantibody generation may be linked.  It was felt that RF, as a heavy 
chain fragment of IgG, may be a target protein for post-translational modifications such 
as carbamylation and citrullination. If this form of modification were to happen at the 
Fc binding site, this could have a dramatic influence in terms of local polarity as a 
ligand and in conformational change of the binding area. A pilot study was devised to 
test this provisional hypothesis, with analysis taking place prior to sample collection 
under IRAS ID 194833.  As such, samples were taken from a pre-existing sample set 
at the National Institute for Health Research (NIHR) Exeter Clinical Research Facility, 
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Exeter, UK.  Directed literature search was undertaken by Dr Hutchinson and Dr. 
Murphy to develop and refine the hypothesis. Dr. Eggleton and Mr. Clarke designed 
the methodology and undertook laboratory studies at Exeter University Medical 
School, Exeter, UK, presenting data via videoconference. Mass spectrometry review 
was undertaken by Dr. Heesom at Bristol University, Bristol, UK.  
Subjects 
Sera from patients and controls were selected from the Bronchiectasis, Asthma, 
Control, Rheumatoid Arthritis (BRACRA) study: a prospective, multicentre, case–
control, observational study, conducted to determine the relationship between 
bronchiectasis, RA, RF and anti-cyclic citrullinated peptide antibodies (anti-CCP as 
the terminology of the BRACRA study, ACPA as used in this study). ethically approved 
under Integrated Research Application System approval number 12324, Health 
Research Authority, London, UK. The original study was supported by a grant from 
Arthritis Research UK. Samples were collected with support of the National Institute 
for Health Research (NIHR) Clinical Research Network, and stored for future use with 
the assistance of the NIHR Clinical Research Facility, Exeter University Medical 
School, Exeter, UK, who were responsible for providing ethically approved healthy 
control serum samples. The overall study design (including assays used for the 
determination of RF and anti-CCP levels) and approval has been previously reported 
[7]. All the RA patients fulfilled the ACR/EULAR 2010 classification criteria for RA with 
definitions of a negative, low positive and high positive RF and anti-CCP as detailed 
within [2]. 
Study design  
Serum samples from four bronchiectasis (BR) seroconverts (anti-CCP positive prior to 
developing RA), four RA smokers without overt lung disease, four bronchiectasis- RA 
(BRRA) never smokers and ten control subjects (five never smokers and five 
current/ever smokers) were studied.   
Protein analysis 
Equal serum protein loads as determined by nanodrop spectrometry were separated 
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on 8-16% SDS-PAGE gradient gels.  A protein band identified by immunoblotting with 
anti-human citrulline antibody, contained numerous citrullinated proteins in the region 
of 37-50 kilodaltons (KDa). The bands were excised from Bio-safe™ Coomasie 
stained gradient gels and subjected to in-gel tryptic digestion using a DigestPro 
automated digestion unit (Intavis Ltd.). The resulting peptides were fractionated using 
an Ultimate 3000 nanoHPLC system. Tandem mass spectra were acquired using an 
LTQ- Orbitrap Velos mass spectrometer controlled by Xcalibur 2.1 software (Thermo 
Scientific) and operated in data-dependent acquisition mode. The raw data files were 
processed and quantified using Proteome Discoverer software v1.4 (Thermo 
Scientific) and searched against the UniProt Human database (131351 entries) using 
the SEQUEST algorithm. Search criteria routinely included carbamidomethylation of 
cysteine (+57.0214) as a fixed modification and oxidation of methionine as a variable 
modification. In addition, citrullination (+0.984Da) at Arg, Asn and Gln and 
carbamylation (+43.006Da) at Lys, Met, Arg, Ser, Thr and Tyr, were included as 
variable modifications in two separate searches.  
Only peptides where citrullination at Arg and carbamylation at Lys were ranked 1 in 
the respective searches (indicating that those residues were the most likely sites of 
modification) were considered.  
This identified IgG heavy chain as one of the most abundant proteins identified as 
being citrullinated and carbamylated. The amino acid sequence of IgG was obtained 
from the Uniprot database and then submitted to a phyre2 search 
(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) to obtain models in 3D. 
The UCSF Chimera protein viewing software (http://www.rbvi.ucsf.edu/chimera/) was 
used to annotate the amino acid modifications of interest to highlight the citrullinated 
and carbamylated sites on each IgG molecule.  
To confirm the presence of citrullination and carbamylation in the light and heavy 
chains of IgG in subjects, IgG was purified from individual sera by protein G affinity 
chromotography using an AKTA FLPC system (GE healthcare) employing unicorn 5.1 
software. Protein aliquots of IgG were run on SDS-PAGE under reducing conditions 
to separate the 25 kDa light (IgGL) and 50 kDa heavy chain (IgGH), then 
immunoblotted and probed with primary anti-citrulline (ab100932) or anti-carbamyl-
lysine (ab175132) specific antibodies. Post-translational modifications were detected 
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by probing the blot with 1:15000 dilutions of IR Dye800-labeled anti-rabbit secondary 
antibody (Li-Cor P/N 925-32213) followed by infrared imaging (Li-Cor Odyssey infra 
imaging system).  
Chapter 5 
The data in this study were collected by myself and trained members of the clinical 
team in the Rheumatology Department, Royal Cornwall Hospital, UK, as part of project 
IRAS ID 194833, approved by South West Regional Ethical Committee (UK). The 
cohort for this chapter consisted of males attending routine rheumatology clinics at the 
Royal Cornwall Hospital, Cornwall, UK from February 2015 to August 2016. Data were 
anonymised at source. Patients reviewed in clinic with a new or existing diagnosis of 
RA during the study period were included for analysis, initially invited to complete a 
written questionnaire. Data were recorded by clinicians in a standard questionnaire via 
face-to-face interview to determine current occupation, former occupation if retired, 
and previously held employments for >1 year.   Missing data were obtained by follow 
up telephone administration of the same questionnaire (Appendix 3). Written consent 
was obtained for patients enrolled as part of the IRAS ID 194833 project investigating 
the role of cadmium inhalation and the development of RA. All job titles were recorded, 
and specific exposure to vapours, gas, dust or fume exposure (VGDF) was recorded, 
with occupations to be coded via Standard Occupational Classification 2010 
(SOC2010) Volume 2 coding index (ONS SOC coding tool, Office for National 
Statistics, UK) [8], with codes generated relating to the International Standard 
Classification for occupations (ISCO). Coding does not form part of the analysis for 
this paper. Individuals were stratified for the number of VGDF exposed occupations 
held for >1 year (0, 1,>2). Age, age of RA onset, disease duration, smoking history 
prior to disease development, RF levels at disease onset and subsequent ACPA levels 
were recorded as part of routine clinical practice. All patients fulfilled 2010 
ACR/EULAR RA criteria at diagnosis [2].  
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Subjects 
726 patients were included for initial analysis.  Of these, 22/726 (3%) had incomplete 
smoking data and were excluded from linear regression analysis. 3/726 (0.4%) had no 
verifiable RF data and were excluded from RF analysis. 54/726 (7%) had no ACPA 
data and were excluded from ACPA analysis. 16/726 (2%) were excluded from 
occupational analysis; 5/16 died during the study period and therefore had incomplete 
occupational data, 3/16 did not want to disclose occupation in writing or on subsequent 
interview. 8/16 did not return initial questionnaires and were lost to follow up (Figure 
2). Prevalence analysis of VGDF and smoking was analysed as a proportion of the 
entire identified cohort (n=726) to bias towards the null hypothesis. 
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Patient involvement 
As previously stated, the initial concept of this research was developed from detailed 
histories of individual patient experiences of RA in Cornwall, UK. Initial hypotheses 
were presented at a local meeting of the National Rheumatoid Arthritis Society, 
attended by over 100 members, the majority of whom were RA patients.  Subsequent 
interest following the meeting led to further discussion as to the development of a 
protocol that would be acceptable to patients in terms of its design and acceptability.  
From initial ideas, this was refined and presented to the committee of the Cornwall 
Arthritis Trust, a local charity supporting arthritis patients.  Specific feedback was 
offered on wording of consent forms, questionnaire design and arrangements for 
follow up on patients who may not have been able to complete written questionnaires.  
Patient involvement in this process was invaluable for how best to manage and 
undertake the research in a way that was minimally intrusive for patients in their regular 
clinical care.  
Dissemination of results to patients will take place via departmental displays post 
publication. 
Autoantibody measurement 
RF was measured with Tina-quant Rheumatoid Factors I1 Test System (Roche 
Diagnostics Corporation), with a value of < 14 IU/ml considered as negative as per 
manufacturer guidelines. ACPA was measured by Second Generation E170 Anti-CCP 
analysis (Roche Modular Analytics), with a negative value of <17 U/ml as per 
manufacturer guidelines. 
Social deprivation analysis 
Social deprivation analysis was undertaken through the UK government validated 
Index of Multiple Deprivation (IMD) [3], a deprivation rank score of 32,844 
neighbourhoods weighted by income, health/disability, education, housing/service 
access, crime and living environment, converted to equal deciles. 
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Statistical analyses 
Values are expressed as a median (interquartile range (IQR), or number (%). The 
Mann-Whitney U test was used for non-parametric comparisons of continuous data of 
differing sample group sizes. All data were analysed using commercially available 
software (Microsoft Excel (Microsoft Corp) and Number Cruncher Statistical System 
for Windows (NCSS60)). 
 
Chapter 6  
 
Given the fascinating findings uncovered on the prevalence of inhalational insults, their 
effect on autoantibody generation, and implications for disease severity, it was felt that 
intra-cohort analysis was needed to analyse possible differences between patients 
with nodular disease and those without.   Initially determining the overall prevalence 
of nodular disease in the Cornish rheumatoid arthritis (RA) cross-sectional patient 
cohort, analysis was made to compare rheumatoid factor (RF) levels, anti-citrullinated 
protein antibody (ACPA) levels and urinary cadmium (Cd) levels amongst nodular and 
non-nodular patients. 
 
Subjects 
 
Two cohorts of RA patients were studied. Cohort 1 (n=303) consisted of all RA males 
and females attending routine rheumatology clinics at the Royal Cornwall Hospital, 
Cornwall, UK from  August 2017  to February 2018 to determine prevalence of nodular 
RA, as part of Departmental Audit. Cohort 2 consisted of prospectively gathered 
nodular RA males and females (n=92),  matched for age (+/– 2 years), sex, and 
smoking history (+/–2 pack years),  to patients previously collected as part of project 
IRAS ID 194833, approved by South West Regional Ethical Committee (UK) as 
previously described [9] (n=133). Specifically more males were recruited to this arm of 
the study as our unit were actively investigating the relationship between occupational 
exposures and the development of male RA. Cohort 2 (n=225) was stratified for 
nodular disease and smoking with comparison made for urinary cadmium. 3 cases 
were excluded as extreme outliers with cutoff value of >3 µmol/mol creatinine used to 
bias towards the null hypothesis. 
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Both cohorts were amalgamated (Cohort 3) with duplicate records excluded (n=24). 
RF and ACPA levels were compared between all RA patients (n=504) stratified for 
nodular disease and smoking. 18 patients were excluded from ACPA analysis due to 
incomplete data (n=6 RF negative, n=3 RF weak positive, n=9 RF strong positive), 
Figure 3. Data was anonymised at source. Age, age of RA onset, disease duration, 
smoking history prior to disease development, RF levels at disease onset and 
subsequent ACPA levels were recorded as part of routine clinical practice. Patient 
occupational histories were recorded as part of ongoing clinical audit using 
methodology previously described [9]. All patients fulfilled 2010 ACR/EULAR RA 
criteria at diagnosis [2]. 
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Autoantibody measurement  
 
RF was measured with Tina–quant Rheumatoid Factors II Test System (Roche 
Diagnostics Corporation), with a value of <14 IU/mL considered as negative as per 
manufacturer guidelines. ACPA was measured by Second Generation E170 Anti–CCP 
analysis (Roche Modular Analytics), with a negative value of <17 U/mL as per 
manufacturer guidelines. 
 
Social deprivation analysis 
 
Social deprivation analysis was undertaken through the UK government validated 
Index of Multiple Deprivation (IMD), a deprivation rank score of 32 844 
neighbourhoods weighted by income, health/disability, education, housing/service 
access, crime and living environment, converted to equal deciles [3]. 
 
Statistical analysis 
 
Chi square tests and multivariate logistic regression analysis was used to examine 
relationships between smoking, nodularity and urinary Cd levels, adjusted for gender. 
The Mann–Whitney U test was used for non–parametric comparisons of continuous 
data of differing sample group sizes, with values are expressed as a median (IQR) or 
number (%). All data were analysed using commercially available software (Microsoft 
Excel (Microsoft Corp) and Number Cruncher Statistical System for Windows 
(NCSS60)). 
 
Urinary Cadmium analysis 
 
Patients supplied first pass morning mid–stream urine samples into 13ml sterile 
polystyrene urine sample tubes (Thermo–Fisher, Newport, UK). Samples were posted 
within 72 hours to the Supra–Regional Assay Service Trace Elements Laboratory, 
Guildford, Surrey. Urinary cadmium was analysed by inductively coupled plasma mass 
spectrometry (ICP–MS), using a fully validated method previously described [1]. An 
appreciably raised urinary Cd was defined as a urinary Cd level above the 95th centile 
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as determined for UK populations unexposed to occupational Cd, equating to 0.65 
mmol/mol creatinine (females), and 0.42 mmol/mol creatinine (males). The median 
levels were reported as 0.19 mmol/mol creatinine and 0.16 mmol/mol creatinine 
respectively for females and males [1]. 
 
Smoking history 
 
Pack years smoked was recorded prior to the diagnosis of RA. One pack year is 
deemed equivalent to smoking 20 cigarettes daily for a year.  A smoker was defined 
as an individual that had smoked in a period up to 20 years before RA diagnosis and 
> 5 pack years total. A non–smoker was defined as an individual who had either never 
smoked or had smoked in the distant past (>20 years prior to the diagnosis of RA) and 
< 5 pack years total. 
 
Subcutaneous rheumatoid nodules 
 
Individuals were examined in clinic to determine the presence of characteristic 
rheumatoid nodules on the hands, forearm, elbow and feet. Patients who had 
undergone surgical removal of nodules and histological examination had confirmed 
the diagnosis, were considered to be a rheumatoid nodular patient irrespective of the 
presence of rheumatoid nodularity at the time of the examination. No  radiological 
evidence of pulmonary rheumatoid nodules was collected. 
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